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Three-dimensional scaffolds and growth factors have been shown to be important for 
articular cartilage tissue engineering. A major problem in using recombinant proteins in vivo, 
however, is the inability to maintain therapeutic levels over prolonged times due to degradation 
or diffusion from the defect site. The goal of this thesis was to develop a method to employ type 
I1 collagen-glycosaminoglycan (CG) scaffolds for the nonviral delivery of the gene encoding for 
insulin-like growth factor (1GF)-1, as a novel means to provide a local, elevated, and prolonged 
release of a therapeutic growth factor via transfection of cells seeded or migrating within the 
scaffold. In  vitro studies were performed to evaluate gene-supplemented CG (GSCG) scaffolds, 
including: 1) the type of expansion medium to use for growing chondrocytes prior to 
transfection, 2) methods of incorporating genes within scaffolds, 3) additional incorporation of 
transfection enhancers, and 4) the use of mesenchymal stem cells (MSCs) as an alternative cell 
source for articular cartilage tissue engineering. 
The medium used during monolayer expansion not only had a significant effect on 
subsequent biosynthesis and chondrogenesis in CG scaffolds, but also on gene transfer to 
chondrocyte monolayers. The expansion medium that resulted in enhanced 3-D biosynthesis and 
gene transfer to cells in monolayer was used throughout the rest of the studies. 
Greater plasmid retention within GSCG scaffolds was achieved by chemically cross- 
linking the plasmid IGF- 1 (pIGF- 1) to the scaffold (compared to simple plasmid absorption), and 
resulted in more steady and prolonged IGF-1 overexpression by seeded chondrocytes. 
Ir~corporation of a lipid transfection reagent or gelatin nanoparticles encapsulating pIGF-1 
significantly enhanced gene expression. The method of gene incorporation and the type of 
transfection enhancer were important variables that controlled the initiation, amount, and 
duration of growth factor release. IGF- 1 overexpression by cells successfully transfected within 
GSCG scaffolds also increased biosynthesis of cartilage matrix molecules and chondrogenesis. 
Finally, MSCs seeded into GSCG scaffolds were able to be successfully transfected and 
mLaintained IGF- 1 overexpression for at least 2 weeks post-seeding. 
These findings show promise in using GSCG scaffolds for providing a local, prolonged, 
and therapeutic release of desired growth factors using nonviral transfection methods for tissue 
engineering or regenerative medicine applications. 
Thesis Advisor: Myron Spector 
Title: Senior Lecturer, Mechanical Engineering & Harvard-MIT Division of Health Science & 
Technology, MIT; Professor of Orthopaedic Surgery (Biomaterials), Harvard Medical School 
THESIS COMMITTEE 
Thesis Supervisor: 
................................... Myron Spector S e n i o r  Lecturer, Mechanical Engineering and 
Harvard-MIT Division of Health Science & Technology 
Massachusetts Institute of Technology 
Professor of Orthopaedic Surgery (Biomaterials) 
Harvard Medical School 
Thesis Committee: 
..................................... Lorna Gibson Professor of Materials Science and Engineering 
Massachusetts Institute of Technology 
.................................. Christine Ortiz. Professor of Materials Science and Engineering 
Massachusetts Institute of Technology 
SPECIAL THANKS 
First and fmemost, I would like to extend my sincere gratitude to Dr. Spector for the 
invaluable advice and guidance over the years on not just research and career issues, but also life 
in general. From the beginning, your optimism and dedication to your work has been inspiring. 
Your generosity, honesty, and willingness to share your thoughts and experiences with me will 
always be treasured and never forgotten. Not only have you supported me throughout my studies 
and research, but you have also been someone I could confide in during the rough times; always 
offering your help in any way that you could. I hope to have the many great qualities that you 
possess as an advisor, and I hope to be an equal monumental influence on fbture generations. I 
feel very fortunate to have ended up in your group and have had the opportunity to work with 
you these past years. I really can't thank you enough. 
To Professors Yannas, Gibson, and Ortiz for your input and advice on my doctoral 
research over the years. It's been a great experience learning fiom and interacting with each and 
every one of you. 
To the many people (past and present) that have supported and helped me both in and 
outside the lab: Brendan, Scott, Nikki, Liqun, Ximing, Tobias, Alix, Hu-Ping, Glyn, and the rest 
of the Tissue Engineering Laboratories-it's been a tremendous pleasure working with you all 
and I wish you the very best in everything you do. 
To all my fiends that have been a monumental source of support and joy in my life: 
Deborah, Nikki, Maureen, Kristy (and Mark), and the wonderful people at Global Fitness. You 
have all made my stay in MA such a memorable and fulfilling experience. Throughout the ups 
and downs, I felt comfort knowing that you were there for me, and I can't tell you how much I 
appreciate the kindness, generosity, and laughter you all have given m e 1  will truly miss you. 
To my family for accepting the person I've become, and for the unconditional love and 
support throughout my life. 
And last but not least, to Dr. Nirav Shah-for without you, I wouldn't be who I am today. 
No matter what the fiture holds for us, you will always be a part of me. Thank you for the 
enlightenment, the challenges, and believing in my potential. 
My deepest appreciation to you all for contributing to the positivity in my life during 
these past years and I wish you all good health, peace, happiness, and satisfacton. 
ACKNOWLEDGEMENTS 
I would like to acknowledge the aid and support of the following individuals: 
From MIT: 
Lorna Gibson, Ph.D. 
Christine Ortiz, Ph.D. 
Ioannis Yannas, Ph.D. 
Brendan Harley, Sc.D. 
Fergal O'Brien, PhD. 
Patricia Reilly 
Anthony Garratt-Reed, Ph.D. 
Cynthia Lee, Ph.D. 
Dawn Hastreiter, M.D., Ph.D. 
From Brigham and Women's Hospital: 
Hu-Ping Hsu, M.D. 
Liqun Zou, M.D. 
Nicole Veilleux, M. S. 
Scott Vickers, M.S. 
Leonide Saad, M.S. 





Hao Wang, Ph.D. 
Zhou Xiang, M.D. 
From Tissue Engineering Laboratories, VA Boston Healthcare System: 
Myron Spector, Ph.D. Camille Francois 
Ximing Xu, Ph.D. Tobias Gotterbarrn, M.D. 
Alix Weaver, B.S. Donald Hurnphries, PhD. 
Erika Marsilio, Ph.D. 
From Harvard Medical School: 
Chris Evans, Ph.D. 
Steven Ghivizzani, Ph.D. 
Glyn Palmer, Ph..D. 
* I would also like to acknowledge the h d i n g  sources that supported this research: 
--The American Society for Engineering Education 
(National Defense Science and Engineering Graduate Fellowship) 
--Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and 
Development Service 
and 
--Geistlich Biomaterials (Wulhusen, Switzerland) for providing 
the type I1 collagen used in these studies 
3 
TABLE OF CONTENTS 
ABSTRACT ......................................................................................................................................................................... 3 
..................................................................................................................................................... THESIS COMMITTEE 4 
............................................................................................................................................... ACKNOWLEDGEMENTS 5 
................................................................................................................................................... TABLE OF CONTENTS 7 
TABLE OF FIGURES ...................................................................................................................................................... 10 
CHAPTER 1: GENERAL INTRODUCTION ......................................................................................................... 13 
1 . 1. BACKGROUND ...................................................................................................................................................... 14 
......................................................................... 1.1.1. Collagen-GAGScaffoldsforArticularCartilageRepair 14 
1.1.2. Role of Growth Factors ............................................................................................................................. -15 
................................................................................. 1.1.3. Rationale for Gene Transfer in Tissue Engineering 17 
1.1.4. Gene Transfer to Cells for Articular Cartilage Tissue Engineering ....................................................... 17 
1.1.5. Tissue Engineering Approaches Incorporating Gene Transfer ............................................................... 19 
1.2. EXPERIMENTAL PPROACH ................................................................................................................................ -22 
1.2.1. Specific Aims ............................................................................................................................................... 24 
1.2.2. Hypotheses ................................................................................................................................................... 25 
1.3. REFERENCES ........................................................................................................................................................ 26 
CHAPTER 2: EFFECT OF EXPANSION MEDIUM ON EX VIVO GENE TRANSFER AND 
CHONDROGENESIS IN TYPE I1 COLLAGEN-GLYCOSAMINOGLYCAN SCAFFOLDS IN VITRO ...... 33 
2.1 . INTRODUCTION .................................................................................................................................................... 33 
2.2. MATERIALS AND METHODS ................................................................................................................................ 35 
2.2.1. Type 11 Collagen Scaffolds Fabrication .................................................................................................... 35 
2.2.2. Cell Isolation and Monolayer Culture ....................................................................................................... 35 
2.2.3. CellProliferationandMorphologyinMonolayers .................................................................................. 36 
2.2.4. Culture of Cell Pellets and Cell-Seeded Collagen Scaffolds ................................................................... 37 
2.2.5. Histology and Immunohistochemistry of Cell Pellets and Cell-Seeded Scaffo Ids .................................. 37 
2.2.6. Monolayer Infection .................................................................................................................................... 38 
2.2.7. Nonviral Gene Transfer in Three-Dimensional Culture .......................................................................... 38 
2.2.8. DNA Analysis .............................................................................................................................................. 39 
2.2.9. GAG Analysis .............................................................................................................................................. 39 
2.2.10. StatisticalAnalysis .................................................................................................................................... 40 
2.3. RESULTS ............................................................................................................................................................... 40 
2.3.1. Proliferation of Monolayer Cultures ......................................................................................................... 40 
2.3.2. Cell Morphology of Chondrocyte Monolayers ........................................................................................ -40 
2.3.3. Appearance and Biochemical Analysis of the Cell Pellets and Cell-Seeded Collagen-GAG Scaffolds43 
2.3.4. Histology and Immunohistochemistry of 3-D Cultures ........................................................................... -44 
2.3.5. IGF-1 Synthesis of Infected Monolayers ................................................................................................... 51 
2.3.6. Nonviral IGF-1 Gene Transfer in CG Scaffolds and Effects on Biosynthesis ........................................ 53 
.......................................................................................................................................................... 2.4. DISCUSSION 54 
2.5. REFERENCES ........................................................................................................................................................ 59 
CHAPTER 3: GENE-SUPPLEMENTED COLLAGEN-GLYCOSAMINOGLYCAN SCAFFOLDS 
(GSCG) FOR NONVIRAL IGF-1 GENE DELIVERY IN ARTICULAR CARTILAGE TISSUE 
ENGINEERING ................................................................................................................................................................ 63 
................................................................................................................................................... 3.1 . INTRODUCTION -63 
................................................................................................................................ 3.2. MATERIALS AND METHODS 65 
................................................................................................................................. 3.2.1. Experimental Design -65 
............................................................................................................... 3.2.2. Type 11 Collagen- GAG Scaffolds 66 
........................................................................................................... 3.2.3. Plasm id Propagation and Isolation 66 
.................................................................... 3.2.4. Plasmid Incorporation into Collagen-GAG (CG) Scaflolds 67 
.............................................. 3.2.5. Plasmid Release from CG Scaflolds and Analysis of Structural Integrity 68 
3.2.6. Transmission Electron Microscopy of GSCG Scafolds ........................................................................... 68 
3.2.7. Chondrocyte Isolation and Expansion ...................................................................................................... 69 
3.2.8. Nonviral Gene Transfer in GSCG Scaffolds ........................................................................................... 69 
3.2.9. DNA Analysis ............................................................................................................................................ 7 0  
3.2.10. GAG Analysis ........................................................................................................................................... 71 
........................................................... 3.2.11. Histology and Immunohistochemistry of Cell-Seeded Scaffolds 71 
3.2.12. Statistical Analysis ................................................................................................................................... 71 
3.3. RESULTS ............................................................................................................................................................... 71 
..................... 3.3.1. IGF-1 Plasmid Release from GSCG Scaffolds-Release Kinetics and Plasmid Integrity 71 
......................................................................................................... 3.3.2. TEM of Unseeded GSCG Sca f fds  7 3  
.................................................... 3.3.3. Nonviral Gene Transfer to Chondrocytes Seeded in GSCG Scafolds 77 
.......................................................................... 3.3.4. Biochemical Analysis of Cell-Seeded GSCG Scafolds 7 9  
3.3.5. Histology and Immunohistochemistry of 3-D Cultures ............................................................................ 82 
3.4. DISCUSSION .......................................................................................................................................................... 89 
3.5. REFERENCES ....................................................................................................................................................... -94 
CHAPTER 4: DELNERY OF PLASMID IGF-1 TO CHONDROCYTES VIA CATIONIZED GELATIN 
NANOPARTICLES .......................................................................................................................................................... 97 
. 4.1 INTRODUCTION ................................................................................................................................................... -97 
................................................................................................................................. 4.2. MATERIALS AND METHODS 99 
............................................................................................................ 4.2.1. Preparation of Cationized Gelatin 99 
..................................................................................................................... 4.2.2. Preparation of Plasmid DNA 99 
4.2.3. Incorporation of Plasmid ZGF-1 into Cationized Gelatin Nanoparticles ............................................ 100 
4.2.4. Environmental Scanning Electron Microscopy ..................................................................................... 100 
.................................................................................. 4.2.5. Determination of Nanoparticle Size Distribution 100 
4.2.6. Zeta Potential ......................................................................................................................................... 101 
4.2.7. Gene Transfer to Adult Articular Chondrocytes in Monolayer Using Gelatin Nanoparticles 
Incorporating pEGFP and pIGF-1 .................................................................................................................... 101 
........................................ 4.2.8. IGF-1 Expression as a Function of Plasmid Loading in the Nanoparticles 102 
.......................... 4.2.9. Collagen-GAG (CG) Scaffolds Seeded with Monolayer Transfected Chondrocytes 102 
4.2.1 0 . DNA Analysis ......................................................................................................................................... 103 
4.2.11. GAG Analysis ......................................................................................................................................... 103 
4.2.12. Statistical Analyses ............................................................................................................................... 104 
............................................................................................................................................................ 4.3. RESULTS 104 
4.3.1. Morphology of the Cationized Gelatin-pIGF-1 Nanoparticles ........................................................... 104 
4.3.2. Particle Sue Distribution .................................................................................................................... 104 
4.3.3. Sugace Charge of Gelatin Nanoparticles .............................................................................................. 105 
4.3.4. Fluorescence Microscopy of the Chondrocytes Transfected with the Nanoparticles Containing 
pEGFP 107 
4.3.5. IGF-1 Gene Expression in Transfected Chondrocyte Monolayers ..................................................... 109 
4.3.6. IGF-1 Gene Expression of Transfected Chondrocytes Seeded in CG Scaffolds and Efects on 
Biosynthesis ........................................................................................................................................................ 113 
4.4. DISCUSSION .........................................-............................................................................................................. 115 
4.5. REFERENCES ................................................................................................................................................ 118 
CHAPTER 5: SCAFFOLD-BASED NONVIRAL IGF-1 GENE DELIVERY USING COLLAGEN-GAG 
................................................................ SCAFFOLDS INCORPORATING TRANSFECTION ENHANCERS 123 
5.1 . INTRODUCTION ................................................................................................................................................. 123 
5.2. MATERIALS AND METHODS ............................................................................................................................. 124 
5.2.1. Type I1 Collagen- GAG Sca f fds  ......................................................................................................... 124 
5.2.2. Plasmid Propagation & Isolation .......................................................................................................... 124 
5.2.3. Preparation of Cationized Gelatin ....................................................................................................... 124 
5.2.4. Cationized Gelatin Plasm id IGF-1 Nanoparticle Synthesis ................................................................. 125 
5.2.5. Incorporation of GP/IGF Complexes or Cationized GelatinWGF-1 Nanoparticles (CGPIN) into CG 
Scaflo lds .................................................................................................................................................................. 1 25 
5.2.6. Swelling Ratio Analysis .......................................................................................................................... 126 
5.2.7. Chondrocyte Isolation and Expansion ................................................................................................... 127 
5.2.8. Cell Seeding GSCG Scaffolds ................................................................................................................ 127 
5.2.9. DNA Analysis ......................................................................................................................................... 128 
5.2.10. GAG Analysis ........................................................................................................................................ 128 
5.2.11. HistologyandImmunohistochemistryofCell-SeededScaffolds ........................................................ 128 
5.2.12. Statistical Analysis ................................................................................................................................ 129 
5.3. RESULTS ......................................................................................................................................................... 129 
5.3.1. EffectofGene-SupplementationonCross-1inkDensity ........................................................................ 129 
5.3.2. Cell-Mediated Contraction of GSCG Scafolds ..................................................................................... 129 
5.3.3. IGF-1 Release in 3-0 Culture Medium ................................................................................................. 133 
5.3.4. Biochemical Analysis of Cell-Seeded GSCG Scaffolds ......................................................................... 137 
5.3.5. Histology and Immunohistochemistry of 3-D Cultures ......................................................................... 137 
5.4. DISCUSSION ....................................................................................................................................................... 144 
5.5. REFERENCES ................................................................................................................................................ 149 
CHAPTER 6: NONVIRAL IGF-1 GENE TRANSFER TO MESENCHYMAL STEM CELLS VIA GENE- 
SlUPPLEMENTED COLLAGEN-GLYCOSAMINOGLYCAN (GSCG) SCAFFOLDS ................................... 151 
6.1. INTRODUCTION ............................................................................................................................................. 151 
6.2. MATERIALS AND METHODS ............................................................................................................................. 152 
6.2.1. TypeIICollagen-GAGScaffolds ............................................................................................................ 152 
6.2.2. Plasmid Propagation & Isolation ........................................................................................................... 152 
6.2.3. Incorporation of GenePorter/plasmid IGF- 1 (GP/IGF) Complexes into CG Scafo lds ..................... 153 
6.2.4. Mesenchymal Stem Cell (MSC) Isolation and Monolayer Expansion ................................................. 153 
6.2.5. Monolayer Transfection of Mesenchymal Stem Cells (MSCs) .............................................................. 154 
6.2.6. Cell Seeding CG Scaffolds, IGF-1 Detection in the Medium. and Scafold Contraction ................... 154 
6.2.7. DNA Analysis ........................................................................................................................................... 155 
6.2.8. GAG Analysis ........................................................................................................................................... 155 
6.2.9. Histo logical Analysis of Cell-Seeded Scaffolds .................................................................................... 155 
6.2.10. Statistical Analysis ................................................................................................................................ 155 
6.3. RESULTS ............................................................................................................................................................ 156 
6.3.1. Cell-Mediated Contraction of GSCG Scafo Ids ..................................................................................... 156 
6.3.2. IGF-1 Release in 3-0 Culture Medium ................................................................................................. 157 
6.3.3. BiochemicalAnalysisofCell-SeededGSCGScafolds ......................................................................... 157 
6.3.4. HistologicalAnalysisof3-DCultures ................................................................................................ 163 
6.4. DISCUSSION ....................................................................................................................................................... 167 
6.5. REFERENCES ..................................................................................................................................................... 173 
CHAPTER 7: LIMITATIONS AND FUTURE WORK ...................................................................................... 175 
CHAPTER 8: SUMMARY ....................................................................................................................................... 177 
CHAPTER 9: CONCLUSIONS ............................................................................................................................... 183 
APPENDICES ................................................................................................................................................................. 185 

without the GP  reagent) after the 2-week culture period. 2 million cells per scaffold were seeded onto 
the scaffolds. Red is a positive stain for the presence of GAG and brown is a positive stain for the 
presence of type I1 collagen .................................................................................................................................... 83 
Figure 3.9 Safranin-0 stain for GAG (red is positive stain) of scaffolds synthesized using Method 2 for 
Controls (a, b) and GSCG scaffolds incorporating IGF-1 plasmid alone (c, d) or  the GPIIGF complexes 
(e, f) after 2-weeks in 3-D culture. 4 million cells were seeded onto the scaffolds ........................................ 85 
F.igure 3.10 Immunohistochemical stain for collagen type I1 (brown is positive stain) of scaffolds 
synthesized using Method 2 for Controls (a, b) and GSCG scaffolds incorporating plasmid IGF-1 alone 
(c, d) or the GPIIGF complexes (e, f) after 2-weeks in 3-D culture. 4 million cells were seeded onto the 
scaffolds ..................................................................................................................................................................... 87 
F:igure 4.1 Environmental scanning electron microcopy images of cationized gelatin-pIGF-1 nanoparticles 
(a, b) and non-cationized (original) gelatin-pIGF-1 microparticles (c, d), using a gelatin-plasmid weight 
ratio of 250:l. ........................................................................................................................................................ 105 
Figure 4.2 Particle size distribution of cationized gelatin-pIGF-1 nanoparticles (CGPIN) and original 
gelatin-pIGF-1 particles (GPIN). Cumulative percentage of nanoparticles, C(d), plotted against particle 
size. Nanoparticles were made with cationized gelatin and original gelatin at a weight ratio of 250:l. 105 
Figure 4 3  Zeta potential of naked IGF-1 plasmid (1'' bar), cationized gelatin (2nd bar), original gelatin 
complexed to pIGF-1 at a 250:l weight ratio (3" bar), and cationized gelatin complexed with different 
amounts of pIGF-1 to yield the following ge1atin:plasmid weight ratios: 150:1,200:1,250:1,300:1, and 
400:l. .................................................................................................................................................................... 107 
Figure 4.4 Fluorescence microscopy of chondrocytes transfected with nanoparticles incorporating pEGFP 
48hrs after transfection using original gelatin (a) or cationized gelatin (b) ................................................ 109 
Figure 4.5 IGF-1 protein released into the medium from monolayer chondrocytes 144 hours after 
treatment with gelatin-plasmid IGF-1 nanoparticles: varying the cationized gelatin to pIGF-1 weight 
ratio using a lOpg plasmid load (a); varying plasmid load using a 250:l weight ratio (b); and comparing 
transfection using original gelatin particles vs. cationized gelatin nanoparticles (c). n = 3-4; mean -c 
SEM. .................................................................................................................................................................... 112 
Fiigure 4.6 IGF-1 released in medium from control cell-seeded scaffolds and chondrocytes transfected in 
monolayer with CGPIN (ge1atin:plasmid IGF-1 of 250:l) and subsequently seeded in CG scaffolds. n = 
6; mean * SEM. .................................................................................................................................................... 113 
Fiigure 4.7 DNA contents (a) and accumulated GAGIDNA (b) measured at the end of the 3-D culture period 
in CG scaffolds seeded with untreated chondrocyte monolayers (Control), chondrocytes treated with 
gelatin alone (Gelatin only), or chondrocytes transfected in monolayer with CGPIN at  a ge1atin:plasmid 
IGF-1 of 250:l (CGPIN). n = 4; mean SEM. ............................................................................................... 114 
Fiigure 5.1 Cross-link density (llswelling ratio) of unseeded control and GSCG scaffolds. n = 4; mean * 
SEM. .................................................................................................................................................................... 131 
Fiigure 5.2 Contraction of cell-seeded Control and GSCG scaffolds over the 2-week 3-D culture period. n = 
12; mean .- SEM. .................................................................................................................................................. 131 
Fiigure 5.3 IGF-1 detected in each media collection (a) and total accumulated IGF-1 (b) over the course of 
the 2-week 3-D culture period for Control and GSCG scaffolds incorporating GPIIGF complexes or 
........................................................................................................................... CGPIN. n = 12; mean A SEM. 135 
Fiigure 5.4 DNA (a) and GAGIDNA (b) content for Control and GSCG scaffolds incorporating GPIIGF 
......................... complexes or  CGPIN at the end of the 2-week 3-D culture period. n = 6; mean + SEM 139 
Fiigure 5.5 Safranin-0 staining (redlpink is a positive stain) for Control (a) and GSCG scaffolds 
................................... incorporating GPIIGF complexes (b) or CGPIN (c) after 2 weeks in 3-D culture. 141 
Fiigure 5.6 Type I1 collagen immunohistochemical staining (brown is a positive stain) for Control (a) and 
...... GSCG scaffolds incorporating GPIIGF complexes (b) or CGPIN (c) after 2 weeks in 3-D culture. 143 
Fiigure 6.1 Diameter change of MSC-seeded CG scaffolds over the 2-week 3-D culture period. n = 11-12; 
.......................................................................................................................................................... mean * SEM 156 
Fiigure 6.2 IGF-1 detected in the medium at each time point from MSC-seeded constructs (a) and total 
... accumulated IGF-1 (b) over the course of the 2-week 3-D culture period. n = 11-12; mean * SEM. 159 
Fiigure 6.3 DNA (a) and GAGIDNA (b) contents of MSC-seeded scaffolds at the end of the 2-week 3-D 
.................................................................................................................. culture period. n = 6; mean * SEM 161 
Figure 6.4 Safranin-0 stain for GAG of MSC-seeded scaffolds after 2 weeks in 3D culture (a) Control 
group, (b) Monolayer transfected group, (c) GenePorter, x-link group, (d) GenePorter, x-link & soak 
group. Scale bars: lSt column is 500 pm and 20d column is 50 pm. Red is a positive stain for GAG. .. 165 
Figure 6.5 Mason's Trichrome stain of MSC-seeded scaffolds after 2 weeks in 3D culture (a) Control group, 
(b) Monolayer transfected group, (c) GenePorter, x-link group, (d) GenePorter, x-link & soak group. 
Scale bars: 1" column is 500 pm and 20d column is 50 pm. Blue stain is collagen and red stain is 
cytoplasm. ....................................................  ................. . . . . .  .......... . ..................... . .................................. 167 
CIHAPTER 1: GENERAL INTRODUCTION 
Current methods for treating articular cartilage defects (e.g. microfiacture, autologous 
chondrocyte implantation, and osteochondral autografting) have been successful in alleviating 
immediate patient pain, however, long term affects of these methods have limited follow-up. 
Currently these methods generally result in the formation of a fibrocartilage tissue that is very 
different from the composition and structure of normal articular cartilage. Several studies have 
investigated the collagen-glycosaminoglycan (CG) scaffold as an implantable scaffold with and 
without autologous cells in regenerating dermis ly2, peripheral nerve 3-5, intervertebral disc 6,  and 
articular cartilage 7-9. From these studies, it has been found that CG scaffolds facilitate the 
reparative process and result in the successful growth of various functioning tissues that are 
closer but not yet identical to the structure of natural tissues. Previous research has also found 
significant and positive affects of specific growth factors on the tissue engineering of articular 
cartilage particularly in enhancing proliferation of chondrogenic cells, cell differentiation, and 
the biosynthesis of cartilage specific matrix molecules by these cells. 
A local and prolonged administration of a growth factor such as insulin-like growth 
factor (1GF)-1 could be a significant benefit to in vivo and ex vivo strategies for articular cartilage 
repair. Despite their promising reparative potential, however, administration of recombinant 
proteins may be hindered in vivo due to delivery problems related to degradation or diffusion 
from the defect site. Recent studies in our lab have concluded that incorporation of plasmid 
DNA (specifically plasmid DNA containing the luciferase reporter gene) in CG scaffolds leads 
to successful transfection of and gene expression by the cells seeded within the scaffold. The use 
of plasmid DNA instead of viruses as a means for induced gene expression is desirable as it 
re:duces the risk of a possible immune response. Although several studies have investigated gene 
th~erapy concepts for a variety of tissue engineering applications, there has not yet been an effort 
to develop gene-supplemented collagen-GAG (GSCG) scaffolds for the nonviral delivery of the 
IGF-1 gene for enhancing the synthesis of articular cartilage in vitro or in vivo. Development of 
a11 effective method to supplement CG scaffolds with plasmid DNA encoding for desired 
proteins could result in a novel gene delivery system that elicits a more prolonged and localized 
release of growth factors: cells seeded within these GSCG scaffolds or migrating into the 
scaffold in vivo may be transfected by taking up the incorporated plasmid DNA, leading to 
production of therapeutic concentrations of growth factors that can enhance the repair of articular 
cartilage defects. 
lam BACKGROUND 
ImImIm COLLAGEN-GAG SCAFFOLDS FOR ARTICULAR CARTILAGE REPAIR 
The use of three-dimensional (3-D) scaffolds that mimic the natural in vivo environment 
(viz., extracellular matrix) of cells has been shown to facilitate the reparative process and result 
in the successful growth of various functioning tissues. The 3-D environment supplied by these 
porous scaffolds serves as a desirable structural support for seeded or migrating cells and allows 
for a much greater surface to volume ratio for increased cell attachment as compared to a 2-D 
surface. There are several requirements for a scaffold to be used as an implant for articular 
cartilage regeneration lo. The scaffold needs to be biodegradable, nontoxic, able to be fixed to 
the defect site, facilitate cell attachment, regulate cell expression, and possess sufficient 
mechanical strength l. Natural polymers such as collagen provide a native surface to cells, since 
it is a major component of the natural extracellular matrix, and possesses ligands that favor 
cellular attachment. Collagen substrates have been shown to modify the morphology, migration, 
and in some cases differentiation of cells 12. Moreover, prior studies have demonstrated that type 
I collagen-glycosaminoglycan (GAG) scaffolds produced by freeze-drying techniques can 
facilitate the regeneration of dermis and peripheral nerve 12'. Type I1 collagen-GAG scaffolds 
7,8,13 have also demonstrated promise for enhancing articular cartilage synthesis . 
Studies have confirmed that the addition of cells seeded within these 3-D scaffolds 
8,14,15 enhance matrix synthesis and increase type I1 collagen production in vivo . There are 
various cell types that may be used to enhance cartilage synthesis when seeded into scaffolds. 
These include articular chondrocytes and chondroprogenitor cells derived from marrow, 
periosteum, or perichondrium ' I .  The advantage of using chondrocytes obtained from articular 
cartilage as a cell source is that they already express the desired phenotype for articular cartilage 
repair (i.e. they can synthesize cartilage matrix molecules such as type I1 collagen and aggrecan) 
16. Chondrocytes, however, are very limited in supply especially for autologous transplantation, 
and expansion in culture is necessary to obtain a number sufficient for enhanced repair. 
Furthermore, the site from which autologous chondrocytes are harvested (usually taken from a 
minimal-load-bearing region of the joint) does not spontaneously regenerate and may pose a 
potential problem. To alleviate this problem of donor site morbidity, other cell sources such as 
bone marrow (for marrow-derived mesenchymal stem cells), which have natural regenerative 
capabilities and are readily accessible, have been investigated for articular cartilage repair l6?l7. 
The chondroprogenitor cells from marrow have been shown to be able to differentiate into a 
cartilage lineage when exposed to the appropriate stimuli l1 and therefore may be a more feasible 
cell source for articular cartilage regeneration. For this reason, both chondrocytes and marrow- 
derived stem cells were investigated as cell sources for culture in GSCG scaffolds. 
1.1.2. ROLE OF GROWTH FACTORS 
While recent studies in our lab have demonstrated the promise of implementing 
chondrocyte-seeded collagen-GAG scaffolds for cartilage repair, there are potential problems 
and significant expense associated with the need to culture a cell-seeded scaffold for several 
weeks prior to implantation. This focuses attention on the implementation of growth factors to 
accelerate cell proliferation and matrix synthesis. Numerous studies have shown the effects of 
vi3rious growth factors on chondrogenesis in vivo, and on chondrocyte proliferation, metabolism, 
and matrix synthesis in vitro. Among the most prominent growth factors investigated for 
articular cartilage tissue engineering are insulin-like growth factors (IGFs) 18-23, bone 
24-26 rnlorphogenetic proteins (BMPs) , basic fibroblastic growth factor (bFGF, also FGF-2) 27-29 
and transforming growth factor-p (TGF-p) 30-36. The effects of growth factors in both monolayer 
and 3-D culture of chondrocytes have been shown to be significant. The complexity of choosing 
th~e correct combinations and doses of growth factors to obtain the optimal tissue engineered 
articular cartilage construct in vitro poses a major challenge. While there are numerous 
combinations of factors that can be investigated relative to the type and dose of growth factor 
used, studies have already demonstrated the profound benefits of certain agents for engineered 
articular cartilage constructs. For example, supplementation of the culture medium with IGF-1 
alone has been shown to increase cell proliferation, proteoglycan synthesis, type-I1 collagen 
synthesis, and chondrogenesis, both in monolayer and in 3-D cultures 18,22,37 
In  vivo, an improved histologic appearance and an increased proportion of type I1 
collagen in full thickness cartilage defects in young mature horses was shown using fibrin 
polymers laden with IGF- 1 38. BMPs (specifically BMP-2 and BMP-7) have also been shown to 
increase proteoglycan and matrix synthesis, maintain the chondrocyte phenotype, and stimulate 
cartilage formation in vivo in a manner similar to endochondral ossification 39. In vivo studies 
using New Zealand White rabbits have demonstrated that full-thickness femoral osteochondral 
defects treated with rhBMP-Zsupplemented collagen sponges displayed a greatly accelerated 
formation of new subchondral bone, an improved histologic appearance of overlying articular 
cartilage, and more type I1 collagen and tissue filling in the defect compared to the controls ". 
BMP-7 (also called osteogenic protein- 1,OP-1) has also been shown to stimulate cartilage 
formation and aggrecan synthesis in subchondral defects in goats 41. FGF-2 has demonstrated to 
be a potent mitogen for chondrocytes and a stimulator of matrix synthesis 39. Furthermore, in 
vivo studies in rabbits 42 have reported that treatment of full-thickness cartilage defects with 
intra-articular FGF-2 can enhance differentiation of mesenchymal cells to the chondrocyte 
phenotype, increase proliferation of differentiated chondrocytes, and increase accumulation of 
type I1 collagen and proteoglycan. 
TGF-p has been shown to be most effective in conjunction with other growth factors in 
eliciting its complex effects on cartilage metabolism 39. Many findings, however, have shown 
contradictory effects of TGF-P supplementation in culture (e.g., effects of cell proliferation and 
proteoglycan synthesis) due to its sensitivity to varying experimental conditions in the different 
studies. The more promising effects of TGF-P supplementation include increasing collagen and 
proteoglycan production and inhibiting matrix breakdown 39. It has also been shown that TGF-P 
has a role in the regulatory network of growth factors that maintains articular cartilage in the 
differentiated phenotype 43 and is an important factor in inducing chondrogenesis in marrow- 
derived mesenchymal progenitor cells ' 7. 
The effects of using combinations of growth factors have also been studied in monolayer 
and 3-D cultures and demonstrate the complex interactions and signaling events that can occur. 
Growth factor-supplemented media used for the expansion of chondrocytes in monolayer have 
been shown to directly influence the outcome of 3-D cell pellet cultures grown in a different 
specified serum-free medium ". Not only does supplementation of the expansion medium with 
specific growth factors affect chondrocyte proliferation, morphology, and phenotype, it also 
influences the chondrocytic potential or ability to redifferentiate back into a chondrocytic 
phenotype when re-introduced into a 3-D environment. 
1.1.3. RATIONALE FOR GENE TRANSFER IN TISSUE ENGINERING 
Growth factors can make significant contributions to cartilage repair procedures and 
tissue engineering by stimulating cell proliferation, migration, differentiation, and matrix 
synthesis. There are, however, major challenges faced in the direct application of human 
recombinant proteins in a clinical setting. Proteins are difficult to administer exogenously in 
accurate, sustained, and therapeutically useful amounts to sites of cartilage injury. Single bolus 
doses of growth factors alone in vivo have short half-lives as a result of degradation or diffusion 
from the defect sight. Various strategies including the use of polymers, pumps, and heparin, 
have been investigated as possible methods by which to achieve constant levels of growth factors 
at a given injured site; however, success remains limited 45. Furthermore, although it is now 
possible to produce large quantities of these recombinant proteins for the purpose of treatment, 
the expense is still another unattractive feature. Delivery of a gene that could be expressed 
within the wound is an attractive alternative to application of the recombinant protein. Gene 
transfer provides the DNA that encodes for the desired protein, so that infected cells can create 
higher and more sustained levels of the growth factor over extended periods of time, a likely 
requirement for effective articular cartilage regeneration. More than one gene can be transferred 
and independently regulated to supply multiple growth factors to the defect site at various time 
points in the repair process. Furthermore, prior work has suggested that endogenously expressed 
proteins, induced by gene transfer, may have a more positive and more potent effect on matrix 
synthesis and biological activity than exogenous recombinant proteins 46. 
1.1.4. GENE TRANSFER TO CELLS FOR ARTICULAR CARTILAGE TISSUE 
ENGINEERING 
Many questions are involved in deciding the best method of gene transfer for articular 
cartilage repair. Such variables include: a) the cell, or cells, to be targeted (e.g., chondrocytes, 
rnLesenchymal stem cells, synovial cells, etc.); b) the protein, or proteins, to be encoded; and c) 
the delivery vector to be employed (which is also dependent on the size of the gene encoding the 
growth factor). The vectors used in gene transfer procedures applied to articular cartilage repair 
include: viral vectors such as adenoviruses, lipid-mediated reagents such as liposomes, and 
naked DNA alone. 
Several studies have focused on adenoviral vectors for the transduction of cells due to 
high infection efficiencies and ease of manufacturing. Both in vitro and in vivo studies have 
proved this method of infection to be beneficial to cartilage regeneration. In monolayer studies, 
cultured articular chondrocytes infected with an adenoviral vector containing the IGF- 1 coding 
sequence 47 found that at an optimal adenovirus-IGF- 1 concentration (1 00 multiplicities of 
infection, MOI), gene expression was detected at therapeutic concentrations for at least 28 days. 
This prolonged expression resulted in an 8-fold increase in matrix products secreted in the 
medium and an increased resistance of the cells to de-differentiation over time under serum- 
starved conditions. Moreover, the cells maintained a normal chondrocyte molecular phenotype 
compared to controls. The significant effects of using different genes separately or in 
combination could be seen in another monolayer study which used rabbit articular chondrocytes 
and compared the effects of adenoviral delivery of IGF-1, TGF-P, and BMP-2 in the absence or 
presence of the inflammatory cytokine, interleukin-1 (IL-1) 46. It was found that proteoglycan 
synthesis was significantly stimulated by the BMP-2 (-8-fold) and IGF-1 (2-3 fold) genes 
separately, and the effects were additive upon co-transduction of chondrocyte monolayers. 
Furthermore, the IGF-1 gene most strongly stimulated collagen and noncollagenous protein 
synthesis. Although the addition of IL- 1 decreased proteoglycan synthesis by 50-60%, IGF- 1 
and TGF-f3 genes restored proteoglycan synthesis to control levels, and BMP-2 gene transfer 
further elevated proteoglycan synthesis beyond control levels. It can thus be seen that finding 
the right genes to use individually or in combination can significantly affect the success of the 
final regenerated tissue. Other studies have demonstrated the successfbl transduction of other 
cell types such as mesenchymal stem cells and synovial cells in monolayer and explant cultures, 
for the delivery of therapeutic proteins 48. 
Although the use of viral vectors has proven to be very effective in enhancing the 
biosynthetic activity of cells in vitro, much caution has to be taken when directly injecting viral 
particle solutions in vivo, due to the immunogenic nature of viruses and the possibility of 
transmission to other tissues and organs. This issue has been addressed in an in vivo study 
comparing the direct injection of adenoviral vectors for IGF-1 or BMP-2 to transplantation of 
fibroblasts infected ex vivo with the same vectors - with respect to virus spread, immune 
response, and cartilage formation 49. Inadvertent spread of the adenoviral vector was observed in 
the liver, lung, and spleen in all mice that had received the vector directly, whereas spread rarely 
occurred in fibroblast-mediated gene transfer. Furthermore, administering the genes via 
injection of ex vivo-infected fibroblasts limited cartilage formation to regions near the injected 
site, and also avoided the strong immune response that was elicited following direct application 
of the viral vector. Ex vivo methods of gene transfer to harvested cells (such as chondrocytes, 
fibroblasts, bone marrow cells, or synovial cells) may therefore be safer than direct injection of 
viral particles alone. 
Nonviral methods of gene transfer are also being developed to avoid the potential 
problems associated with adenoviral vectors. Nonviral vector systems offer the advantages of 
low immunogenicity, simplicity of vector design, and relative ease of large-scale production 50. 
Although transfection efficiencies for nonviral vectors have been known to be much lower than 
that of viral vectors, significant advances in the development of more efficient non-viral 
transfection reagents are emerging. Lipid-mediated gene transfer has been shown to result in the 
transfection of articular chondrocytes, and the maintenance of prolonged gene expression. One 
study implemented the lipid-mediated transfection reagent, FuGENE 6, with a hyaluronidase 
treatment to transfect bovine articular chondrocytes with a plasmid vector containing the cDNA 
for human IGF-1. Transfection efficiencies were reported to be about 41% with gene expression 
lasting for over 4 weeks in vivo 51952. Transplantation of the transfected chondrocytes onto the 
surface of articular cartilage explants led to the formation of a new tissue layer on the explant 
surface, which was characterized by the presence of type I1 collagen and proteoglycan and the 
absence of type I collagen, consistent with hyaline-like cartilage. Furthermore, the tissue formed 
by transfected chondrocytes was thicker and contained more cells than the controls. The 
overexpression of IGF-1 also increased DNA and glycosaminoglycan synthesis by the 
underlying explant cartilage chondrocytes 52. A follow-up in vivo study in a rabbit model 
showed that chondrocytes transfected with the IGF- 1 gene, encapsulated in alginate, and 
transplanted in osetochondral defects improved articular cartilage repair and accelerated the 
formation of the subchondral bone at early and later time points compared to controls 53. 
1.J. 5. TISSUE ENGINEERING APPROACHES INCORPORA TING GENE TRANSFER 
A promising approach for enhancing gene transfer and retention of genes or expressed 
proteins within a defect site employs 3-D scaffolds. The combination of gene therapy and tissue 
engineering could provide the ultimate treatment for articular cartilage defects as it involves a 
supporting scaffold that can serve as a carrier for gene vectors or infected cells resulting in a 
sustained, prolonged, and localized delivery of therapeutic proteins in vivo. It has also been 
demonstrated that cells first seeded into 3-D scaffolds and then transfected show higher gene 
expression levels and longer expression times compared to 2-D transfection 54. This observation 
is important in demonstrating how the 3-D environment can influence cell behavior and 
processes, including the transfectibility of cells. 
Most studies using gene therapy and tissue engineering concepts for the regeneration of 
55,56 articular cartilage involve ex vivo infection of cells that are virally transduced or nonvirally 
transfected 57 in vitro and then subsequently seeded into 3-D scaffolds (e.g., fibrin or synthetic 
polymer scaffolds). Several cell types and genes have been investigated for this application 
including: transfection of articular chondrocytes with the IGF-1 gene 57; transduction of 
periosteal stem cells with the OP-1 gene 55; and transduction of mesenchymal cells from rib 
perichondrium with the BMP-2 and IGF-1 genes 56. In all of these cases, chondrogenesis and 
matrix synthesis was significantly enhanced in vivo, following implantation of the constructs. 
The disadvantage of implanting cells transfected or transduced ex vivo as described above 
is that there may be a decrease in expressed protein over time as the infected cells apoptose or 
migrate. It would be ideal if the scaffold could serve as a vehicle to immobilize gene vectors so 
that when implanted: 1) cells migrating into the scaffold and proliferating could take up the gene; 
and/or 2) surrounding cells could take up the genes released as the scaffold degrades. The DNA 
vector as well as the transiently expressed therapeutic protein would be retained within the defect 
site, thereby increasing the opportunity for a maximal therapeutic response 58. With time, more 
endogenous cells could become infected and a prolonged release of growth factor could be 
maintained over the full duration of cartilage regeneration. This scaffold-based gene transfer 
approach could be particularly beneficial in regenerative medicine applications since in vitro 
culture would not be required (i.e. a non-cell-seeded gene-supplemented scaffold could be 
implanted in vivo for endogenous cells to infiltrate and become transfected resulting in the 
release of therapeutic growth factors). Several studies have investigated the use of nonviral 
scaffold-based gene delivery for the treatment of a variety of tissue defects. These studies are 
summarized in the table below with regard to the scaffold material, type and amount of plasmid, 
and the application. 
Table 1.1 Summary of Studies Using Scaffold-Based Nonviral Gene Delivery 
C Publication Scaffold I pMAT- 1 




pNT-3 (7.5 mg) 
Cationized-gelatin 
Vanoparticles pBMP-2 




(in vivo-canine) I Bonadio et al. " I Collagen I I Tyrone et al. 61 Healing-dermal ulcer fin vivo-rabbits) Collagen I 
Retina-optic nerve (in 
vivo-rat) Collagen I 
I Hosseinkhani et. al. PGA reinforced 
Collagen (I) sponge 
MSCs 
(for bone) 
Segura et al. 65 HA-Collagen I hydrogel surface Fibroblasts 
Block renal intersitial 
fibrosis (in vivo-mice 
kidney) I Kushibiki et a1 " 1 Cationized gelatin hydrogel 






I Andree et al. " Fibrin (w/ I keratinocvtes) Wound healing, (in vivo-mice) 
Kidney, endothelial, 
fibroblasts Trentin et al. 68 
Covalently I immobilized in Fibrin 
Granulation 
tissue/blood vessels (in 
vivo-rats) 
Shea et al. 69 Poly(1actide-co- glycolide) 
Poly(1actide-co- 
Poly(1actide-co- Jang J. et al. glycolide) 
PEI-DNA 












osteoblastic cell line 
(bone) 
1.2. EXPERIMENTAL APPROACH 
The main goal of this thesis was to use a nonviral scaffold-based gene delivery approach 
specifically developing collagen (type 11)-glycosaminoglycan (CG) scaffolds incorporating the 
gene encoding for insulin-like growth factor (IGF)-1 to induce a localized and prolonged IGF-1 
overexpression for enhancing articular cartilage tissue formation in v i to  and ultimately in vivo. 
Plasmid containing the IGF-1 gene was used throughout the scope of this thesis and chosen on 
the basis of prior work that demonstrated the beneficial effects of IGF-1 on proliferation, 
biosynthesis, and chondrogenesis 18,19,21,22,23,48 
My preliminary studies fust focused on evaluating certain medium conditions both in 
monolayer and in 3-D culture. Prior studies " have found that using a specific medium for 
expanding chondrocytes in monolayer has a direct effect on chondrocyte proliferation and 
chondrocyte rediffaentiation when subsequently placed in pellet cultures and cultured in a 
serum-free 3-D culture medium. More importantly, the use of a serum-free medium in 3-D 
culture would be advantageous in eliminating the variability introduced when using fetal bovine 
serum (FBS) and is desirable when preparing 3-D constructs to be placeplaced in vivo to prevent 
any inherent immunogenicity associated with the addition of FBS. Furthermore, the use of a 
serum-fkee medium in my experiments would ensure that the detected IGF-1 protein in the 3-D 
culture medium is a reflection of successful gene transfer to cells seeded within gene- 
supplemented CG (GSCG) scaffolds, and not IGF-1 protein contributed by FBS. 
Since the expansion medium was found to significantly influence the outcome of 
constructs in 3-D culture (i.e. cell pellets), it was hypothesized that the expansion medium may 
also have a significant effect on the ability to transfer specific genes into cells. To test this, a 
monolayer culture experiment was carried out using either a nonviral or viral method of 
transferring the IGF-1 gene into adult chondroctyes expanded in monolayer using two different 
types of medium. If one expansion medium demonstrated enhanced gene transfer susceptibility 
of cells in monolayer, then that specific medium would be commended for expansion of 
chondrocytes to be subsequently seeded within GSCG scaffolds to increase probable gene 
transfer in 3-D culture. 
Once the specific media were chosen for use during monolayer expansion and subsequent 
3-D culture, various methods to synthesize GSCG scaffolds were investigated. Based on the 
significant enhancement in gene transfer using a lipid mediated transfection reagent 
(Geneporter@) in the prior monolayer culture studies, we investigated incorporating within the 
CG scaffolds, plasmid alone or plasmid complexed to the lipid transfection reagent. Preliminary 
studies eliminated the feasibility of mixing the plasmid solutions within the collagen slurry due 
to issues related to possible degradation of the plasmid within the acidic slurry solution and post 
sterilization techniques that may also compromise plasmid integrity. Methods to incorporate 
plasmid within the scaffolds, therefore, were focused on trying to add the plasmid after the CG 
slurry had been freeze-dried to form porous constructs. 
Although others have successfully added plasmid to 3-D scaffolds using naked plasmid 
DNA alone, significant amounts of plasmid (on the order of milligram levels per scaffold) were 
required to see any beneficial effect. One of the goals of this thesis was to use microgram 
amounts of plasmid DNA per scaffold (for safety and cost reasons) that would still result in 
beneficial amounts of growth factor release by developing a method to better retain the plasmid 
within the scaffold so that not all incorporated plasmid would be released in a short period of 
time. This would entail more than just a mechanical entrapment of the plasmid between the 
collagen fibrils of the CG scaffold. One method that is commonly used in our lab as a means to 
chemically cross-link the CG scaffold is a carbodiimide cross-linking treatment. Upon further 
investigation, this carbodiimide chemical can be used to cross-link proteins to proteins and also 
proteins to nucleic acids. Therefore, one of the methods to incorporate the plasmid into CG 
scaffolds included the use of this carbodiimide treatment to cross-link plasmid DNA alone or 
with the transfection reagent to the collagen scaffold. 
The use of a transfection reagent to enhance nonviral gene transfer is an important aspect 
to also minimize the amount of naked plasmid required to produce therapeutic amounts of 
overexpressed protein. We looked to develop gelatin nanoparticles as a potential alternate to the 
G;enePorter transfection reagent to not only enhance gene transfer to cells, but to also allow 
fiirther control over the lunetics of gene transfer and subsequent gene expression by having the 
ability to alter the processing parameters involved in nanoparticle synthesis. Gelatin is a natural 
material that seemed to be logically compatible with the collagen scaffold and has been 
successfully synthesized into micro- and nanoparticles for drug delivery applications. The 
development of gelatin nanoparticles to be used in conjunction with the CG scaffold to enhance 
gene transfer was, therefore, an important aspect in this thesis. 
After an optimal gene transfer system was determined for chondrocytes in GSCG 
scaffolds, preliminary studies were undertaken to use mesenchymal stem cells (MSCs) as an 
alternative cell source. The goal was to evaluate the behavior of MSCs within GSCG scaffolds 
that were synthesized using optimal conditions for gene incorporation (determined with 
chondrocytes), and to evaluate the ability of MSCs to be transfected and to express the desired 
encoded protein when seeded into GSCG scaffolds. These studies would validate the use of 
GSCG scaffolds as an MSC-seeded construct or as an unseeded gene delivery vehicle to be used 
in conjunction with a microfracture procedure in vivo. In the latter scenario, a microfracture 
procedure in the cartilage defect would allow MSCs from the bone marrow to infiltrate the 
defect, after which an unseeded GSCG scaffold could be placed and serve as both a scaffold for 
cells to migrate and a source for the delivery of genes encoding for desired growth factors that 
can enhance in vivo regeneration. 
1.2.1. SPECIFIC AIMS 
Below are the specific aims of the thesis work: 
1. Determine which medium conditions to use for chondrocyte expansion and 3-D culture 
for evaluation of GSCG scaffolds and investigate if the expansion medium can also 
significantly affect subsequent gene transfer to cells. 
2. Develop a protocol for incorporating plasmid IGF-1 with or without a lipid-mediated 
transfection reagent into CG scaffolds that results in successful gene transfer to seeded 
chondrocytes and elevated expression of the IGF-1 protein over a prolonged time. 
3. Develop gelatin nanoparticles as a means to enhance and control gene transfer to cells 
and evaluate the potential use of these nanoparticles in conjunction with the CG scaffold 
for prolonged growth factor release. 
4. Evaluate the use of undifferentiated mesenchyrnal stem cells (MSCs) as an alternative 
cell source in GSCG scaffolds, for implanting a cell-seeded GSCG scaffold or an 
unseeded GSCG scaffold with a microfi-acture procedure. 
5. Determine the optimal GSCG construct to be used for subsequent in vivo studies using a 
goat model. 
1.2.2. HYPOTHESES 
1. The composition of the monolayer expansion medium not only has a direct effect on 
biosynthesis and chondrogenesis in 3-D culture but also has an effect on gene transfer to 
cells. 
2. Cross-linking naked plasmid DNA to the CG scaffold can result in a more prolonged 
delivery of genes and expression of the encoded growth factor compared to plasmid 
addition without cross-linking. 
3. A lipid transfection reagent complexed to the pIGF-1 can be successfully incorporated 
and cross-linked to CG scaffolds and can result in enhanced gene transfer to seeded cells. 
4. Gelatin nanoparticles can successfully enhance the transfection of chondrocytes and can 
be used in conjunction with a CG scaffold to produce a localized and prolonged release 
of encoded protein. 
5. MSCs can be transfected using GSCG scaffolds and can maintain overexpression of 
desired proteins over prolonged times. 
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CHAPTER 2: EFFECT OF EXPANSION MEDIUM ON EX VIVO GENE 
TRANSFER AND CHONDROGENESIS IN TYPE I1 COLLAGEN- 
GLYCOSAMINOGLYCAN SCAFFOLDS IN VITRO 
1 .  INTRODUCTION 
Several studies have demonstrated that the growth of certain cell types in three- 
dimensional (3-D) scaffolds for articular cartilage tissue engineering can enhance matrix 
synthesis and increase type I1 collagen production in vivo '". These cell types include 
differentiated articular chondrocytes and chondroprogenitor cells derived from marrow, 
periosteum, or perichondrium 4. The advantage of using chondrocytes obtained from articular 
cartilage as a cell source is that they already express the desired phenotype for articular cartilage 
repair and they have been shown to have the ability to synthesize matrix containing type I1 
collagen and aggrecan 5 .  These cells, however, are limited in supply for autologous 
transplantation and expansion in culture is necessary to obtain a number sufficient for cartilage 
repair procedures. Yet, it has been demonstrated that articular chondrocytes lose their 
chondrocytic phenotype (viz., the cells no longer display a rounded morphology or synthesize 
cartilage-specific macromolecules such as collagen type I1 and aggrecan) during in vitro 
expansion in monolayer 697. 
Although studies have shown that monolayer-expanded chondrocytes can redifferentiate 
into the chondrocytic phenotype when introduced into a 3-D environment such as in cell pellets 
or porous scaffolds 899, the greater the number of serial passages, the more fibroblast-like 
chondrocytes become-producing molecules such as collagen type I and versican and losing 
th~eir capability to redifferentiate when put back into a 3-D environment lo. Both the monolayer 
expansion medium and redifferentiation medium (used in 3-D culture) have recently been shown 
to directly influence the ability of chondrocytes to redifferentiate ' . I2 .  Not only does a specific 
combination of growth factors in the expansion medium affect chondrocyte proliferation and 
differentiation, it also influences the chondrocytic potential or ability to redifferentiate when 
transferred back into a 3-D environment (cell pellets) 12. 
Just as selected growth factors have proven to be of importance as supplements to the 
m,edia used for monolayer expansion and redifferentiation of chondrocytes, they have been 
shown to be useful stimulants for chondrogenesis and enhanced biosynthesis for cartilage repair 
strategies. A local and prolonged administration of insulin-like growth factor- 1 (IGF- 1) in vivo 
or in vitro could significantly benefit articular cartilage tissue regeneration, as the IGF-1 
recombinant protein has been shown to increase chondrocyte proliferation, proteoglycan 
synthesis, type-I1 collagen synthesis, and chondrogenesis 3. Administration of the recombinant 
protein alone in vivo, however, may be insufficient for therapeutic results due to protein 
degradation or diffusion fiom the defect site. A promising alternative for a prolonged, localized 
release combines tissue engineering and gene therapy strategies involving ex-vivo gene transfer 
14. In this approach, cells could be transfected in vitro with the genes for proteins that have been 
shown to enhance differentiation and biosynthesis, and then immediately implanted in vivo so 
that the desired proteins can be expressed over the time course of regeneration. In using this 
strategy, the effect that the expansion medium has on the gene transfer susceptibility of cells has 
never been investigated. 
Prior studies have confirmed successful IGF-I gene transfer to chondrocytes in 
monolayer with both viral 15*16 and nonviral l7 techniques. These studies also demonstrated that 
cells overexpressing IGF-1 can enhance chondrogenesis and biosynthesis of matrix molecules in 
monolayer l5 or when subsequently implanted in vivo l6>l7. Prolonged expression of the protein 
fi-om cells infected in monolayer, however, may still be limited in vivo due to possible apoptosis 
or migration of these cells from the defect site. Localization and maintenance of infected cells 
within the defect site may be accomplished using 3-D scaffolds onto which seeded cells can 
attach, migrate within, and proliferate. It has been shown that nonviral gene transfer to cells may 
also be enhanced by the stiffness of the substrate material upon which the cells are grown 18. 
The investigators speculated that the modulation of gene uptake by cells by surface rigidity was 
due to the control over cell proliferation. The type I1 collagen-glycosaminoglycan (CG) scaffold 
has been shown to promote biosynthesis and proliferation of seeded adult articular chondrocytes 
in vitro l9 and improve cartilage repair in vivo 320. Based on this prior work, the ability to 
transfect cells seeded within a type I1 CG 3-D scaffold was also investigated. Not only might the 
type I1 CG scaffold be used to promote chondrogenesis and proliferation, but it may also enhance 
gene transfer to cells seeded within the scaffold. 
There were three objectives in the present work: 1.) To determine the effects of two 
different expansion media (each having different additives and growth factors) on the ability of 
monolayer-expanded adult canine articular chondrocytes to produce cartilage matrix molecules 
(viz., GAG) in cell pellets or when seeded in type I1 CG scaffolds, 2) to determine if the 
expansion medium can also have an effect on the gene transfer susceptibility of adult articular 
chondrocytes in monolayer using the plasmid containing the IGF- 1 gene, and 3) using the better 
of the two media, to determine the possibility of transfecting cells in 3-D culture using CG 
scaffolds Achieving these objectives will allow us to determine certain culture conditions that 
can favor the subsequent chondrogenic potential and biosynthesis of cells in 3-D culture and 
enhanced gene transfer to cells either in monolayer or 3-D culture. 
2,,2. MATERIALS AND METHODS 
2.2.1. Type I1 Collagen Scaffolds Fabrication 
Porous sheets of type I1 collagen were fabricated by freeze-drying a porcine cartilage- 
derived slurry (Geistlich Biomaterials, Wolhusen, Switzerland). Similar type I1 scaffolds have 
been reported in prior studies to have a porosity of 89 * 2% (mean * standard deviation) and a 
pore diameter of 125 * 42 pm 21. 
The collagen sheets were sterilized and cross-linked by dehydrothermal treatment 22. 
Nine-mm diameter disks (-3mm thick) were punched out and additionally cross-linked by a ten 
minute carbodiimide treatment 23 containing an aqueous solution of 14 mM 1 -ethyl-3-(3- 
dimethylaminopropyl) carbodiimide hydrochloride and 5.5 mM N-hydroxysuccinimide (EDAC; 
Sigma Chemical Co., St. Louis , MO). Excess EDAC was removed by rinsing in PBS. The 
m~echanical properties of EDAC-treated collagen-GAG scaffolds have been previously reported 
23 
2.2.2. Cell Isolation and Monolayer Culture 
Chondrocytes were isolated from the trochleae of the knees (stifle joints) from one adult 
m~ongrel dog (2-4 yrs old). Cells from one animal were used in this study in order to eliminate 
variability related to inter-animal differences. The cells were obtained using a sequential 
digestion of pronase (20 Ulml, 1 hr) and collagenase (200 Ulml, overnight) as previously 
described 24. Isolated chondrocytes were then split and suspended in either one of the following 
expansion media: 
1) Medium 1 : Dulbecco's modified Eagle's medium, DMEMIF 12 (Gibco Life 
Technologies, Carlsbad, CA) supplemented with 10% (vlv) fetal bovine serum (FBS, 
Hyclone Technologies, Logan, UT), 25 pglml ascorbic 2-phosphate (Wako Chemical, 
Osaka, Japan), and a penicillin/streptomycin/fixngizone cocktail (Gibco). 
2) Medium 2: High glucose DMEM (4.5 glL D-glucose, without L-glutamine and with 1 
mM sodium pyruvate) containing 10% (vlv) FBS, 0.1 mM nonessential amino acids, 10 
mM N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonc (HEPES) buffer, 1 00 UImL 
penicillin, 100 pg/mL streptomycin glutamate, and supplemented with the following 
growth factors (all from R&D Systems, Minneapolis, MN): 5 ng/mL of fibroblast growth 
factor-2 (FGF-2), 10 n g l d  of platelet-derived growth factor-pp (PDGF-pp), 1 ng/mL of 
transforming growth factor- f3 1 (TGF- PI). 
Medium 1 employed in the present investigation was one that has been widely used as an 
expansion medium for growing chondrocytes in monolayer, while Medium 2 has been found in a 
prior study l2 to increase chondrocyte proliferation and preserve the redifferentiation potential of 
expanded chondrocytes when subsequently placed in pellet cultures and grown in a defined 
serum-free medium. 
Primary chondrocytes were plated in 6-well culture plates at 250,000 cellslwell for 
proliferation studies and in 75-cm2 flasks at 2 million cellslflask for expansion and use in 3-D 
culture or in monolayer gene transfer studies. The cells were incubated at 37OC and 5% COz. 
Once cells reached confluence (PO cells), they were trypsinized, resuspended, and re-plated to 
obtain P 1 cells. 
2.2.3. Cell Proliferation and Morphology in Monolayers 
The cell counts for confluent monolayers of PO and P1 chondrocytes were obtained by 
counting the cells (by hemacytometry) at confluence in 6-well plates with an initial plating 
density of 250,000 cells per well. The total cell number at confluence was used for comparison 
in order to incorporate the effects of the media on both cell attachment onto tissue culture plates 
and cell proliferation. 
2.,2.4. Culture of Cell Pellets and CellMeeded Collagen Scaffolds 
A portion of PO chondrocytes fiom the two different expansion media cultures were 
either spun down to obtain cell pellets or seeded into the porous type I1 collagen scaffolds using 
a static seeding method. The culture of cell pellets is a common method used to easily assess 
cell behavior in 3-D culture, and is used in this study to compare results from prior work 12. Cell 
pellets were obtained by spinning 5 x lo5 cells in 1.5 ml polypropylene conical tubes at 4500 
rpm for 30 seconds. For collagen type I1 scaffolds, scaffolds were pre-wet with serum-free 
medium and placed on agarose-coated wells. Two million cells were added to each scaffold by 
pipetting a suspension of 1 million cells (in 20 p1 medium) onto each side with a 10 minute 
incubation period in between. By this static seeding method approximately 1.6 million 
chondrocytes have been found to attach to the scaffolds. 
While the cells were expanded in two different culture media, the cell pellets and cell- 
seeded scaffolds were cultured in the same defined serum-free medium (SFM), found in previous 
work l2  to enhance differentiation. The SFM used consisted of high glucose DMEM (4.5 g/L D- 
gllucose, without L-Glutamine and with 1mM Sodium Pyruvate), O. l mM nonessential amino 
acids, 10 mM HEPES buffer, 100 U/mL penicillin, 100 pg/mL streptomycin glutamate, ITS" 
(1. OOx, by Sigma Chemical, St. Louis, MO), 0.1 mM ascorbic 2-phosphate, 1.25 mg/ml bovine 
serum albumin, 10 ng/mL of TGF-PI, and 100 nM dexamethasone. Medium was changed every 
2-3 days (0.5 ml for pellets and 0.8 or 1.5 ml for scaffolds). Cultures were terminated after 2 
weeks for histological evaluation and biochemical analysis. For DNA and GAG analysis, pellets 
and scaffolds were lyophilized and enzymatically digested using proteinase K (Roche 
Dliagnostics, Indianapolis, IN). 
2.2.5. Hisrology and Immunohistochemistry of Cell Pellets and Cell-Seeded Scaffolds 
Cell pellets (n = 2) and cell-seeded scaffolds (n = 2) were fixed in 10% neutral buffered 
formalin, dehydrated, embedded in paraffin, and sectioned (eight-micrometer thick) by 
microtomy. Sections were stained with hematoxylin and eosin to determine cell'rnorphology and 
distribution and Safi-anin-0 for sulfated GAG. For type I1 collagen immunohistochemical 
analysis, sections were enzymatically digested by protease type XIV for 45 minutes and stained 
with a standard avidin-biotin complex peroxidase-based antibody staining technique (Vectastain, 
Vector Laboratories, Burlingane, CA). Mouse anti-chick monoclonal antibody for type 11 
collagen was obtained from the Developmental Studies Hybridoma Bank (Iowa City, IA). 
2.2.6. Monolayer Infection 
PO chondrocytes expanded in both types of media were plated in 24-well plates for gene 
transfer studies. At confluence, the cell monolayers were rinsed with phosphate buffered saline 
and incubated with either an aliquot of lipid-mediated transfection reagent (Geneporter@, Gene 
Therapy Systems, Inc. San Diego, CA) complexed to the plasmid encoding for IGF- lor with the 
adenovirus (ad)IGF-1 vector (both vectors supplied by the Center for Molecular Orthopedics, 
Harvard Medical School). An 8: 1 (pVpg) ratio of transfection reagent to IGF- 1 plasmid per 
well was used for nonviral transfections. For viral transductions, 100 x lo6 viral particles were 
added to each well. Three hours later, the vector solutions were removed from cultures and 
replaced with 0.5 ml of SFM. SFM was used during gene transfer and throughout the 2-week 
culture period during which medium was collected and changed every 2-3 days after infection. 
A sandwich ELISA kit for the human IGF-1 protein (R&D Systems) was used to detect the 
amount of IGF- 1 in the medium (n = 3), which reflected the effect of the expansion medium on 
vector uptake by cells, transfection efficiency, and subsequent release of the growth factor. For 
the ultimate purpose of employing the monolayer-expanded cells in constructs for implantation, 
it is the amount of growth factor released that is the principal measure and not necessarily the 
transfection efficiency. It may be that only a few transfected cells are needed to produce 
meaningful therapeutic levels of the growth factors. 
2.2.7. Non viral Gene Transfer in Th ree-Dimensional Culture 
Chondrocytes expanded in the medium that yielded the more favorable results in the 3-D 
chondrogenic assays and monolayer transfection experiments (which proved to be Medium 2) 
were seeded onto the type I1 CG scaffolds as described above. Two hours after seeding, the cells 
seeded in the scaffolds were transfected nonvirally by submerging the construct in a solution 
containing plasmid IGF- 1 (pIGF- 1) complexed with the Geneporter@ (GP) transfection reagent 
using an 8: 1 ratio (v/w) of GP:pIGF- 1. Four micrograms of plasmid was used to transfect cells 
per scaffold (n = 3). Two hours later, the cell-seeded scaffolds were transferred onto agarose- 
coated wells and 0.8 ml of SFM was added to each well. The controls cultured in parallel were 
cell-seeded scaffolds without the addition of plasmid. 
Over a 2-week culture period, medium was collected from the 3-D cultures at various 
time points and assayed for IGF- 1 using the human IGF-1 sandwich ELISA kit (R&D Systems, 
Minneapolis, MN). Less medium was used for these 3-D cultures (0.8 mVscaffold versus 1.5 
m~llscaffold for the chondrogenic assays) in order to concentrate the IGF-1 released in the 
medium. At the end of the culture period, scaffolds were lyophilized and enzymatically digested 
using proteinase K for DNA and GAG analysis. 
2.2.8. DNA Analysis 
The DNA content of cell pellets and cell-seeded scaffolds was measured using the 
Hroechst 33258 dye method 25 (n = 3-4). A 50 yl aliquot of the proteinase K digest mixed with 2 
mil of Hoechst dye solution (10% Hoechst dye in 10 mM Tris, 1 mM Na2EDTA and 0.1 M Na 
CL, pH 7.4) was assayed fluorometrically. The results were extrapolated from a standard curve 
established using calf thymus DNA. 
The sulfated GAG content of cell pellets and cell-seeded scaffolds was determined by the 
dimethylmethylene blue (DMMB) dye assay 26 (n = 3-4). A 100 y1 aliquot of the proteinase K 
digest was mixed with 2 ml of the DMMB dye and the absorbance at 525 nm was measured with 
a spectrophotometer. The results were obtained by extrapolating from a standard curve using 
shark chondroitin-6-sulfate. Newly accumulated GAG was determined by subtracting the 
unseeded values from the sample values. 
2.2.10. Statistical Analysis 
Data were analyzed by one, two, three-factor ANOVA, and Fisher's PLSD post-hoc 
testing using StatView (SAS Institute Inc, Cary, NC). Data are presented as mean + standard 
error of the mean. 
2.3. RESULTS 
2.3.1. Prolifration of Monolayer Cultures 
There were significant differences in the cell counts for PO and P1 chondrocytes 
expanded in monolayer using the two types of media (Fig. 2.1). The cell counts for PO and P1 
chondrocytes grown in Medium 1 were 2.3 million + 0.2 and 2.5 million + 0.1, respectively, 
whereas, cell counts for chondrocytes grown in Medium 2 were 2.7 million + 0.2 for PO and 8.3 
million + 0.3 for P1 cells. P1 cells expanded in Medium 2 showed more than a 3-fold higher cell 
number compared to cells grown in Medium 1 after 4 days (Fig. 2.1). Two-factor ANOVA 
revealed a significant effect of the expansion medium (p < 0.001; power = 1.00) and passage 
number (p < 0.001; power = 1.00) on the proliferation of chondrocytes in monolayer culture. 
2.3.2. Cell Morphology of Chondrocyte Monolayers 
Morphological differences of cells grown in the two different expansion media were 
observed by light microscopy (Figs. 2.2a and b). Chondrocytes expanded in Medium 1 (Fig. 
2.2a) were larger and cell vacuoles were more visible compared to those expanded in Medium 2 
(Fig. 2.2b). Furthermore, when using Medium 2, there were a significant number of cells that 
had a rounded morphology (Fig. 2.2b) instead of the fibroblast-like elongated morphology that is 
usually seen during monolayer expansion of chondrocytes. 
Medium 1 
Medium 2 
Figure 2.1 Cell counts of chondrocyte monolayers grown in Medium 1 or Medium 2. PO cells were 
cultured for 120 hrs and P1 cells were cultured for 96 hours. n = 5-6; mean t SEM. 
Figure i . ~  Light micrographs (phase contrast) of Pl chondrocyte monolayers grown in (a) Medium 1 or 
(b) Medium 2 at confluence (5 days). 

2.) 3.3. Appearance and Biochemical Analysis of the Cell Pellets and Cell-Seeded Collagen- 
GA G Scaffolds 
Over the 2-week culture period the cell pellets slightly increased in size to a final 
maximum diameter of approximately 1.5 mm. The cell-seeded collagen-GAG scaffolds 
contracted only slightly fiom their original diameter of 9 mm. Of note was the disc-like shape of 
the pellets that was maintained throughout the culture period (pellets did not contract to become 
more spherical in shape). There were no statistically significant differences in DNA and total 
GIAG contents for cell pellet cultures prepared with cells expanded in either type of medium. 
The DNA content of cell pellets for chondrocytes expanded in Medium 1 and Medium 2 were 
2.2 A 0.1 pg and 2.4 0.1 pg, respectively. The GAG content of these pellets was 84.7 k 2.1 pg 
for Medium 1-expanded cells and 83.2 * 2.8 pg for Medium 2-expanded cells. 
In contrast to the results fiom the pellet assay, the GAGDNA contents of the collagen- 
G)AG scaffolds seeded with cells expanded in Medium 2 were significantly higher than values 
from constructs prepared with Medium 1-expanded cells (Fig. 2.3). There was also a noticeable 
effect of the amount of medium added per scaffold. For both types of medium, 1.5ml added per 
scaffold produced 40-50% higher GAGDNA values compared to adding 0.8ml of medium per 
scaffold. Scaffolds seeded with cells expanded in Medium 2 showed a 20-40% increase in 
GAGDNA produced compared to cells expanded in Medium 1. Two-factor ANOVA revealed a 
significant effect of both expansion medium and amount of medium on GAGDNA values (p < 
0.0001; power = 1.00). 
Medium 1 Medium 2 Medium 1 Medium 2 
(0.8 ml) (0.8 ml) (1.5 ml) (I .5 ml) 
Figure 2.3 GAGIDNA content of chondrocyte-seeded CG scaffolds (2-week culture) for chondrocytes 
expanded in Medium 1 or Medium 2 with either 0.8ml or 1.5ml of media added per well. n=4; mean SEM. 
2. 3. 4. Histology and Imm unohistochemistry of 3-D Cultures 
Histology revealed that chondrocytes expanded in both types of medium produced 
cartilaginous constructs when cultured as cell pellets for 2 weeks (Fig. 2.4). Most of the cells 
displayed a rounded morphology and appeared in lacunae (Fig. 2.4a and b), consistent in 
appearance with the distinguishing cellular features of hyaline cartilage. Cells near the surface 
of all pellets assumed a more elongated appearance, with a lower percentage contained within 
lacunae. Some areas near the pellet surface were completely devoid of cells (Figs. 2.4a and b). 
A continuous extracellular matrix rich in GAG was clearly demonstrated in the 
histochemical sections of pellets prepared with the cells expanded in either type of media, 
revealed by the intense staining with Safianin 0 (Figs. 2 . 4 ~  and d). In some pellets, however, the 
surface zone (approximately 50 pm thick) had a deficient number of cells and displayed little 
staining for GAGS (Fig. 2.4~). The cell pellet sections also showed positive 
immunohistochemical staining of type I1 collagen (Figs. 2.4e and f) for both types of expansion 
media. Qualitatively, there was more intensive type I1 collagen staining in sections of pellets 
prepared with cells expanded in Medium 2 (Fig. 2.40 compared to pellets prepared with cells 
expanded in Medium 1 (Fig. 2.4e). Although the GAG distribution in pellets was generally 
uniform throughout (except in the surface zone), the distribution of type I1 collagen staining 
generally was more intense on the outer periphery of the pellets and more diffuse in the center 
(Fig. 2.4g and h). 
The cell density in the chondrocyte-seeded collagen-GAG scaffolds was markedly less 
than in the cell pellets. A lower percentage of cells in the collagen scaffolds displayed the 
chondrocytic morphology compared to the pellets, with no noticeable effect of expansion 
medium (Fig. 2.5a and b). For cell-seeded CG scaffolds, chondrocytes expanded in Medium 2 
showed more areas of GAG accumulation within the scaffolds compared to cells expanded in 
Medium 1 (Figs. 2 . 5 ~  and d). Chondrocytes expanded in both types of medium also stained 
positive for type I1 collagen in the CG scaffolds with greater staining found in areas surrounding 
cells (Figs. 2.5e and f ) .  As demonstrated in the cell pellets, cells expanded in Medium 2 showed 
more intense staining for type I1 collagen in the scaffolds compared to cells expanded in Medium 
1 (Figs. 2.5e and f ) .  

Figure 2.4 Histology and immunohistochemistry of chondrocyte pellets (2-week culture) for cells 
expanded in Medium 1 (a, c, e) or  Medium 2 (b, d, f) and differentiated in SFM. Sections were stained with 
Hemotoxylin and Eosin (a, b) to show cell morphology and distribution and with Safranin-0 (c, d) for 
glycosaminoglycans (red is positive stain). Sections were also immunohistochemically stained for type II 
collagen (brown is positive stain) (e, f). Lower magnification micrographs of cell pellets from cells expanded 
in Medium 1-Safranin-0 (g) and collagen type I1 (h). 
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Figure 2.5 Histology and immunohistochemistry of chondrocyte-seeded CG scaffolds (2-week culture) 
for cells expanded in Medium 1 (a, c, e) or  Medium 2 (b, d, f) and redifferentiated in SFM. Sections were 
stained with Hemotoxylin and Eosin (a, b) to show cell morphology and distribution within the scaffolds and 
with Safranin-0 (c, d) for glycosaminoglycans (red is positive stain). Sections were also 
immunohistochemically stained for type I1 collagen (brown is positive stain) (e, f). Lower magnification 
micrographs of scaffolds seeded with cells expanded in Medium 1 S a f r a n i n - 0  (g) and collagen type I1 (h). 

2.3.5. IGF-I Synthesis of Infected Monolayers 
Control monolayers did not display any IGF-1 release into the medium. In contrast, IGF- 
1 protein release reflecting gene transfer was observed for all transfected or transduced 
monolayers (Fig. 2.6). GP/pIGF- 1 transfection of monolayers grown with both media 
formulations demonstrated substantially greater IGF- 1 release within the first 7 days of culture 
(Fig. 2.6a). The peak of IGF-1 release for transfected cells expanded in the Medium 2, however, 
occurred earlier (day 2) than the peak release for cells expanded with Medium 1 (day 5). After 
the peak, IGF-1 release for these monolayers showed a general drop at day 7 followed by a 
gradual decrease in IGF- 1 production until minimal expression was detected in the day- 12 
collection. Monolayers transduced with ad-IGF-1 demonstrated a different IGF- 1 release profile 
compared to transfected monolayers (Fig. 2.6b). For both transduced monolayers, there was 
very little detectable IGF-1 in the medium at the day 2 collection, and both showed similar 
release profiles up to day 9. Thereafter, cells expanded in Medium 2 showed a noticeably higher 
IGF-1 release over monolayers expanded with Medium 1 (days 12 and 14). In contrast to 
transfected monolayers, transduced monolayers showed a significantly lower IGF- 1 expression 
at the early collections, but maintained a more steady release of IGF- 1 (no significant peak) over 
the two-week culture. Although infection conditions were not optimized for either type of gene 
transfer method in this study, the kinetics of gene expression for transfected and transduced 
monolayers appear to correspond with the general trend associated with these types of infection 
methods. 
Three-factor ANOVA demonstrated significant effects of expansion medium (P = 0.02; 
power = 0.63)' method of gene transfer (P < 0.0001; power = I), and time (P < 0.0001; power = 
1) on IGF-1 release in the medium over the two-week period. While the effect of expansion 
medium in the 3-factor ANOVA had only a moderate power (0.63)' subsequent Fisher's PLSD 
post hoc test demonstrated a highly significant difference between Medium 1 and Medium 2 (P < 
0.0001). In order to more fully examine statistical differences between these two types of media, 
1 --factor ANOVA was performed for each time point and gene transfer method comparing the 
two media types. Statistically significant differences in IGF-1 release between Medium 1 and 
Medium 2 for Geneporter03 transfected monolayers occurred at day 2 (P < 0.0001; power = 1)' 
di~y 5 (P = 0.0005; power = I), and day 7 (P = 0.0004; power = 1). Significant differences for 
transduced monolayers were seen at day 2 (P < 0.0001; power = l), day 5 (P = 0.0012; power = 
I), day 7 (P = 0.0212; power = 0.71 I), and day 14 (P = 0.0004; power = 1). 
Of significance is that the accumulated amount of IGF-1 reached a therapeutic level (e.g., 50- 
100 nglml 13) for both gene transfer methods over the two-week period. Moreover, this 
therapeutic level was reached by a nonviral gene transfer method only 5 days after transfection. 
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Figure 2.6 IGF-1 protein production detected in the medium over the 2-week chondrocyte monolayer 
culture grown in Medium 1 or Medium 2 transfected with GP/pIGF-1 complexes (a) or transduced with 
adIGF-1 (b). n = 3; mean * SEM (error bars hidden by symbols). IGF-1 amounts for control cultures are on 
the zero axis. 
2.3.6. Nonviral IGF-I Gene Transfer in CG Scaffolds and Effects on Biosynthesis 
IGF- 1 gene transfer to Medium 2-expanded chondrocytes in type I1 CG scaffolds resulted 
in a substantial elevation of IGF-1 synthesis over the non-transfected control group (Fig. 2.7). 
Chondrocytes grown in type I1 CG scaffolds without treatment with the plasmid (controls) 
produced only minute amounts of IGF-1 in the medium with a total accumulation of about 600 
pg over the 2-week culture (Fig. 2.7). There was, however, evidence of a slight increase in IGF- 
1 production at the end of the 2-week period for these control scaffolds. Transfected 3-D 
cultures showed a 35-fold higher elevation in accumulated IGF-1 collected in the medium over 
the 2-week culture compared to control scaffolds. For transfected cultures, there was a peak 
release of IGF-1 in the medium at about a week (-6 nglml), after which IGF-1 release started to 
slightly decline (Fig. 2.7). 
8000 
-t Control 
-+ Cells transfected in 3D 
Figure 2.7 IGF-1 protein production detected in the collected media of chondrocytes expanded in 
Medium 2 and seeded in type I1 CG scaffolds, with or without subsequent transfection with 
GenePorterWpIGF-1. n = 3; mean SEM. 
IGF-1 over-expression by chondrocytes grown in type I1 CG scaffolds resulted in a 
significant increase of GAGDNA synthesis over control scaffolds. There was a 40% higher 
GAGDNA value for IGF- 1 transfected cultures compared to the control group (Fig. 2.8); the 
control group is the same as the 0.8 ml, Medium 2 group in Fig. 2.3. One-factor ANOVA 
revealed a significant effect of IGF-1 over-expression on GAGDNA (P < 0.0001; power = 1). 
Control Cells Transfected in 
- 3D 
Figure 2.8 GAGIDNA (2-week cultures) of type I1 CG scaffolds seeded with chondrocytes expanded in 
Medium 2, with or without subsequent transfection with GenePorter@/pIGF-1. n = 3; mean + SEM. 
2.4. DISCUSSION 
The current investigation demonstrated that the specific medium used in expanding 
chondrocytes in monolayer has a significant influence on GAG synthesis and chondrogenesis 
when chondrocytes are subsequently grown in a tissue engineering scaffold comprised of 
collagen (Type 11)-GAG. As in previous work 12, addition of specific growth factors within the 
expansion medium significantly increased proliferation of chondrocytes in monolayer. The cell 
morphology, which is one indicator that can define a chondrocyte phenotype, was also affected. 
At confluence, cultures grown in Medium 2 were made up of chondrocytes that were smaller and 
that possessed a rounded morphology (characteristic of a chondrocytic phenotype) compared to 
cultures grown in Medium 1. The smaller cell size of chondrocytes expanded in the Medium 2 
may be a result of a greater number of cells present at confluence. Using Medium 2 resulted in a 
more than 4-fold difference in cell number for P1 cells at confluence. This may be very 
advantageous for decreasing the time needed to obtain a sufficient number of cells for 
preparation of tissue-engineered articular cartilage constructs for implantation. 
Pellet cultures yielded the characteristic small diameter spheroids that contained high 
levels of GAG and type I1 collagen. The small diameters of these cell pellets, however, render 
these constructs undesirable for implantation. There was no significant difference in the total 
GAG accumulated within cell pellets for chondrocytes expanded in Medium 1 compared to 
Medium 2. That the total GAG values may have been maximum levels achieved in the pellet 
cultures, may explain why there were no detectable differences in pellets comparing the two 
expansion media. Despite this undetectable difference in GAG, more intense collagen type I1 
staining was present with chondrocytes expanded in Medium 2, demonstrating greater 
chondrogenesis in these pellets. 
There was a more prominent difference in the effects of expansion media when P1 
chondrocytes were grown in CG scaffolds, compared to the pellet assay. The expansion medium 
demonstrated a significant effect on DNA, total GAG accumulation, and GAG per DNA content 
when chondrocytes were seeded in CG scaffolds and cultured in SFM for 2 weeks. Furthermore, 
a greater number of areas that stained for GAG were apparent in histological sections for 
constructs seeded with chondrocytes expanded in Medium 2. A notable finding was the 
significantly higher amount of total GAG accumulation and GAG staining within cell pellets 
compared to cell-seeded CG scaffolds. It is speculated that this difference between cell pellet 
and scaffold culture may be related to the effects of cell density-cell pellets having a greater 
concentration of cells compared to the seeded scaffolds. Prior work investigating the 
chondroinduction of mesenchymal stem cells in pellet cultures has also supported an association 
between pellet contraction, and hence increasing cell density, to chondrogenesis 27. In the 
present investigation, areas within scaffolds that appeared to have a higher cell density displayed 
more staining for GAG. Within cell pellets, where the cell density was uniform and plentiful 
throughout, there was a continuous matrix rich in GAG. It is also possible that the porosity of 
the scaffold itself may allow for diffusion of GAGS from the scaffold into the medium, as seen in 
a prior study 23, making it more difficult for GAG to accumulate within the matrix. The tighter 
packing of cells within cell pellets may facilitate GAG accumulation. 
Chondrocyte-seeded CG scaffolds also showed evidence of chondrogenesis with the 
positive staining for type ZI collagen. Like the cell pellets, there was more intense staining of 
type 11 collagen within CG matrices that incorporated cells expanded in Medium 2, suggesting 
that more articular cartilage-specific matrix molecules may be produced by these cells compared 
to ones expanded in Medium 1. The varied morphology (including the presencelabsence of 
lacunae) indicated that there was phenotypic heterogeneity in the cell populations within CG 
scaffolds and pellets. Therefore, it was likely that some cells were producing non-cartilagenous 
matrix molecules (including collagen types other than type 11). In the context of the objective to 
produce constructs to facilitate cartilage repair in vivo, future animal studies will be required to 
determine to what extent this heterogeneity in cell phenotype affects cartilage repair. After two 
weeks in in vitro culture, the presence of type I1 collagen serves as an indication that at least 
some of the cells are proceeding down the path of chondrogenesis. 
A significant finding of this study was that viral and non-viral transgene expression levels 
of chondrocytes in monolayer were directly affected by the medium used to expand the cells. 
For transduced monolayers, the effect that the expansion medium had on IGF-1 release was not 
significant until the later collection periods (days 12 and 14), where IGF-1 release from cells 
expanded in Medium 2 had significantly higher levels than those expanded in Medium 1. For 
transfected cells, monolayers expanded in Medium 2 demonstrated an earlier peak in IGF-1 
synthesis compared to cells expanded in Medium 1. This earlier peak in protein synthesis may 
indicate that the cells expanded in Medium 2 were more receptive to non-viral gene transfer. 
This enhanced receptiveness allowed therapeutic levels of IGF-1 to be accumulated in vitro 
sooner (in 2 days) than with cultures of chondrocytes grown in Medium 1. It is speculated that 
the enhanced nonviral gene transfer with Medium 2 may be due to an increased mitotic activity 
of the cells as reflected in the proliferation data. During cell division, the cell membrane and 
nuclear envelope is disrupted, and hence gene uptake and transfer within the cell nucleus may be 
facilitated. The greater number of cell divisions that resulted when using Medium 2 for 
expansion, may therefore enhance the transfection efficiency and may have resulted in the 
increased IGF-1 release especially at the earlier time points. It would be interesting in future 
studies to investigate the effects of medium composition directly on transfection efficiency with 
the use of reporter genes. 
For in vivo applications, an earlier release of growth factor may be advantageous in the 
first stages of repair. The kinetics of growth factor release, however, would most likely require a 
prolonged and more sustained level to enhance biosynthesis over the regeneration process, not 
just a single peak of protein release at an early time point. This may require a system where 
genes can be incorporated within tissue engineering scaffolds to provide continuous transfection 
of seeded or endogenous cells in vivo as the scaffold degrades, to sustain growth factor release 
for the span of in vivo repair. In this study, the make-up of the medium in which chondrocytes 
are expanded may have a meaningful effect on gene transfer and should be considered when 
deciding optimal conditions for both in vitro and in vivo gene transfer. 
Transfecting Medium 2-expanded chondrocytes seeded in type I1 CG scaffolds resulted 
in elevated IGF-1 synthesis when compared to controls that were not treated with the plasmid. 
Interestingly, chondrocytes seeded in 3-D scaffolds (without plasmid) did show some IGF- 1 
release in the medium, in contrast to no expression detected in monolayer control cultures. This 
might indicate that the cell interaction with the type I1 CG scaffold alone can potentially act as a 
stimulus for IGF- 1 expression. The production of IGF- 1 from control scaffolds was most 
noticeable at the end of the 2-week culture period. It should be noted that the actual levels of 
IGF- 1 localized within the scaffold could be significantly higher than the concentrations detected 
in the medium. Future work will investigate methods to quantify IGF-1 expressed by cells that is 
retained within the scaffold in order to determine the minimum local therapeutic concentration 
needed to enhance chondrogenesis. 
IGF-1 release kinetics resulting from cells transfected in the CG scaffolds also differed 
from transfected monolayer cultures. Transfected monolayer cultures showed a maximum 
release of IGF-1 at the beginning of culture period and decreased significantly within a week. In 
contrast, IGF- 1 levels in the medium from transfected cell-seeded scaffolds showed a steadier 
release profile with a gradual increase up to about a week followed by a slight decrease at the 
end of the two-week period. This may indicate that using 3-D scaffolds with gene transfer 
methods may provide a more steady expression of desired growth factors in vitro and in vivo 
over prolonged times. 
In this study, a significant increase in GAG biosynthesis was associated with an 
overexpression of IGF-1 in cultures of Medium 2-expanded cells that were transfected while 
growing in the scaffold. This finding is consistent with prior work demonstrating that IGF-1 
stimulates chondrocyte biosynthesis 13. Future work needs to investigate the biosynthesis of 
other cartilage matrix molecules and the histological features of chondrogenesis. 
Of interest in the present study was the finding that the volume of medium strongly 
affected GAG synthesis, with a 40% increase in GAGIDNA in the cultures with 1.5 ml per 
scaffold compared to the cultures with 0.8 ml per scaffold. GAGIDNA values in cultures 
growing in 0.8 ml of medium, however, was stimulated by IGF-1 overexpression fi-om 
chondrocytes transfected within CG scaffolds up to levels similar to the non-transfected cultures 
grown using 1.5 ml of medium. A possible reason for this finding is that the minimum amount 
of growth factors and nutrients needed for optimal biosynthesis in these 3-D scaffolds was not 
attained using just 0.8ml of medium per scaffold, but additional IGF-1 overexpression by 
transfected cells within the scaffolds stimulated more GAG production. This demonstrates the 
effectiveness of IGF-1 to stimulate GAG production in less than optimal in vitro culture 
conditions. It is speculated that IGF-1 overexpression by transfected cells may also have this 
beneficial effect in vivo where conditions are less controlled. 
Although this study involved the use of cells fi-om one animal, there is reason to believe 
that the major conclusions of this paper will still hold if more experiments are repeated, based on 
other studies involving the use of multiple canines using the same chondrocyte isolation and 
growth conditions presented in these studies. In similar in vitro studies, the coefficient of 
variation between different animals of this specific breed of canine was about 10% (assessing the 
final accumulated GAG values in similar tissue-engineered constructs after 2-weeks in culture). 
This inter-animal variation is smaller than the difference in the present data between 
experimental groups, and therefore the statistically significant differences between the groups in 
this study is most likely a reflection of the varying culture conditions and not from animal to 
animal differences. 
In conclusion, this study demonstrated that the expansion medium used to grow 
chondrocytes has a significant effect on chondrocyte proliferation in monolayer, subsequent 3-D 
culture using type I1 CG matrices, and ex vivo gene transfer. Not only does Medium 2 decrease 
the amount of time it takes to obtain a sufficient number of cells for developing tissue- 
engineered articular cartilage constructs, it also enhances gene transfer kinetics and improves the 
production of matrix molecules and chondrogenesis when cells are seeded within CG scaffolds. 
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CHAPTER 3: GENE-SUPPLEMENTED COLLAGEN- 
GLYCOSAMINOGLYCAN SCAFFOLDS (GSCG) FOR NONVIRAL IGF-1 
GENE DELIVERY IN ARTICULAR CARTILAGE TISSUE 
ENGINEERING 
3.1. INTRODUCTION 
Three-dimensional scaffolds and recombinant growth factors are effective stimulants for 
chondrogenesis and enhanced biosynthesis in articular cartilage tissue engineering. One major 
obstacle in using recombinant proteins for therapeutic delivery in vivo, however, is the inherent 
inability to maintain therapeutic levels of the cytokine for prolonged periods due to their short 
half-lives and the inability to contain the activity in a localized area. A promising alternative for 
a prolonged, localized release of growth factors combines tissue engineering and gene therapy 
strategies where infected cells seeded within tissue engineering scaffolds can express the desired 
proteins over the time course of regeneration. 
Ex vivo gene transfer to cells in two-dimensional (2-D) monolayer culture for subsequent 
transplantation, with or without a three-dimensional (3-D) scaffold, is a common method to 
provide a more prolonged release of desired growth factors for tissue repair, compared to a single 
bolus dose of the recombinant proteins Prolonged expression of the protein from infected 
cells, however, is limited in vivo due to migration of these cells from the defect site or apoptosis. 
An alternative approach that is recently being investigated is a scaffold-based or "substrate- 
mediated" gene transfer approach, in which tissue-engineering scaffolds are used as gene 
delivery vehicles to seeded cells and/or endogenous cells in vivo. This method could provide a 
continual transfection of cells and subsequent protein expression that can be achieved over 
extended periods of time (weeks to months). 
4,7-12 Both viral and nonviral vectors have been employed to provide an elevated 
release of desired proteins fiom infected cells for tissue engineering applications. Although viral 
methods generally have a much higher gene transfer efficiency, especially for slowly dividing or 
non-dividing cells, the inherent immunogenicity of viral vectors commends nonviral methods for 
tissue engineering applications. Furthermore, overexpression of desired proteins in tissue 
engineering applications is needed only through the time period of tissue repair, and therefore 
gene incorporation into the host genome, which is usually associated with viral transductions, is 
not required. Tissue engineering scaffolds incorporating nonviral vectors have the ability to 
localize the concentration of nonviral vector release within the defect area for prolonged times, 
which increases the probability of gene uptake by surrounding cells. Various scaffolding 
materials incorporating nonviral gene vectors that have been shown to provide successll 
prolonged and elevated expression include poly(1actide-co-glycolide) (PLGA) )lo*' '*I3, poly(D,L- 
lactide)-poly(ethyleneg1y col) (PLA-PEG) l, and collagen 7,8,9,12,14 
A local and prolonged administration of insulin-like growth factor (1GF)- 1 could 
substantially enhance cartilage repair, as the IGF-1 recombinant protein has been shown to 
increase chondrocyte proliferation, proteoglycan synthesis, type-I1 collagen synthesis, and 
15-20 chondrogenesis . Although studies have shown effective IGF-1 gene transfer to cells using 
1,4,21 an ex vivo approach for enhancing articular cartilage tissue engineering , there has not yet 
been an investigation demonstrating IGF- 1 gene transfer to cells using a substrate-mediated 
nonviral gene transfer approach using tissue engineering scaffolds. 
In this study, gene-supplemented type 11 collagen-glycosarninoglycan (GAG), GSCG, 
scaffolds were investigated using naked plasmid DNA encoding for the IGF-1 protein, alone or 
with a lipid mediated transfection reagent, Geneporter@. The kinetics of plasmid release 
comparing two different methods of gene supplementation was investigated: 1) soaking the 
scaffold in the plasmid solution followed by freeze-drying, and 2) covalently linking the plasmid 
to the scaffold using a carbodiimide cross-linking agent. It was hypothesized that the first 
method would provide a rapid release of the plasmid and the second a prolonged release, thus 
offering a range for controlling the timing of transfection. 
Adult canine articular chondrocytes were seeded into these scaffolds to assess the ability 
of the GSCG scaffolds to facilitate gene transfer and provide a localized, elevated, and prolonged 
expression of IGF-1. After two weeks in culture, the DNA and accumulated GAG contents were 
assessed by biochemical assays and chondrogenesis assessed by immunohistochemical staining 
for type I1 collagen. The type I1 collagen-GAG (CG) scaffold was used in the current work 
23,24 based on promising prior studies in vitro 22 and in vivo . 
3.2. MATERIALS AND METHODS 
3.2.1. Experimental Design 
GSCG scaffolds incorporating the plasmid for IGF-1 were prepared using 2 methods 
(described in detail in a following section). Specimens were allocated for the evaluation of 
plasmid release kinetics from GSCG scaffolds using a biochemical measurement of DNA, and 
the assessment of the structural integrity of the released and retained plasmid by gel 
electrophoresis. Because of the dramatically different plasmid release kinetics resulting fiom 
leaching studies comparing the two methods of GSCG fabrication, we selected different culture 
conditions (viz., plasmid load and cell seeding density) for evaluating chondrocyte-seeded GSCG 
scaffolds prepared using the two methods. These conditions were based on what we expected 
would be of value for future work in vivo. The goal of the present work was not to perform a 
parametric analysis of the effects of cell seeding density and plasmid load on the transfection of 
cells seeded within the GSCG scaffolds, but rather to determine the nonviral transfection and 
gene expression kinetics that results fiom using the two different incorporation methods with or 
without the addition of a lipid transfection reagent. 
Chondrocyte-seeded GSCG cultures were employed to determine successful transfection 
of seeded chondrocytes by assessing IGF-1 release in the 3-D culture medium using ELISA and 
to determine the effects on biosynthesis by biochemically measuring GAG accumulation in the 
scaffolds over a 2-week culture period. Other samples were allocated for histological evaluation. 
The plasmid containing the gene encoding for the enhanced green fluorescent protein (EGFP) 
was implemented to allow for the imaging of transfected cells seeded within GSCG scaffolds 
using conventional fluorescence and confocal microscopy. Table 3.1 summarizes the 
experimental outline and the allocation of samples used for the aforementioned characterization 
techniques. 
Table 3.1 Experimental Summary for In Vitro Evaluation of 
Gene-Supplemented Collagen-GAG Scaffolds 
3.2.2. Type 11 Collagen- GA G Scaffolds 
Porous sheets of a type I1 CG scaffold were fabricated by freeze-drying a porcine type I1 
collagen-GAG slurry (Geistlich Biomaterials, Wolhusen, Switzerland). Similar scaffolds have 
been reported in prior studies to have a porosity of 89 2% (mean standard deviation) and a 
pore diameter of 125 k 42 pm 25.  The collagen sheets were sterilized and cross-linked by 
dehydrothermal treatment 26, and 8 mm diameter disks (-2 mm thick) were prepared using a 
dermal biopsy punch (Moore Medical, New Britain, CT). 
3.2.3. Plasmid Propagation and Isolation 
Multiplication of plasmids encoding for IGF- 1 (pIGF- 1, obtained from the Center for 
Molecular Orthopedics, Harvard Medical School, Boston, MA) and enhanced green fluorescent 
protein (pEGFP, BD Biosciences, Bedford, MA) was accomplished by heat shock transformation 
into Escherichia coli DH5a competent cells grown overnight in Luria-Bertani (LB) medium 
containing ampicillin and kanamycin, respectively. The pEGFP was used as a reporter gene to 
visualize the transfection of chondrocytes by conventional fluorescence and confocal 
microscopy. Plasmid was isolated and purified using a Mega QIAfilterTM Plasmid kit (Qiagen, 
Valencia, CA). The absorption ratio at 260 nm and 280 nm was used to determine plasmid 
concentration and purity while plasmid integrity was verified by polyacrylamide gel 
electrophoresis. The size of pEGFP was 4.7 Kb, and pIGF-1 was 6-7 Kb. 
3.2.4. Plasmid In corporation into Collagen- GAG (CG) Scaffolds 
Two methods were employed for incorporation of the pIGF-1 into CG scaffolds. 
Method 1 involved additional cross-linking of the DHT-treated scaffolds with a ten-minute 
carbodiimide treatment 27 in an aqueous solution of 14 mM 1 -ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride and 5.5 mM N-hydroxysuccinimide (EDAC; Sigma Chemical Co., 
St. Louis , MO) at room temperature. Excess EDAC was removed by rinsing in phosphate 
buffered saline (PBS). A 250 p1 aliquot of a diluted pIGF-1 solution containing 4 pg of pIGF-1 
(at pH = 8) was added to each scaffold followed by incubation for a minimum of one hour at 
room temperature. This incubation in the plasmid solution allowed swelling of the collagen 
fibrils and absorption of the plasmid solution onto the walls/struts of the scaffold. Scaffolds 
were then freeze-dried to allow collapse of the collagen fibrils and entrapment of the plasmid. 
The second method (Method 2) investigated to synthesize GSCG scaffolds involved 
placing a 60 p1 aliquot of the diluted pIGF- 1 solution containing 10 pg of pIGF- 1 onto the DHT- 
treated scaffolds followed by incubation for an hour at room temperature. A 1 ml aliquot of the 
EDAC cross-linking solution described above was then added to each scaffold and incubated for 
about 30 minutes to allow cross-links to forrn among the collagen molecules and between the 
plasmid and collagen (see schematic in Fig. 3.1 for potential chemical bonds that may form 
between the plasmid DNA and collagen protein molecules). Excess EDAC was removed by 
rinsing the scaffolds in PBS for one hour. Additional GSCG scaffolds incorporating pEGFP 
were prepared using Method 2 for imaging analyses to demonstrate success~l  transfection of 
seeded chondrocytes over time. Control scaffolds were run in parallel and synthesized by 
substituting the plasmid solution with tris disodium ethylenediamine tetraacetate (TE) buffer. 
For cell culture studies, plasmid DNA alone or with a Geneportem (GP) lipid 
transfection reagent (Gene Therapy Systems, Inc, San Diego, CA) was incorporated within CG 
scaffolds using Methods 1 and 2. For the groups incorporating the GP transfection reagent with 
pIGF-1, GenePorterIpIGF-1 complexes were made using a 5: 1 (yllyg) ratio of GP:plasmid and 
was used as the plasmid solution for incorporation within CG scaffolds as described above. 
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Figure 3.1 Potential peptide bonds (dotted arrows) that can form between plasmid DNA and collagen 
proteins during plasmid incorporation within the collagen-GAG scaffold by EDAC cross-linking. 
3.2.5. Plasmid Release from CG Scaffolds and Analysis of Structural Integkty 
GSCG scaffolds synthesized with a 20 vg pIGF-1 load and using the two types of 
incorporation methods described above, were submerged in TE buffer (pH = 8) over a 2-week 
period to investigate the plasmid release kinetics. At selected time points, buffer was collected 
from the samples and the wells were replenished with equal volumes of fiesh buffer. After two 
weeks, GSCG scaffolds were digested overnight using Proteinase K (Roche Diagnostics, 
Indianapolis, IN) at 60 OC to release the plasmid remaining within the scaffolds. Plasmid 
released in the buffer and retained in the scaffolds was quantified by the Picogreen assay 
(Molecular Probes, Inc, Eugene, OR). Aliquots of the released and residual plasmid were 
analyzed by gel electrophoresis for comparison with the stock pIGF-1 used to synthesize the 
GSCG scaffolds. Samples run on the gel were digested with the restriction enzyme, XbaI (New 
England BioLabs, Ipswich, MA) to assess plasmid integrity. 
3.2.6. Transmission Electron Microscopy of GSCG Scaffolds 
Nonseeded Control and GSCG scaffolds (made using Method 2), fixed in glutaraldehyde 
and dehydrated in ethanol, were examined by transmission electron microscopy (TEM). 
Samples were postfixed in osmium tetroxide and embedded in Epon. Images of ultrathin 
sections (-600 nm) of the scaffolds were obtained on a Phillips TEM (FEI EM410) at 80kV. 
3.2.7. Chondrocyte Isolation and Expansion 
Chondrocytes were isolated from the trochleae of both knees (stifle joints) from one adult 
mongrel dog (approximate age 2-4 yrs). The cells were obtained using a sequential digestion of 
pronase (20 Ulml, 1 hr) and collagenase (200 Ulml, overnight) as previously described 28. 
Isolated chondrocytes were expanded in monolayer culture using "Medium 2" described in the 
previous chapter, consisting of high glucose Dulbecco's modified Eagle's medium, DMEM (4.5 
g/L D-glucose, without L-glutamine and with 1mM sodium pyruvate), containing 10% (vlv) fetal 
bovine s e w  (FBS), 0. lmM nonessential amino acids, 10 mM N-2-Hydroxyethylpiperazine-Nt- 
2-ethanesulfonic (HEPES) buffer, 100 UImL penicillin, and 100 pg/mL streptomycin glutamate. 
The medium was supplemented with the following growth factors (all from R&D Systems, 
Minneapolis, MN): 5 ng/mL of fibroblast growth factor-2 (FGF-2), 10 ng/mL of platelet-derived 
growth factor-bb (PDGF-bb), 1 ng/mL of transforming growth factor-p1 (TGF-PI). The cells 
were incubated at 37 "C and 5% C02. Once cells reached confluence, they were trypsinized, 
resuspended, and re-plated to obtain passage (P)1 cells for seeding into the scaffolds. 
3.2.8. Nonviral Gene Transfer in GSCG Scaffolds 
Two separate experiments were carried out to assess the behavior of chondrocytes seeded 
within the GSCG scaffolds. The first experiment used a 4 pg plasmid load per scaffold and 
compared the pIGF-1 treatment with and without the GP reagent prepared using Method 1 (soak 
and freeze-dry method). The second experiment used a 10 pg plasmid load per scaffold and 
compared the two different plasmid solutions using Method 2 (cross-linking the plasmid to 
scaffolds). After GSCG scaffolds were prepared and pre-wet in culture medium, scaffolds were 
dried briefly on sterile filter paper, and placed on agarose-coated 12-well tissue culture plates. 
For the first experiment, 2 million cells were seeded onto each scaffold by pipetting a 20 p1 
suspension containing half of the total amount of cells on each side of the scaffold with a 10 
minute incubation period in between. By this static seeding method approximately 80% of the 
seeded chondrocytes have been found to attach to the scaffolds. For the second experiment, the 
amount of cells seeded on to the scaffolds was increased to 4 million cells per scaffold in order to 
increase the rate of scaffold degradation and facilitate the release of the plasmid cross-linked to 
the collagen fibers. The same pipette seeding method was used in the second experiment. 
Cell-seeded scaffolds were cultured in a defined serum-fiee medium (SFM), found in 
previous work 29 to enhance differentiation. The SFM consisted of high glucose DMEM (4.5 g/L 
D-glucose, without L-glutamine and with 1mM sodium pyruvate), 0.1 mM nonessential amino 
acids, 10 mM HEPES buffer, 100 U/mL penicillin, 100 pg/mL streptomycin glutamate, insulin- 
transferrin-selenium (ITS)" (1 OOx, Sigma Chemical, St. Louis, MO), 0.1 mM ascorbic acid 2- 
phosphate, 1.25 mg/ml bovine serum albumin, 10 ng/mL of TGF-p1, and 100 n M  
dexamethasone. Medium was collected and changed at various time points over a two-week 
culture period to assess the amount of IGF-1 released from transfected cells. 
The amount of IGF-1 in the collected medium (n = 3-6) released from the cell-seeded 
scaffolds was detected by a sandwich ELISA kit for the human IGF-1 protein (R&D Systems, 
Minneapolis, MN). The IGF-1 values were reported as rates of release by dividing by the time 
period since the last media exchange, and as accumulated IGF-1 by summing the values of the 
IGF-1 in the medium samples over time. Cultures were terminated after 2 weeks for histological 
evaluation and biochemical analysis of the DNA and GAG contents of the constructs. For DNA 
and GAG analysis, scaffolds were lyophilized and enzymatically digested using proteinase K 
(Roche Diagnostics, Indianapolis, IN). 
Chondrocytes cultured within scaffolds incorporating pEGFP were observed under 
fluorescence and confocal microscopy at various time points to visualize chondrocyte 
transfection over time. Constructs were placed on a sterile glass bottom petri dish to observe 
under the microscope and then returned to the tissue culture wells containing medium. 
3.2.9. DNA Analysis 
The DNA content of cell-seeded scaffolds was measured using the Picogreen Dye assay 
kit (Molecular Probes, Inc, Eugene, OR) (n = 4). The Picogreen dye was used with the reagents 
and standard provided according to the manufacturer instructions. 
3. 2. 10. GAG Analysis 
The sulfated GAG content of cell-seeded scaffolds after the 2-week culture period was 
determined by the dimethylmethylene blue (DMMB) dye assay 30 (n = 4). An aliquot of the 
proteinase K digest was mixed with the DMMB dye and the absorbance at 525 nm was measured 
with a spectrophotometer. The results were obtained by extrapolating from a standard curve 
using shark chondroitin-6-sulfate. Newly accumulated GAG was determined by subtracting the 
unseeded values fiom the sample values. The GAG content was normalized to the estimated 
volume of the cell-seeded scaffolds; reported as the GAG density. 
3m2mlm Histology and Immunohistochemishy of CellSeededed Scaffolds 
Cell-seeded scaffolds (n = 2-3) were fixed in 10% neutral buffered formalin, dehydrated, 
embedded in paraffin, and center-cut sections (6pm thick) were stained with S a w n - 0  for the 
presence of sulfated GAG. For type I1 collagen immunohistochemical analysis, sections were 
enzymatically digested by protease type XIV for 45 minutes and stained with a standard avidin- 
biotin complex peroxidase-based antibody staining technique (Vectastain, Vector Laboratories, 
Burlingane, CA). Mouse anti-chick monoclonal antibody for type I1 collagen was obtained fiom 
the Developmental Studies Hybridoma Bank (Iowa City, IA). 
3. 2. 12. Statistical Analysis 
Data were analyzed by one- or two-factor analysis of variance (ANOVA), and the 
Fisher's protected least squares differences (PLSD) post-hoc test using StatView (SAS Institute 
Inc, Cary, NC). Data are presented as mean standard error of the mean. 
3.3. RESULTS 
3. 3. 1. I G M  Plasmid Release from GSCG Scaffolds-Release Kinetics and Plasmid Integrity 
There was a dramatic difference in the amount of pIGF-1 initially incorporated into the 
GSCG scaffolds and the plasmid release profiles comparing the two different incorporation 
methods (Fig. 3.2). Approximately 60% of the loaded plasmid (20 pg) was incorporated in 
scaffolds using Method 1 (soak and freeze-dried), whereas, -40% was incorporated using 
Method 2 (cross-linking plasmid to scaffold). GSCG scaffolds synthesized by Method 1, 
however, released most of the incorporated plasmid (-83%) within the first two days of soaking 
in the TE buffer solution. Only 12% of incorporated plasmid remained in the Method 1 scaffolds 
at the end of the 2-week plasmid release study (Fig. 3.2). In contrast, GSCG scaffolds with 
plasmid cross-linked to the scaffold (Method 2) released only minute amounts of plasmid in the 
buffer during the leaching period, resulting in -99% plasmid retention after 2 weeks in buffer 
(Fig. 3.2). 
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Figure 3.2 Plasmid amounts detected in the leaching buffer and remaining in the GSCG scaffolds after 
the 2-week leaching study (scaffolds loaded with 20pg plasmid IGF-1). n = 3; mean SEM. 
Since most of the plasmid from GSCG scaffolds produced with Method 1 was released in 
the buffer, and most of the plasmid incorporated in GSCG scaffolds synthesized using Method 2 
was retained in the scaffolds, plasmid released in the buffer for Method 1 samples and plasmid 
retained in the scaffolds for Method 2 samples were analyzed by gel electrophoresis for 
comparison with the original pIGF-1 stock solution. Fig. 3.3 shows the gel containing the cut 
and uncut IGF-1 plasmid stock solution (columns b and c, respectively); cut and uncut plasmid 
released in the buffer from Method 1 samples (column d and e, respectively); and cut and uncut 
plasmid obtained from digesting the Method Zsynthesized GSCG scaffolds after the two week 
leach period (columns f and e, respectively). The plasmid released in the buffer from the Method 
1-prepared samples and the plasmid retained in the scaffold for the Method 2-prepared samples 
retained similar migration characteristics compared to the IGF- 1 plasmid stock with and without 
restriction enzyme digestion (Fig. 3.3), thus demonstrating that the structural integrity of plasmid 
released Erom and retained in the GSCG scaffolds was maintained. 
Figure 3.3 Gel electrophoresis of 1Kb DNA ladder (a); IGF-1 plasmid stock solution (b) cut and (c) 
uncut; plasmid released from Method 1-synthesized GSCG scaffolds (d) cut and (e) uncut; and plasmid 
retained within Method 2-synthesized GSCG scaffolds after the 2-week leaching study ( f )  cut and (g) uncut. 
Restriction enzyme XbaI was used to cleave the various IGF-1 plasmid samples. 
3.3.2. TEM of Unseeded GSCG Scaffolds 
Transmission electron micrographs of CG scaffolds incorporating pIGF- 1 alone showed a 
thin darker plasmid layer lining the wall of of the scaffold strut (Fig. 3.4a) compared to no 
apparent dark lining in Control samples (Fig. 3.4b). Scaffolds incorporating GPIIGF complexes, 
on the other hand, revealed aggregation of the complexes and showed clusters of particles lining 
the walls of the scaffold struts (Fig. 3.4~). 

Figure 3.4 Transmission electron micrographs of Control (a) and GSCG scaffolds incorporating pIGF- 






w-.q * L 
-s7 
\ 
* *  
5 
--Q@4 
\ .  
~m 
s 
GP/IGF 3.: .. -8. 
# 
complex 
ec lus ters  
.* + P 
I. * 
. . '  0 
. (c) .. - E r n  . 
-

3.3.3. Nonviral Gene Transfer to Chondrocytes Seeded in GSCG Scaffolds 
For GSCG scaffolds synthesized using Method 1, there was no difference in the IGF- 1 
release profiles for scaffolds incorporating naked pIGF-1 alone (IGF group) and the Control 
group (Fig. 3.5a). Incorporation of the GP transfection reagent (GPIIGF group) into the CG 
scaffolds, however, showed significant elevations of IGF-1 release in the medium above the 
controls for all media collections except for the last collection at Day 14 (Fig. 3.5a). The 
GPIIGF group showed a peak in IGF- 1 release rate after about one week in culture (-20 pglhr), 
after which there was a rapid decline fiom Day 11 to Day 14. There was no difference in the 
amount of IGF-1 detected in the Day 14 collection for the GPIIGF group compared to the control 
and IGF groups. After the two-week culture period, the GPIIGF group showed a 7-fold higher 
accumulated IGF-1 level at around 5 ng/ml versus the control and IGF groups at about 0.7 nglml 
(Fig. 3.5b). Two-factor ANOVA showed a significant effect of time (P < 0.01, power = 0.88) 
and type of gene supplementation (P < 0.0001, power = 1) on IGF-1 release. 
GSCG scaffolds synthesized by cross-linking plasmid IGF- 1 to the collagen scaffolds 
with (x-GPIIGF) or without (x-IGF) the transfection reagent (Method 2) resulted in noticeable 
elevated IGF-1 expression levels above the Controls (Fig. 3.5~). Like the GSCG scaffolds 
prepared using Method 1, scaffolds incorporating plasmid IGF-1 complexed to the transfection 
reagent produced significantly higher levels of IGF-1 compared to control scaffolds or scaffolds 
containing plasmid IGF- 1 alone (Fig. 3.5~).  Scaffolds containing the GP reagent and prepared 
using Method 2 (x-GPIIGF group) showed a significant increase in IGF-1 release rate between 
the first two collection time points, followed by a steady release between collections 2 and 4, and 
finally a rise in the IGF- 1 release rate to about 14 pg/hr at the end of the 2-week culture period 
(Fig. 3.5~). There were 4.5-fold and 14.5-fold higher accumulated IGF- 1 levels for the x- 
GPIIGF group compared to the x-IGF and Control groups, respectively (Fig. 3.5d). Two-factor 
ANOVA revealed a significant effect of time (P < 0.0001, power = 1) and type of gene 
supplementation (P<0.000 1, power=l) on IGF- 1 release from cell-seeded GSCG scaffolds 
fabricated using Method 2. 
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Figure 3.5 IGF-1 release rates (a, c) and accumulated IGF-1 (b, d) detected in the serum-free medium 
over the 2-week 3-D culture period from GSCG scaffolds synthesized using Method 1 (a, b), n = 3 and 
Method 2 (c, d), n = 6. mean + SEM. 
GFP expression in chondrocytes seeded within scaffolds supplemented with pEGFP with 
or without the transfection reagent using Method 2 was observed with fluorescence (Fig. 3.6a-c) 
and confocal microscopy (Fig. 3.6d). After 5 days in culture, chondrocytes seeded in Control 
scaffolds (no plasmid) did not show any evidence of GFP expression (Fig. 3.6a). Chondrocytes 
seeded in scaffolds supplemented with pEGFP alone (Fig. 3.6b) or with the GP transfection 
reagent (Fig. 3 .6~)  displayed evidence of transfection, with a significantly higher number of cells 
fluorescing in scaffolds incorporating the plasmid with the transfection reagent. Evidence of 
continued transfection (i.e. presence of fluorescing cells in the scaffold) was still apparent up to 2 
months in the scaffolds. Confocal microscopy of GSCG scaffolds containing the 
plasmid/transfection reagent complex seven days after seeding showed that only a small 
percentage of cells in the scaffold were transfected at that time point (Fig. 3.6d). 
Figure 3.6 Fluorescent microscopy images of GSCG scaffolds synthesized using method 2 (a) without 
any supplementation (control), (b) with incorporation of pEGFP alone, and (c) with incorporation of pEGFP 
and the GenePorter @ transfection reagent after 5 days in 3-D culture. Confocal image of GSCG scaffold 
incorporating pEGF'P and the GenePorter @ transfection reagent using Method 2, after 7 days in culture (d). 
3.3.4. Biochemical Analysk of Cell-Seded GSCG Scaffolds 
Control scaffolds and scaffolds incorporating IGF-1 plasmid alone synthesized using 
Method 1 were similar in DNA content after two weeks in culture with -1 0 pg DNAIscaffold 
(Fig. 3.7a). For the GPIIGF group created using Method 1, however, the DNA content was 
significantly lower, at about half the amount of DNA found in the IGF and Control groups (Fig. 
3.7a). In contrast, GSCG scaffolds incorporating plasmid IGF- 1 with the transfection reagent 
using Method 2 showed a 25% higher DNA content (-21 pg/scaffold) compared to the x-IGF 
and Control scaffolds (Fig. 3.7b). One-factor ANOVA showed a significant difference between 

the GPIIGF group versus the IGF or Control groups (P < 0.0001, power = 1) and the x-GP/IGF 
group versus the x-IGF or Control groups (P < 0.0001, power = 1). 
There was no significant difference in the accumulated GAG densities at the end of the 2- 
week culture period for Method 1-synthesized GSCG scaffolds and its controls, with GAG 
densities of about 1 p g / ~ m 3  for all groups (Fig. 3.7~). For Method Zsynthesized scaffolds, there 
was a significant elevation (-2-fold increase) in accumulated GAG density in the GSCG samples 
compared to the Controls (P < 0.03, power = 0.7). There was no significant difference in 
accumulated GAG density between the x-IGF and x-GP/IGF groups (Fig. 3.7d). 
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Figure 3.7 DNA contents (a, b) and accumulated GAG densities (c, d) measured at the end of the 2- 
week 3-D culture period in GSCG scaffolds synthesized using Method 1 (a, c) and Method 2 (b, d). n = 3-4; 
mean SEM. 
3.3.5. Histology and Immunohistochemistry of 3-D Cultures 
Histochemical results for the Controls and Method 1-synthesized GSCG scaffolds (with 
or without the transfection reagent) were all similar with regard to the amount of tissue 
formation, Safianin-0 staining, and type I1 collagen staining. Most of the cells in these scaffolds 
were elongated fibroblast-like cells with evidence of some tissue formation in the pores. There 
was very little staining for GAG (Fig. 3.8a and c) or collagen type I1 (Fig. 3.8b and d) in the 
synthesized tissue and a significant amount of the scaffold was still present after the 2-week 
culture period. 
Scaffolds prepared in the experiment using Method 2 to synthesize GSCG constructs, on 
the other hand, showed a greater amount of tissue formation even for Control scaffolds (Figs. 3.9 
and 3.10). For all groups in this experiment, there were some cells present in the constructs that 
displayed a rounded chondrocytic morphology and were located in lacunae (see arrows in Fig. 
3.10). The x-IGF and the x-GPAGF groups showed more tissue formation, GAG staining and 
collagen type I1 staining compared to the Control group (Figs. 3.9 and 3.10). For the Control and 
x-IGF groups, more tissue formation was present at the outer faces of the constructs. The x- 
GPAGF group showed the most tissue formation throughout the whole construct, number of cells 
with chondrocyte-like features, Safranin-0 staining, and type I1 collagen staining (Figs. 3.9e and 
f; 3.10e and f )  compared to the other groups. There was still evidence of the collagen scaffold 
still present for all groups (stained green in Fig. 3.9) after 2-weeks in 3-D culture. 
Areas of histological sections that stained for GAG generally seemed to correlate with the 
areas that stained for type 11 collagen (Figs. 3.9 and 3. lo), with more intense staining for GAG 
and type I1 collagen in areas with greater tissue synthesis. Within these areas, there was also a 
smaller amount of residual scaffold (indicating a greater degree of scaffold degradation), a higher 
cell density, and more cells displaying a chondrocytic phenotype (Figs. 3.9 and 3.10). 
Figure 3.8 Typical Safranin-0 stain for GAG (a, c) and immunohistochemical stain for type I1 collagen 
(b, d) from chondrocyte-seeded Control scaffolds and GSCG scaffolds synthesized using Method 1 (with or 
without the GP reagent) after the 2-week culture period. 2 million cells per scaffold were seeded onto the 
scaffolds. Red is a positive stain for the presence of GAG and brown is a positive stain for the presence of 
type I1 collagen. 

Figure 3.9 Safranin-0 stain for GAG (red is positive stain) of scaffolds synthesized using Method 2 for 
Controls (a, b) and GSCG scaffolds incorporating IGF-1 plasmid alone (c, d) or the GPAGF complexes (e, f )  
after 2-weeks in 3-D culture. 4 million cells were seeded onto the scaffolds. 

Rgure 3.10 Immunohistochemical stain for collagen type I1 (brown is positive stain) of scaffolds 
synthesized using Method 2 for Controls (a, b) and GSCG scaffolds incorporating plasmid IGF-1 alone (c, d) 
or the GP/IGF complexes (e, f) after 2-weeks in 3-D culture. 4 million cells were seeded onto the scaffolds. 

3.4. DISCUSSION 
A notable finding of this study was that covalently linking as little as 10 pg of plasmid 
DNA to a type I1 collagen-GAG scaffold can result in the prolonged overexpression of the 
encoding growth factor, thus allowing (nonviral) gene transfer to be successfully combined with 
tissue engineering principles. Prior work using naked plasmid DNA incorporated within 
scaffolds have also demonstrated elevated levels of encoded protein production, but most of 
these studies required the use of significantly higher plasmid loads 7,31-35 (on the order of 
milligram levels per scaffold) compared to the current study. Control over plasmid release rates 
from GSCG scaffolds and incorporating a lipid transfection reagent (compared to the use of 
naked plasmid DNA alone) significantly improved prolonged expression and increased gene 
transfer to seeded cells. 
The kinetics of IGF-1 plasmid release fkom these scaffolds can be modified using 
different incorporation methods. Two approaches were investigated to synthesize GSCG 
scaffolds and resulted in a dramatic variation in plasmid release kinetics over a 2-week leaching 
study. Plasmid incorporation by submerging scaffolds in a plasmid solution followed by a 
freeze-drying step resulted in a faster release of plasmid DNA, with about 82% of incorporated 
plasmid released within the first two days in buffer. It is likely that this passive release was due 
to the weak mechanical entrapment of the plasmid between the collagen fibrils, which resulted 
from the swelling and collapsing of the collagen fibrils during the supplementation and 
subsequent freeze-drying procedure. Once these scaffolds were re-hydrated in solution, the 
collagen fibrils swelled again and released the entrapped plasmid at a rate that was dependent on 
collagen swelling and diffusion kinetics. The 12% plasmid retained in these GSCG scaffolds 
after the 2-week culture may have been due to plasmid that was more securely entangled within 
the collagen network, and which would only be released upon scaffold degradation. Chemically 
cross-linking the plasmid to the scaffold, on the other hand, resulted in 99% retention of 
incorporated plasmid in the scaffold after the 2-week leach study. Although only 40% of loaded 
plasmid was actually incorporated into the scaffold using this procedure (as opposed to 60% 
incorporation with Method I), the fact that most of the plasmid resisted passive release and 
remained within the scaffold commends this method of supplementation for prolonged release. 
In this case, incorporated plasmid would only be released upon scaffold degradation, and 
therefore transfection and subsequent gene expression could occur as long as residual scaffold 
remains over the time course of tissue repair. Of importance was that the integrity and 
functionality of the pIGF-1 released in buffer or remaining in GSCG constructs was preserved, 
indicating that the plasmid structure was not significantly altered by the interaction with the 
collagen scaffold. 
The kinetics of plasmid release fiom GSCG scaffolds had a direct effect on the amount 
and kinetics of IGF-1 protein synthesized by seeded and subsequently transfected chondrocytes. 
Interestingly, chondrocytes placed in a scaffold without any plasmid supplementation also 
showed production of IGF-1 that was released in the medium after about one week in 3-D 
culture, albeit in very low amounts. This IGF- 1 expression by non-transfected chondrocytes may 
have been stimulated by the cellular interaction with the type I1 collagen-GAG scaffold. For 
Method 1-synthesized scaffolds where most of the incorporated plasmid was released within the 
first 2 days in solution, there was no overexpression of IGF- 1 over the controls for scaffolds 
containing naked plasmid IGF-1 alone. With the transfection reagent, there was a significant 
elevation of IGF-1 detected in the medium over control scaffolds, however, IGF-1 release rates 
reached a maximum after about a week and then declined to control levels at the end of the 2- 
week culture period. This peak and decline in IGF-1 release may indicate that transfection of the 
seeded cells may have only occurred near the beginning of the culture period. The decline to 
control IGF-1 levels at the end of the 2-week period was evidence that GPIIGF complexes most 
likely were no longer present in the scaffold at the end of the two week culture period, and that 
the transient expression of earlier transfected cells had faded. 
Unlike GSCG scaffolds made using Method 1, scaffolds created by cross-linking naked 
plasmid IGF- 1 alone demonstrated noticeable elevations in IGF- 1 released in the medium over 
controls. As opposed to a fast release of plasmid only at the beginning of the culture period as 
displayed by Method 1-synthesized GSCG scaffolds, it is speculated that cross-linking the 
plasmid alone to the collagen scaffold (x-IGF group) may have allowed for a continued presence 
and concentration of plasmid as the scaffold was degraded by the seeded cells. This prolonged 
concentration of plasmid may have increased the probability of cellular uptake of the plasmid 
leading to subsequent gene expression. Cells seeded in GSCG scaffolds incorporating both the 
plasmid and transfection reagent using Method 2 resulted in increased release rates up to one 
week, followed by a steady release of IGF- 1, and finally a spike in the IGF- 1 release rate within 
the last 2 days of the 2-week culture. This IGF-1 release profile may indicate the continued 
transfection of seeded cells throughout the culture period (and further on) as the scaffold 
degrades. It is important to note that the actual levels of IGF-1 localized within the scaffold 
could be significantly higher than the concentrations detected in the medium. Future work will 
need to investigate methods to quantify IGF-1 produced by transfected cells that is retained 
within the scaffold in order to determine the minimum local therapeutic concentration required 
for enhanced biosynthesis. 
Visual evidence of prolonged gene expression using GSCG scaffolds was demonstrated 
by incorporating the EGFP gene using Method 2. The presence of fluorescing cells within 
GSCG scaffolds, resulting from successful gene transfection, continued up to about 2 months in 
3-D culture. Although confocal imaging demonstrated that only a small percentage of cells 
showed gene expression at any given time-point, a high transfection efficiency may not be 
required to produced local therapeutic levels of desired growth factors. These findings prove 
that not only can these GSCG scaffolds maintain both plasmid integrity and functionality, but 
they can also facilitate gene transfer to seeded cells resulting in prolonged and elevated gene 
expression. 
Of interest is the effect of the plasmid and the lipid transfection reagent on the resulting 
cell number (reflected in the DNA measurements) at the end of the 2-week culture period. Of 
note is the lower DNA content for the GP/IGF group in the Method-1 prepared scaffolds and the 
elevated DNA content for the x-GP/IGF group in the Method-2-fabricated GSCG scaffolds. 
These results seem to indicate that supplementing collagen scaffolds with the GPIIGF complexes 
using Method 1 may interfere with initial cell attachment. It is speculated that the lipidplasmid 
complexes may have coated the walls of the collagen scaffold, which could have masked some 
of the ligands present on the collagen fibrils preventing integrin-mediated cellular attachment 
directly to the scaffold walls. Cells that were seeded onto these scaffolds may have effectively 
associated with the lipidplasmid "coating" but then could have become detached once the 
collagen fibrils swelled and released the weakly attached complexes. On the other hand, 
chemical cross-linking these lipid/plasmid complexes to the collagen scaffold may still have 
resulted in the association of cells with the lipidplasmid complexes incorporated into the 
scaffold, but detachment of cells could have been prevented due to the stronger chemical bond 
between the lipid/plasmid complexes and the collagen fibrils. Future work using electron 
microscopy may be needed to further understand the cellular interactions with these GSCG 
scaffolds. 
Although the DNA content that was measured in the scaffolds may have included the 
plasmid remaining fkom gene supplementation of the scaffolds as well as the nuclear material 
from the cells, measurements of plasmid DNA loaded into GSCG scaffolds with the transfection 
reagent (data not presented) showed that when plasmid was complexed to the transfection 
reagent it could not be detected by the Picogreen assay. The presence and retention of the 
GP/IGF complexes within the scaffolds was indirectly determined through hctional assays (i.e., 
gene expression of IGF- 1 or GFP proteins), which did indicate that plasmid was present within 
the scaffolds. It is speculated that the lipid transfection reagent may have prevented the 
Picogreen dye fkom interacting with the plasmid DNA, leading to the lack of detection. The 
majority of the DNA content reported for the GSCG groups that incorporated the GP/IGF 
complexes, therefore, was most likely a reflection of the number of cells present at the end of the 
2-week culture period. 
The effect of IGF-1 overexpression of cells seeded in GSCG scaffolds on biosynthesis 
was assessed by the accumulated GAG density amounts and histochemical analysis after 2- 
weeks in 3-D culture. For scaffolds synthesized by Method 1, there was no significant difference 
among the three groups with regard to accumulated GAG density and histochemical staining. 
All of these scaffolds showed minimal staining, if any, for Safianin-0 or type I1 collagen. 
GSCG scaffolds synthesized by Method 2, however, showed a much higher amount of tissue 
formation, more GAG synthesis, and the presence of type I1 collagen, even for the controls, 
compared to scaffolds fabricated with Method 1. This difference in histogenesis may have been 
due to an insufficient cell-seeding density used in the Method 1-synthesized scaffolds (2 million 
cells/scaffold). Even though IGF-1 was significantly elevated in the GPIIGF group, its effects on 
biosynthesis and chondrogenesis may not have been apparent if the cell number was not high 
enough to result in a measurable difference in tissue formation. Prior studies 36y37 have 
demonstrated the importance of cell density on biosynthesis and chondrogenesis in 3-D culture. 
Future work needs to investigate if increasing the cell seeding number in GSCG scaffolds 
supplemented using Method 1 will show the effect of IGF-1 overexpression on biosynthesis and 
chondrogenesis. 
In contrast to the experiment using the Method 1-prepared scaffolds, there was a 
noticeable difference in tissue formation among the groups in the cultures using the cross-linking 
method of gene-supplementation. In this study, 4 million cells were seeded per scaffold. The 
effect of elevated IGF-1 levels over the control group for the x-IGF and x-GPAGF groups was 
reflected in the higher accumulated GAG densities. Both of the groups with plasmid 
supplementation showed an almost two-fold increase in accumulated GAG density over controls. 
Although there was a slightly higher GAG density for the x-GPAGF group over the x-IGF group, 
this difference was not significant. The difference in GAG synthesis was more apparent in the 
histological staining for Safkanin-0, where most tissue formation and GAG synthesis was 
present in the x-GPIIGF group. Scaffolds incorporating plasmid IGF- 1 with the transfection 
reagent also showed the most collagen type I1 staining and the highest number of cells located in 
lacunae and displaying a rounded chondrocyte-like morphology. The x-IGF group also 
displayed a greater degree of histogenesis, GAG synthesis, and type I1 staining compared to the 
Control group. Of note in the histological results is the association among cell density, degree of 
scaffold degradation, and amount of tissue formation and chondrogenesis. These findings 
demonstrate that IGF-1 overexpression by cells transfected when seeded within GSCG scaffolds 
can result in enhanced biosynthesis and chondrogenesis. 
In conclusion, a more prolonged release of plasmid from GSCG scaffolds can be 
successf~lly accomplished by covalently linking the plasmid to the CG scaffold with a 
carbodiimide cross-linking treatment. The kinetics of IGF-1 plasmid release has a direct effect 
on gene expression and IGF-1 release over time from adult canine articular chondrocytes seeded 
within GSCG scaffolds. Furthermore, incorporating a lipid transfection reagent in conjunction 
with the plasmid DNA significantly increases gene transfer and subsequent protein synthesis. A 
local, elevated, and prolonged overexpression of IGF-1 by transfected cells seeded within GSCG 
scaffolds (with or without a transfection reagent) can result in enhanced cartilage formation. 
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CHAPTER 4: DELIVERY OF PLASMID IGF-1 TO CHONDROCYTES 
VIA CATIONIZED GELATIN NANOPARTICLES 
4.1. INTRODUCTION 
It has become increasingly clear that a number of tissue engineering applications would 
benefit from the administration of selected growth factors in conjunction with a biomaterial 
scaffold One approach being investigated for prolonged overexpression of growth factors by 
cells in vivo is the incorporation of gene vectors into 3-D scaffolds 5-7. In an effort to implement 
the safest methodology for wedding gene therapy and tissue engineering, several studies have 
focused on the incorporation of non-viral vectors directly into the scaffold 8y9. An alternative 
approach is to encapsulate plasmid DNA containing the gene encoding for the selected growth 
factor into nanoparticles, which can be injected or implanted along with or bound to a scaffold 
prior to its implantation. The benefit to using nanoparticles as gene delivery vehicles is the 
capability to easily direct and control gene expression kinetics by altering various processing 
parameters used to make nanoparticles. A wide army of materials are undergoing investigation 
as nanoparticle delivery vehicles for plasmid DNA. Because our own work has employed 
collagen-based scaffolds '03' ', we were prompted to investigate gelatin nanoparticles for this 
application. Gelatin, the water-soluble molecular chain resulting from the heat dissolution and 
partial hydrolysis of collagen, has been investigated for the production of nanoparticles for drug 
delivery for almost three decades 12.13. 
While gelatin nanoparticles were initially introduced as carriers for small molecular 
14,15 weight drugs, they were later investigated as carriers for peptides 16. More recently gelatin 
nanoparticles have been studied as delivery vehicles for DNA 17-19. Issues related to the use of 
gelatin nanoparticles for these applications include size distribution 19, charge 20, stability, and 
reproducibility. Methods for producing gelatin nanoparticles 2' include solvent evaporation 
techniques 22, water-in-oil emulsion 23324, complex coacervation 17, and an emulsifier-fiee 
emulsion method 16. While all of these methods can be employed to incorporate small molecules 
into gelatin nanoparticles, a few are particularly useful for incorporating large molecules such as 
plasmid DNA. The advantage of complex coacervation, which is the separation caused by 
interaction of two oppositely charged colloids, is that it is simple and quick, and leads to the 
condensation of plasmid DNA 17. 
Gelatin is ideal for nanoparticle formation due to its versatility to be chemically modified 
and cross-linked to meet specific controlled release needs. In one case, thiolated gelatin 
nanoparticles were developed to release the incorporated molecules in a highly reducing 
environment ". In other studies, DNA-containing poly(ethy1ene glycol)-modified (PEGylated) 
gelatin nanoparticles were synthesized in order to develop systemically administered non-viral 
gene therapy vectors for solid tumors 26y27. Still other applications benefited fiom the 
modification of the surface of gelatin nanoparticles by covalent attachment of biotin-binding 
proteins, enabling the binding of biotinylated drug targeting ligands by avidin-biotin-complex 
28-30 formation . Antibody modified gelatin nanoparticles have also been used as drug carrier 
systems to target nanoparticles to specific cell types 31. Of particular interest is the modification 
of the charge (increased positivity) of gelatin by cationization 19. Cationized gelatin 
nanoparticles have been used for a myriad of applications 18~32-35 that benefit from the increased 
positive charge on the gelatin nanoparticles. As delivery vehicles for plasmid DNA, positively 
charged gelatin nanoparticles could be capable of condensing DNA and favoring interactions 
with the negatively charged cell membrane to facilitate endocytosis. 
The objective of the present study was to investigate the use of gelatin nanoparticles for 
non-viral delivery of plasmid DNA encoding for insulin-like growth factor (1GF)-1 into adult 
articular chondrocytes in vitro. The ultimate goal would be to use such nanoparticles along with 
or incorporated into collagen scaffolds loyl for cartilage tissue engineering. IGF- 1 was 
implemented in the study on the basis of prior in vitro and in vivo studies that have demonstrated 
its favorable effects on chondrogenesis. Supplementation of culture medium with IGF-1 alone 
has been shown to increase cell proliferation, proteoglycan synthesis, type-I1 collagen synthesis, 
and chondrogenesis, both in monolayer and in three-dimensional cultures 36-41. In addition, the 
combination of IGF-1 and osteogenic protein (0P)- 1 promotes increased survival of and matrix 
synthesis by normal and osteoarthritic human articular chondrocytes 42. In vivo, fibrin polymers 
laden with IGF-1 resulted in improved histologic appearance and increased proportion of type I1 
collagen in full-thickness cartilage defects in young mature horses 43. Moreover, ex vivo gene 
transfer of a human IGF-1 cDNA into chondrocytes was found to enhance cartilage tissue 
engineering both in vitro " and in vivo 45. 
4.2. MATERIALS AND METHODS 
4.2.1. Preparation of Cationized Gelatin 
Gelatin (porcine skin; G2625, Sigma-Aldrich, Inc., St. Louis, MO) was chemically 
33-35 
modified by grafting amino groups to carboxyl groups as previously reported using a 
carbodiimide chemical treatment: 
EDAC 0 I I 
R-COO- + NH3-NH3 r-b R-C- NH-NH,+ 
Briefly, 2.5 g gelatin was dissolved in 0.1 M phosphate-buffered solution (pH 5.0), to which 
were added 7.9 ml ethylenediamine (Sigma-Aldrich, Inc.) and 1.34 g 1 -ethyl-3-(3- 
dimethylaminopropyl) carbodiimide hydrochloride, EDAC (Sigma-Aldrich, Inc.). The pH was 
immediately adjusted to 5.0 with 5-6 N hydrochloric acid. The mixture was stirred at room 
temperature for 16- 18 hours, dialyzed for 48 hours in distilled water, and then fieeze-dried to 
obtain the cationized gelatin. 
4.2.2. Preparation of Plasmid DNA 
The plasmids encoding for IGF- 1 (pIGF-1) and enhanced green fluorescent protein 
(pEGFP) were amplified in Escherichia coli host strain DHSa, and purified by column 
chromatography with the QIAfilter plasmid Mega kit (QIAGEN 1nc.-USA, Valencia, CA) 
according to the manufacturer's protocol. The plasmid for EGFP was used as a reporter gene to 
visualize the transfection of chondrocytes by fluorescence microscopy. The antibiotics used to 
select pIGF- 1 and pEGFP transformed cells were ampicilin and kanamycin, respectively. The 
size of the pEGFP was 4.7 Kb and the pIGF-1 was between 6 and 7 Kb in size. The yield, 
purity, and integrity of the prepared plasmids were evaluated with an ultraviolet 
spectrophotometer and by gel electrophoresis. 
4.2.3. Incorporation of Plasmid IGF-1 into Cationized Gelatin Nanoparticles 
Cationized gelatin-plasmid IGF- 1 nanoparticles (CGPIN) were prepared by complex 
coacervation, in which separation is caused by the interaction of two oppositely charged colloids. 
The cationized gelatin stock solution (80 mg/ml) was made by dissolving 0.24 g cationized 
gelatin in 3 ml distilled water. The solution was then filtered (pore size = 22 pm) for 
sterilization. Working solutions with different cationized gelatin concentrations were diluted 
with sterilized water. The pIGF-1 and pEGFP working solutions (200 pglml) were prepared 
with sterile filtered 50 mM sodium sulfate (Fisher Scientific, Hampton, NH). Aliquots (100-1 50 
pl) of the cationized gelatin and pIGF-1 or pEGFP solutions were heated separately at 55OC for 
30-45 min. Equal volumes of the solutions were quickly mixed and vortexed for 60 sec. 
Nanoparticles, which were prepared with either the pIGF-1 or the pEGFP, were used without 
further purification. The nanoparticles containing pEGFP were prepared with cationized gelatin 
using a ge1atin:plasmid weight ratio of 250: 1 whereas a variety of ratios were investigated when 
making nanoparticles encapsulating pIGF-1. As a control group, nanoparticles were also 
synthesized using the original (non-cationized) gelatin material. 
4.2. 4. Environmental Scanning Electron Mirroscopy 
Environmental scanning electron microscopy (ESEM, XL30, FEIPhilips, Hillsboro, OR) 
was used to investigate the size and shape of the nanoparticles. Samples were prepared by 
placing 1 pl of the nanoparticle suspension onto glass slides and air drying. The air-dried 
samples were then observed directly under ESEM, without the need to coat the samples with a 
conducting layer as required for conventional SEM. 
4. 2.5. Determination of Nanoparticle Size Distribution 
The particle size distribution was determined by a dynamic light scattering technique, 
performed at 25OC using a Brookhaven 200SM goniometer, a BI-9000AT digital auto-correlator, 
and Spectra-Physics Argon laser operating at 5 14 nm (Brookhaven Instruments Corporation, 
Holtsville, NY). The measured scattering intensities were analyzed by software provided by 
Brookhaven. 
4.2.6. Zeta Potential 
The zeta potential of the nanoparticles, with different weight ratios of gelatin to plasmid 
were measured with a Brookhaven Zeta Plus apparatus (Brookhaven Instruments Corporation). 
The electrophoretic mobility was determined at 25OC, and the zeta potential calculated. 
4* 2.7. Gene Transfer to Adult Articular Chondrocytes in Monolayer Using Gelatin 
Nanoparticles Incorporating pEGFP andpIGF-1 
Chondrocytes were isolated from the trochleae of both knees (stifle joints) from one adult 
mongrel dog (approximate age 2-4 yrs) using a sequential digestion of pronase (20 Ulml, 1 hr) 
and collagenase (200 Ulml, overnight). The cells were expanded in number in monolayer culture 
with medium containing Dulbecco's modified Eagle's medium (DMEM, high glucose 4.5% 
without L-glutamine), 0.1 mM nonessential amino acids, 1 OmM N-2-Hydroxyethylpiperazine-N'- 
2-ethanesulfonic (HEPES) buffer, 100 UIrnL penicillin, 100pgImL streptomycin glutamate, 10% 
FBS (Invitrogen Corporation, Carlsbad, CA), and a mixture of the following growth factors 
(R&D Systems, Minneapolis, MN): TGF-p1 (1 ng/ml), FGF-2 (5 nglml) and PDGF-bb (10 
nglml). At confluence, cells were trypsinized and either plated onto glass bottom microwell 
dishes (MatTek Corporation, Ashland, MA) for transfection with nanoparticles incorporating 
pEGFP or into 24-well tissue culture plates for transfection with nanoparticles incorporating 
pIGF- 1. Passage 0 cells were seeded in both types of dishes at a density of 5x1 o4 cells per well 
(density of 30,000 cellslcm2) and were allowed to expand overnight to about 80-90% confluence 
(about 100,000 cells) before transfection. 
For transfection with gelatin nanoparticles incorporating either plasmid, the medium was 
removed and replaced with a 250 pl suspension of nanoparticles diluted in a serum-free medium. 
The serum-free medium consisted of DMEM (high glucose 4.5% without L-glutamine), 0.1 mM 
nonessential amino acids, 10 mM HEPES buffer, 100 UImL penicillin, 100 pg/mL streptomycin 
glutamate, ITS" (loox, by Sigma Chemical, St. Louis, MO), 0. lmM ascorbic acid 2-phosphate, 
1.25 mglml bovine serum albumin, 10 ng/mL of TGF-B 1, and 100 nM dexamethasone. Five 
hours later, the nanoparticle solution was removed and replaced with fi-esh serum-free medium 
(500 ullwell) that did not contain nanoparticles. Based on an average nanoparticle diameter and 
a gelatin density of about 1 glml, we estimated that the number of nanoparticles added to the 
monolayer chondrocytes was on the order of 1012. Assuming that the cultures to which the 
nanoparticles were added contained approximately 100,000 cells, the number of nanoparticles 
per cell was estimated to be lo7. 
Monolayers that were treated with cationized gelatin nanoparticles incorporating pEGFP 
at a weight ratio of 250: 1 and a plasmid amount of 10 pg per well were examined by transmitted 
fluorescence microscopy 48 hours after transfection in order to visualize successfbl gene transfer 
to cells using these nanoparticles. 
4D2D8D IGF-I Expression as a Function of Plasmid Loading in the Nanoparticles 
For IGF- 1 transfected monolayers, the effects of cationized ge1atin:IGF- 1 ratio and 
plasmid amount added to each well were investigated. Five different cationized ge1atin:IGF-1 
ratios were investigated (by weight): 150: 1,200: 1,250: 1,300: 1, and 400: 1. For these groups, a 
constant plasmid load of 10 pg per well was used. In experiments in which plasmid amount was 
the main variable, the five different plasmid amounts used were 2,5, 8, 10, and 12 pg of plasmid 
per well, at a constant cationized gelatin to pIGF-1 weight ratio of 250: 1. Control conditions 
consisted of pIGF- 1 only (10 pg) or no treatment (just added serum free medium). Nanoparticles 
synthesized using unmodified (original) gelatin at a ge1atin:IGF-1 ratio of 250: 1 was also 
included as an experimental condition to deterimine the effect of cationization on nanoparticle 
characteristics and transfectibility. The serum-fiee medium £iom IGF-1 transfected cultures was 
collected at 144 hrs after transfection and assessed for the presence of IGF- 1 protein (n = 4) with 
a human IGF-1 sandwich ELISA kit (R&D Systems, Minneapolis, MN). 
4.2.9. Collagen-GAG (CG) Scaffolds Seeded with Monolayer Transfected Chondrocytes 
Porous sheets of type I1 collagen were fabricated by freeze-drying a porcine cartilage- 
derived slurry (Geistlich Biomaterials, Wolhusen, Switzerland). The collagen sheets were 
sterilized and cross-linked dehydrothermally by placing the sheets in a vaccum oven at 105 OC 
for 24 hours. Nine-mm diameter disks (-2mm thick) were punched out using a dermal punch 
(Moore Medical, New Britain, CA) and additionally cross-linked by a 10 minute carbodiimide 
treatment containing an aqueous solution of 14 mM 1 -ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride and 5.5 mM N-hydroxysuccinimide (EDAC; Sigma Chemical Co., 
St. Louis , MO). Excess EDAC was removed by rinsing in PBS. 
Using CGPIN synthesized with a ge1atin:plasmid weight ratio of 250: 1, chondrocyte 
monolayers were transfected and subsequently seeded in CG scaffolds approximately 24 hours 
after transfection to assess the duration of IGF-1 overexpression in 3-D culture and the effects 
on biosynthesis. Four million transfected cells were seeded onto each scaffold by pipetting a 20 
pl suspension containing half of the total amount of cells on each side of the scaffold with a 10 
minute incubation period in between. By this static seeding method approximately 80% of the 
seeded chondrocytes have been found to attach to the scaffolds. Cell-seeded scaffolds were 
cultured in the serum-fiee medium described above. Medium was collected and changed every 
2-3 days over a 14-day culture period. The amount of IGF-1 in the medium (n = 6) was detected 
by a sandwich ELISA kit for the human IGF-1 protein (R&D Systems). Cultures were 
terminated after 2 weeks and scaffolds were lyophilized and enzymatically digested using 
proteinase K (Roche Diagnostics, Indianapolis, IN) for DNA and GAG biochemical analysis. 
4.2. 10. DNA Analysis 
The DNA content of cell-seeded scaffolds was measured using the Picogreen Dye assay 
kit (Molecular Probes, Inc, Eugene, OR) (n = 4-6). The Picogreen dye was used with the 
reagents and standard provided according to the manufacturer instructions. 
4.2.11. GAG Analysis 
The sulfated GAG content of cell-seeded scaffolds was determined by the 
dimethylmethylene blue (DMMB) dye assay 46 (n = 4-6). An aliquot of the proteinase K digest 
was mixed with the DMMB dye and the absorbance at 525 nm was measured with a 
spectrophotometer. The results were obtained by extrapolating fiom a standard curve using 
shark chondroitin-6-sulfate. Newly accumulated GAG was determined by subtracting the 
unseeded values from the sample values. 
4a2m12m Statistical Analyses 
Data were analyzed by one or two-factor analysis of variance (ANOVA), and the Fisher's 
protected least squares differences (PLSD) post-hoc tests to determine the significance in the 
difference between selected groups using StatView (SAS Institute Inc, Cary, NC). Data are 
presented as mean * standard error of the mean. 
4.3. RESULTS 
4.3. 1. Morplr ology of the Cationized Gelatin-pIGF-1 Nanoparficles 
ESEM (Fig. 4.1) revealed different sizes and morphologies of the pIGF-1-containing 
nanoparticles prepared with cationized gelatin versus regular gelatin (using the same 
ge1atin:plasmid weight ratio of 250: 1). The cationized gelatin nanoparticles (Fig. 4. la  and b) 
generally appeared to be of spherical shape less than 200 nm in diameter. In contrast, the 
original gelatin formed micro-scale particles with spherical and ellipsoid shapes (Fig. 4. lc  and 
d), with the average diameter (and long axis) appearing to be from 10 pm to greater than 20 pm. 
For both the cationized and non-cationized ge1atin:plasmid preparations, the nanoparticles and 
microparticles, respectively, generally appeared to be of uniform size. 
4.3.2. Particle Size Distribution 
Dynamic light scattering revealed that the size of the cationized gelatin nanoparticles 
ranged from 7 nm to 387 nm, with an average diameter of 172 nm. The original gelatin particles 
displayed a wider size range fiom 139 nm to 1.8 pm (Fig. 4.2). 
Figure 4.1 Environmental scanning electron microcopy images of cationized gelatin-pIGF-1 
nanoparticles (a, b) and non-cationized (original) gelatin-pIGF-1 microparticles (c, d), using a gelatin-plasmid 
weight ratio of 250:l. 
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Figure 4.2 Particle size distribution of cationized gelatin-pIGF-1 nanoparticles (CGPIN) and original 
gelatin-pIGF-1 particles (GPIN). Cumulative percentage of nanoparticles, C(d), plotted against particle size. 
Nanoparticles were made with cationized gelatin and original gelatin at  a weight ratio of 250:l. 

4.3.3. Surface Charge of Gelatin Nanoparticles 
The zeta potential (Fig. 4.3) of the naked plasmid IGF-1 solution was -48 * 2 mV (mean 
h standard error for 5 runs of the same sample). When the plasmid was coupled with different 
amounts of the positively charged cationized gelatin (+I8 h 0.7 mV for cationized gelatin alone), 
the zeta potential went from a negative value to a positive value and increased by approximately 
50-58 mV. Interestingly, with the increasing cationized ge1atin:plasmid weight ratio, the surface 
charge of the nanoparticles did not show a significant change. Cationized gelatin pIGF- 1 
nanoparticles displayed a 4-fold higher positive charge compared to particles made with the 
unmodified gelatin (GPIN) using a 250: 1 gelatin to plasmid weight ratio. 
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Figure 4.3 Zeta potential of naked IGF-1 plasmid (1" bar), cationized gelatin (2'* bar), original gelatin 
complexed to pIGF-1 at a 250:l weight ratio (3rd bar), and cationized gelatin complexed with different 
amounts of pIGF-1 to yield the following ge1atin:plasmid weight ratios: 150:1,200:1,250:1,300:1, and 400:l. 
4.3.4. Fluorescence Microscopy of the Chondrocytes Transfected with the Nanoparticles 
Containing pEGFP 
There was no noticeable fluorescence from the cells treated with the nanoparticles 
prepared with the original (non-cationized) gelatin particles containing the pEGFP (Fig. 4.4a). In 
contrast numerous cells in the group transfected with the cationized gelatin-pEGFP nanoparticles 
were found to fluoresce indicating successful transfection and gene expression (Fig. 4.4b). 

Figure 4.4 Fluorescence microscopy of chondrocytes transfected with nanoparticles incorporating 
pEGFP 48hrs after transfection using original gelatin (a) or cationized gelatin @). 
4.3.5. IGF-I Gene Expression in Transfeeeted Chondrocyte Monolayers 
The coefficients of variation for the IGF-1 levels recorded fiom all but two of the nine 
experimental groups, varying gelatin to plasmid weight ratios and plasmid loading (n = 4), were 
from 10-30%. In two of the groups (10pg loading with a ge1atin:plasmid ratio of 400: 1 and 10 
pg loading with 250:l) the coefficients were around 60% owing to an outlier in each that was 
about twice the mean value for the group. It was decided to omit the elevated data point in each 
of the two groups, reducing the sample size from 4 to 3, but taking a more conservative approach 
to the analysis of the data (i.e. omitting the outliers decreased the detected levels of protein). 
There was a clear effect of varying the weight ratio of gelatin to pIGF-1 on gene transfer 
and subsequent IGF- 1 release in the medium (Fig. 4.5a). Optimal IGF- 1 expression was 
recorded for gelatin to plasmid weight ratios of 200-300: 1. There was a 5-fold elevation in the 
amount of IGF-1 produced fiom the group treated with nanoparticles synthesized at a weight 
ratio of 250: 1 compared to the control group that was treated with pIGF-1 alone (Fig. 4.5a). 
One-factor ANOVA revealed a significant effect of the weight ratio of cationized gelatin to 
pIGF-1 on the amount of IGF-1 synthesized by the cells (p < 0.0002; power = 1). Fisher's PLSD 
post-hoc testing demonstrated that all plasmid ratios had statistically significant elevations of 
IGF- 1 production over the control condition treated with plasmid only (i.e. no incorporation in 
nanoparticles, p < 0.04). Among the ge1atin:plasmid weight ratios, there was no statistically 

significant difference between the 200: 1,250: 1, and 300: 1 groups, but there was a significant 
difference comparing these groups with the 150: 1 group (p < 0.03), and comparing the 250: 1 and 
300: 1 groups versus the 400: 1 group (p < 0.02). 
There was also a notable effect of varying the amount of plasmid added to each well on 
IGF-1 produced by the transfected chondrocytes (Fig. 4.5b). There was a gradual increase in 
IGF-1 expression with increasing plasmid load. Linear regression analysis demonstrated a 
correlation between IGF-1 expression and plasmid load ( R ~  = 0.65). One-factor ANOVA 
showed a significant effect of plasmid amount added per well on IGF-1 expression (p < 0.000 1 ; 
power = 1). Post-hoc testing revealed that there was a statistically significant elevation in IGF-1 
produced for all plasmid loads except the 2 pg load when compared to the control group. The 12 
pg load showed a statistically significant elevation of IGF-1 expression above the plasmid load 
groups of 8 pg or less (p < 0.02). The 10 pg load showed a significant elevation above plasmid 
loads of 5 pg or less (p < 0.01). There was, however, no significant difference between the 5 and 
8 pg plasmid load groups or the 10 and 12 pg groups. 
The difference between using unmodified (non-cationized) gelatin and cationized gelatin 
nanoparticles for the transfection of the chondrocytes was clearly demonstrated (Fig. 4 .5~) .  
There was a 5-fold elevation in the amount of IGF-1 produced by transfected cells when using 
the cationized gelatin nanoparticles (Fig. 4.5~). ANOVA showed a statistically significant 
difference in the IGF-1 expression between the groups (p < 0.003; power =0.99). 
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Figure 4.5 IGF-1 protein released into the medium from monolayer chondrocytes 144 hours after 
treatment with gelatin-plasmid IGF-1 nanoparticles: varying the cationized gelatin to pIGF-1 weight ratio 
using a 1Opg plasmid load (a); varying plasmid load using a 250:l weight ratio (b); and comparing 
transfection using original gelatin particles vs. cationized gelatin nanoparticles (c). n = 3-4; mean * SEM. 
4. 3.6. IGF-1 Gene Expression of Transfected Chondrocytes Seeded in CG Scaffolds and 
Effects on Biosyn thesis 
Scaffolds seeded with chondrocytes that were transfected in monolayer using 
gelatin1pIGF- 1 nanoparticles (CGPIN group) showed a clear elevation of IGF- 1 release above 
the Control (no treatment, medium only) and Gelatin (gelatin alone, no plasmid) groups for all 
media collections (Fig. 4.6). The CGPIN group showed a steady IGF-1 release of about 2200 
pg/ml every 3 days over the course of the 12-day period. There was no noticeable amount of 
IGF-1 released in the media for the Control or Gelatin groups. Two-factor ANOVA verified a 
significant effect of transfection with gelatin1pIGF- 1 nanoparticles on IGF- 1 release from cell- 
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Figure 4.6 IGF-1 released in medium from control cell-seeded scaffolds and chondrocytes transfected in 
monolayer with CGPIN (ge1atin:plasmid IGF-1 of 250:l) and subsequently seeded in CG scaffolds. n = 6; 
mean * SEM. 
There was a slight, significant elevation in DNA content (Fig. 4.7) at the end of the 
culture period for the Control group compared to the other groups (P < 0.03, power = 0.7). GAG 
and DNA analysis showed the highest level of accumulated GAG per DNA for the CGPIN 
group, with a 60% higher level than the Control group and a 40% higher GAGDNA level than 
the Gelatin group. Constructs seeded with cells treated in monolayer with gelatin alone (Gelatin 
group) also showed a 38% higher GAG/DNA content than the Control group. ANOVA showed 
a significant effect of monolayer treatment on the resulting accumulated GAGIDNA content at 
the end of the 3-D culture period (P < 0.001, power = 1). 
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Figure 4.7 DNA contents (a) and accumulated GAGJDNA (b) measured at the end of the 3-D culture 
period in CG scaffolds seeded with untreated chondrocyte monolayers (Control), chondrocvtes treated with 
gelatin alone (Gelatin only), or chondrocytes transfected in monolayer with CGPIN at a geiatin:plasmid IGF- 
1 of 250:l (CGPIN). n = 4; mean * SEM. 
4.4. DISCUSSION 
The results of the present study demonstrated the benefits of altering the charge of gelatin 
through cationization, with respect to its use as a delivery vehicle for plasmid IGF-1 for non-viral 
gene transfer to chondrocytes. Increasing the positive charge of gelatin enabled it to condense 
the pIGF- 1 such that smaller (nanometer-sized) particles could be produced. When complexed 
with the plasmid, unmodified gelatin tended to form particles of substantially larger size and 
broader size range. The change in the charge of the gelatin nanoparticles with cationization was 
demonstrated in the zeta potential measurements, with the cationized nanoparticles displaying a 
4-fold higher positive charge than particles synthesized using the original gelatin. 
Of interest were the findings demonstrating the difference in the functionality of the 
cationized and non-cationized gelatin particles as transfection agents for the plasmids encoding 
EGFP and IGF- 1. Virtually no fluorescence was detected in chondrocytes treated with the 
marker gene, EGFP, incorporated in the unmodified gelatin particles, while many cells were 
transfected with the pEGFP using the cationized gelatin nanoparticles. This difference was also 
demonstrated by the 5-fold difference in expression of IGF-1 between groups treated with the 
cationized gelatin-pIGF- 1 versus the non-cationized-pIGF- 1 particles indicating that there are 
important functional differences imparted by charge modification, perhaps owing to a difference 
in particle size or surface charge. A higher positive surface charge may increase interactions 
with the negatively charged cellular membrane and a smaller particle diameter may increase 
probable entry into to cell, resulting in enhanced gene expression. Additional studies will be 
required to provide a deeper understanding of the transfection mechanisms that are responsible 
for the differences in the behavior of the cationized and non-cationized particles. 
The present findings also revealed an optimal cationized ge1atin:pIGF-1 weight ratio 
range for transfecting adult articular chondrocytes, with maximum IGF- 1 expression recorded for 
weight ratios of 200-300: 1. The surface charge of the nanoparticles made with the varying 
weight ratios, however, may not have been a significant factor influencing gene transfer to 
chondrocytes as the surface charge did not seem to change significantly using different weight 
ratios. It will be useful in future work to evaluate other potential mechanisms related to the 
ability of these nanoparticles to transfect cells, such as particle size and morphology and the 
kinetics of plasmid release from nanoparticles prepared with other ge1atin:plasmid weight ratios. 
The current investigation demonstrated a nearly linear increase in IGF-1 production by 
cells with increasing plasmid load applied to the cultures when using cationized gelatin 
nanoparticles. Based on an estimated cell number in each well of about 100,000 cells and using 
a cationized ge1atin:IGF-1 weight ratio of 250: 1, one would need about 50 pg of incorporated 
plasmid within cationized gelatin nanoparticles per cell for meaningful gene expression. The 
approximately 1 ng of IGF-1 collected in the first 144 hours after transfection (using a 250: 1 
cationized ge1atin:pIGF-1 and a 10 pg plasmid load) is well below the minimum therapeutic 
levels generally found in vitro to elicit a response from chondrocytes using the recombinant IGF- 
1 as a medium supplement. However, this 1 ng level was achieved after only 5 hours of 
incubation of the cells with the nanoparticles. Moreover, in a contained defect in vivo, small 
levels of overexpressed IGF-1 concentrated locally may still be able to achieve therapeutic 
results. 
The effect of localized and elevated levels of IGF-1 expression on biosynthesis was 
demonstrated by comparing CG scaffolds seeded with untreated chondrocytes and chondrocytes 
transfected in monolayer with CGPIN. These results showed that IGF- 1 overexpression above 
the control groups can be maintained when transfected chondrocytes are seeded within CG 
scaffolds for up to about 2 weeks in 3-D culture. The CGPIN group showed very steady IGF-1 
release levels with no evidence of decreasing IGF-1 overexpression at the end of the 1 Zday 
culture period. The elevated levels of IGF-1 for the CGPIN group resulted in a 60% greater 
GAG/DNA content than the Control group after 12-days in 3-D culture. Surprisingly, constructs 
containing chondrocytes treated with gelatin alone (without plasmid) in monolayer also resulted 
in a significantly higher GAG/DNA content (38% higher) verses the Control group even though 
there was no elevation in IGF-1 expression for this group compared to the Control. This finding 
seems to indicate that gelatin alone can affect chondrocytes in monolayer and may induce 
elevations in biosynthesis when these cells are subsequently grown in CG scaffolds. 
Few studies have yet investigated the mechanisms by which gelatin nanoparticles gain 
entry into cells. One recent transmission electron microscopy study 23 provided evidence of the 
endocytosis of gelatin nanoparticles by fibroblasts. While the nanoparticles in the cytoplasm of 
the cells appeared to disrupt the F-actin and beta-tubulin cytoskeleton, there was no evidence of 
toxicity. Additional work is necessary to more completely understand the mechanisms by which 
gelatin nanoparticles are endocytosed, and the contained plasmid released and incorporated into 
the cell nucleus. 
In conclusion, the present work demonstrates that gelatin nanoparticles can be 
synthesized to incorporate the plasmid IGF-1 and successfully transfect expanded chondrocytes 
in monolayer culture. Chemical modification of gelatin by cationization for nanoparticle 
synthesis, varying the cationized gelatin to plasmid weight ratio, and varying the amount of 
plasmid added to the cells all significantly affect resulting gene expression and growth factor 
release kinetics. Furthermore, chondrocytes transfected with pIGF using cationized gelatin 
nanoparticles are able to maintain steady IGF- 1 overexpression when subsequently seeded within 
CG scaffolds for up to two weeks in 3-D culture, and show enhanced biosynthesis. These 
findings warrant additional study of the implementation of cationized gelatin nanoparticles 
incorporating growth factor plasmids in conjunction with scaffolds to facilitate tissue 
engineering. 
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CHAPTER 5: SCAFFOLD-BASED NONVIRAL IGF-1 GENE 
DELIVERY USING COLLAGEN-GAG SCAFFOLDS INCORPORATING 
TRANSFECTION ENHANCERS 
5.1. INTRODUCTION 
The combination of nonviral gene delivery and tissue engineering strategies via gene 
incorporation within 3-D scaffolds is an effective means to provide a prolonged release of 
desired growth factors for enhancing tissue regeneration. Previous chapters have demonstrated 
that the Geneporter@ (GP) lipid mediated transfection reagent and cationized gelatin 
nanoparticles can be used to facilitate transfer of the gene encoding for insulin-like growth factor 
(1GF)-1 to adult canine articular chondrocytes, and that IGF- 1 overexpression by transfected 
cells can result in enhanced biosynthesis in type I1 collagen-GAG (CG) scaffolds in vitro. The 
objective of this study was to evaluate the use of these transfection enhancers in combination 
with the type I1 CG scaffold with regard to the ability to successfully transfect seeded goat 
chondrocytes and the ability to control subsequent IGF-1 release kinetics. In order to investigate 
potential techniques for varying vector release from the scaffolds, two methods of incorporating 
the GP/IGF complexes or cationized gelatin pIGF-1 nanoparticles (CGPIN) were employed. The 
first method (Method 1) involved cross-linking half of the total amount of plasmid IGF-1 (5 pg) 
to the scaffold and then adding the second half of the load (5 pg) by absorption into scaffold, 
whereas, the second method (Method 2) involved cross-linking the full plasmid load (10 pg) to 
the scaffold. During the 2-week 3-D culture period, scaffold contraction was monitored and 
media was collected at various time points to detect IGF-1 released in the medium. At the end of 
the culture period, scaffolds were allocated for biochemical and histological analysis to assess 
the effects on biosynthesis and chondrogenesis. 
5.2. WTERIALS AND METHODS 
5.2.1. Type II Collagen- GA G Sea ffolds 
Porous sheets of a type I1 CG scaffold were fabricated by fieeze-drymg a porcine type I1 
collagen-GAG slurry (Geistlich Biomaterials, Wolhusen, Switzerland). Similar scaffolds have 
been reported in prior studies to have a porosity of 89 * 2% (mean * standard deviation) and a 
pore diameter of 125 * 42 pm '. The collagen sheets were sterilized and cross-linked by 
dehydrothermal treatment 2, and 8 mm diameter disks (-2 mm thick) were prepared using a 
dermal biopsy punch. 
5.2. 2. Plasmid Propagation & Isolation 
Multiplication of plasmid encoding for IGF- 1 (pIGF- 1) was accomplished by heat shock 
transformation into Escherichia coli DH5a competent cells grown overnight in Luria-Bertani 
(LB) medium containing ampicillin. Plasmid was isolated and purified using a Mega 
QIAfilterTM Plasmid kit (Qiagen, Valencia, CA). The absorption ratio at 260 nm and 280 nm 
was used to determine plasmid concentration and purity while plasmid integrity was 
demonstrated by polyacrylamide gel electrophoresis. The size the pIGF-1 was 6-7 Kb. 
5.2.3. Preparation of Cationized Gelatin 
Gelatin (fiom porcine skin; G2625, Sigma-Aldrich, Inc., St. Louis, MO) was chemically 
modified to increase the overall positive charge by grafting amino groups to carboxyl groups as 
previously reported3-'. Briefly, a 2% gelatin solution (w/v) was made using 0.1 M phosphate- 
buffered solution (pH 5.0). Ethylenediamine (Sigma-Aldrich, Inc.) and N-(3- 
dimethylaminopropy1)-N'-ethylcarbodiimide hydrochloride (EDAC, Sigma-Aldrich, Inc.) were 
added to obtain a gelatin solution consisting of 6% (v/v) ethylenediamine and 1% (w/v) EDAC. 
The pH was immediately adjusted to 5 with 5-6 N HCl. The mixture was stirred at room 
temperature for 16- 18 hours, dialyzed for 48 hours in distilled water, and then freeze-dried to 
obtain the cationized gelatin. 
5.2. 4. Cation ized Gelatin Plasm id IGF-1 Nan oparticle Synthesis 
Cationized gelatin plasmid IGF-1 nanoparticles (CGPIN) were prepared by a complex 
coacervation method where separation into nanoparticles is caused by the interaction of two 
oppositely charged colloids. An 8% aqueous cationized gelatin stock solution (wlv) was made 
and sterile filtered. Working solutions of cationized gelatin were obtained by dilution in 
sterilized water. The plasmid IGF-1 working solution (200 pg/ml) was prepared with sterile 
filtered 50 mM sodium sulfate (Fisher Scientific, Hampton, NH). 100- 150 pl of the cationized 
gelatin and pIGF-1 solutions were heated separately at 55 OC for 30-45 min. Equal volumes of 
the solutions were quickly mixed and vortexed for 60 seconds. Nanoparticles were used without 
further purification. The nanoparticles containing pIGF- 1 were prepared with a cationized 
gelatin to plasmid weight ratio of 250: 1. 
5.2. 5. Incorporation of GPLGF Complexes or Cationized GelatinbIGF-I Nanoparticles 
(CGPIN) into CG Scaffolds 
To investigate a scaffold-based gene transfer approach to provide a prolonged release of 
nonviral vectors in vitro or in vivo, GPIIGF complexes or CGPIN were incorporated into the 
scaffolds using two methods that would result in a varied vector release profile. The first method 
(Method 1) used to synthesize GSCG scaffolds involved placing a 60 p1 aliquot of the plasmid 
solution containing 5 pg of plasmid onto the DHT-treated scaffolds followed by incubation for 
an hour at room temperature. A 1 ml aliquot of an aqueous carbodiimide solution consisting of 
14 mM 1 -ethyl-3-(3 -dimethylaminopropyl) carbodiimide hydrochloride and 5.5 mM N- 
hydroxysuccinimide (EDAC; Sigma Chemical Co., St. Louis, MO) was added to the scaffold and 
incubated at room temperature for about 30 minutes to allow cross-links to form among the 
collagen molecules and between the plasmid and collagen. Excess EDAC was removed by 
rinsing the scaffolds in PBS. Scaffolds were then briefly dried on filter paper and a 30 pl aliquot 
of plasmid solution containing another 5 pg of pIGF- 1 was added to each scaffold and incubated 
for about an hour before seeding chondrocytes. This method of incorporation provided a total 
load of 10 pg of pIGF- 1 (complexed to the lipid transfection reagent or the cationized gelatin 
nanoparticles) some of which were cross-linked and not cross-linked to the CG scaffold. 
The second method (Method 2) used to synthesize GSCG constructs involved cross- 
linking the full plasmid load to the scaffold. A 60 p1 aliquot of the plasmid solution containing 
10 pg of plasmid onto the DHT-treated scaffolds followed by incubation for at least an hour at 
room temperature. A 1 ml aliquot of the EDAC solution was added to the scaffold and incubated 
at room temperature for about 30 minutes. Excess EDAC was removed by rinsing the scaffolds 
in PBS. Below is a summary of the various conditions investigated in this study. 
Table 5.1 Experimental Conditions: CG Scaffolds Supplemented with GPDGF Complexes 
or Cationized Gelatin pIGF-1 Nanoparticles 
5.2.6. Swelling Ratio Analysis 
Contraction (12) 
IGF-1 ELISA (12) 
The swelling ratio (i.e. inverse of the cross-link density) was determined for unseeded 
control scaffolds and scaffolds containing GPlIGF complexes or CGPIN to determine if gene 
incorporation during the carbodiimide treatment affects the degree of scaffold cross-linking (n = 
4). Scaffolds were immersed in a 90 "C water bath for 2 minutes and placed in between sheets 
of filter paper (Whatman No. 1, Fisher Scientific, Pittsburgh, PA). A one-kilogram weight was 
placed on top of the filter paper for 20 seconds after which the weight was taken off and the 
scaffold was removed and weighed to obtain the wet weight (WM). Scaffolds were then 
completely dried by placing them in a 105 "C oven overnight. The dry weight (DM) was then 
Nanoparticles 















IGF-1 ELISA (12) 
Biochemical (6) 
Histochemical ( 
determined for each scaffold and the swelling ratio was calculated according to the following 
equation: 
Swelling ratio = [(DMAQ + ((Will-DM)/r.,,.)] x r f l M  
where r, = 1.32 g/cm3 (density of collagen) and rWate, = 1 .OO g/cm3 (density of water). The 
inverse of the swelling ratio was then calculated to obtain the cross-link density. 
5.2.7. Chondrocyte Isolation and Expansion 
Chondrocytes were isolated from the trochleae of both knees (stifle joints) from six adult 
Spanish goats (4-5 yrs old). The cells were obtained using a sequential digestion of pronase (20 
Ulml, 1 hr) and collagenase (200 Ulml, overnight) as previously described 7. Isolated 
chondrocytes were expanded in monolayer culture using a medium consisting of high glucose 
Dulbecco's modified Eagle's medium (DMEM, 4.5 g/L D-glucose, without L-glutamine and 
with 1 mM sodium pyruvate), containing 10% (vlv) fetal bovine serum (FBS), 0.1 mM 
nonessential amino acids, 1 0 mM N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic (HEPES) 
buffer, 100 UImL penicillin, and 100 pg/mL streptomycin glutamate. The medium was 
supplemented with the following growth factors (all from R&D Systems, Minneapolis, MN): 5 
ng/mL of fibroblast growth factor-2 (FGF-2), 10 ng/mL of platelet-derived growth factor-bb 
(PDGF-bb), 1 ng/mL of transforming growth factor-p1 (TGF-PI). The cells were incubated at 
37 "C and 5% C02. Once cells reached confluence, they were trypsinized, resuspended, and re- 
plated to obtain passage (P) 1 cells. 
5.2.8. Cell Seeding GSCG Scaffolds 
Four million cells were seeded onto each scaffold by pipetting a 20 pl suspension 
containing half of the total amount of cells on each side of the scaffold with a 10-minute 
incubation period in between. By this static seeding method approximately 80% of the seeded 
chondrocytes have been found to attach to the scaffolds. Cell-seeded scaffolds were cultured in 
serum-free medium consisted of DMEM (high glucose 4.5% without L-glutamine), 0.1 mM 
nonessential amino acids, 10 mM HEPES buffer, 100 U/mL penicillin, 100 pglmL streptomycin 
glutamate, ITS+' (loox, by Sigma Chemical, St. Louis, MO), 0.1 mM ascorbic acid 2-phosphate, 
1.25 mg/ml bovine serum albumin, 10 ng/mL of TGF-PI, and 100 nM dexamethasone. Medium 
was collected and changed at various time points over a two-week culture period. At each 
medium exchange, the diameter of each scaffold was measured to monitor any change in 
scaffold size (n = 12; 2 scaffolds per goat). The amount of IGF- 1 in the collected medium (n = 
12; 2 scaffolds per goat) was detected by a sandwich ELISA kit for the human IGF-1 protein 
(R&D Systems). Cultures were terminated after 2 weeks for histological evaluation and 
biochemical analysis. For DNA and GAG analysis, scaffolds were lyophilized and 
enzymatically digested using proteinase K (Roche Diagnostics, Indianapolis, IN). 
5.2.9. DNA Analysis 
The DNA content of cell-seeded scaffolds was measured using the Picogreen Dye assay 
kit (Molecular Probes, Inc, Eugene, OR) (n = 6). The Picogreen dye was used with the reagents 
and standard provided according to the manufacturer instructions. 
5.2.10. GAG Analysis 
The sulfated GAG content of cell-seeded scaffolds after the 2-week culture period was 
determined by the dimethylmethylene blue (DMMB) dye assay (n = 6). An aliquot of the 
proteinase K digest was mixed with the DMMB dye and the absorbance at 525 nm was measured 
with a spectrophotometer. The results were obtained by extrapolating fiom a standard curve 
using shark chondroitin-6-sulfate. Newly accumulated GAG was determined by subtracting the 
unseeded values fiom the sample values. 
5.2.11. Histology and Immun ohistochemis of Cell-Seeded Scaffolds 
Cell-seeded scaffolds (n = 6) were fixed in 10% neutral buffered formalin, dehydrated, 
embedded in paraffin, and sectioned (six-micrometer thick) by microtomy. Sections were 
stained with Safranin-0 for the presence of sulfated GAG. For type I1 collagen 
immunohistochemical analysis, sections were enzymatically digested by protease type XIV for 
45 minutes and stained with a standard avidin-biotin complex peroxidase-based antibody 
staining technique (Vectastain, Vector Laboratories, Burlingame, CA). Mouse anti-chick 
monoclonal antibody for type I1 collagen was obtained from the Developmental Studies 
Hybridoma Bank (Iowa City, IA). 
5.2.12. Statistical Analysis 
Data were analyzed by one or two-factor analysis of variance (ANOVA), and the Fisher's 
protected least squares differences (PLSD) post-hoc test using StatView (SAS Institute Inc, Cary, 
NC). Data are presented as mean 2 standard error of the mean. 
5.3. RESULTS 
5.3.1. Effect of Gene-Supplemen tation on Cross-lin k Density 
Swelling ratio results demonstrated that the Control group was the least cross-linked 
among the groups and that GSCG scaffolds incorporating CGPIN had the highest amount of 
cross-links (Fig. 5.1). There was about a 15% and a 30% higher cross-link density for scaffolds 
containing GPIIGF complexes and CGPIN, respectively, compared to the Control group. 
ANOVA showed a significant effect of gene incorporation on the resulting cross-link density (P 
< 0.002, power = 1). Post hoc analysis revealed a significant difference in the density of cross- 
links for the Control group versus the other groups (PC0.04, power=l), the GenePorter (x-link & 
soak) group verses the Nanoparticles (x-link & soak) and Nanoparticles (x-link) groups (P < 
0.02, power = I), and the GenePorter (x-link) group compared to the Nanoparticles (x-link & 
soak) group (P < 0.04, power = I). 
5.3.2. Cell-Mediated Con traction of GSCG Scaffolds 
GSCG scaffolds incorporating GP/IGF complexes using either method of incorporation 
showed the most contraction, with about a 30% decrease in diameter at the end of the 2-week 
culture. There was no noticeable decrease in size for scaffolds incorporating CGPIN and the 
Control group showed a slight 10% decrease in diameter. Two-factor ANOVA revealed a 
significant effect of type of gene-supplementation (P < 0.0001, power = 1) and time (P < 0.0001, 
power = 1) on scaffold contraction. 

Control GenePorter, x- GenePorter, x- Nanoparticles, Nanoparticles, 
link & soak link x-link d soak x-link 
Figure 5.1 Cross-link density (llswelling ratio) of unseeded control and GSCG scaffolds. n = 4; mean 
SEM. 
+ Control 
-.k- GenePorter, x-link & soak 
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Figure 5.2 Contraction of cell-seeded Control and GSCG scaffolds over the 2-week 3-D culture period. 
n = 12; mean SEM. 

5.3.3. IGF-I Release in 3 -0  Culture Medium 
There was an obvious elevation in IGF-1 protein released in the medium for all GSCG 
scaffolds containing either the GPlIGF complexes or CGPIN above the Control group except for 
the Nanoparticles (x-link) group (Fig. 5.3a). In all groups, there seemed to be a peak in IGF-1 
release after about a week in culture. The GenePorter (x-link & soak) group displayed the most 
IGF-1 release in the 3-D culture medium for all time points. Two-factor ANOVA revealed a 
significant effect of time (P < 0.03, power = 0.7) and type of gene-supplementation on IGF-1 
release in the medium (P < 0.0001, power = 1). Post hoc analysis confirmed a significant 
difference in IGF-1 release for the Controls versus the GenePorter (x-link & soak) group (P < 
0.0001, power = l), GenePorter (x-link) group (P < 0.0002, power = 0.984), and Nanoparticles 
(x-link & soak) group (P < 0.01, power = 1). The GenePorter (x-link & soak) group showed 
significantly higher IGF-1 release over all the other groups (P < 0.0001, power = 1) and there 
was a significant difference between the Nanoparticles (x-link & soak) group compared to the 
Nanoparticles (x-link) group (P < 0.01, power = 1). 
Over the 2-week culture period, the total accumulated IGF-1 detected in the medium 
revealed a 50-fold higher level for the GenePorter (x-link & soak) group and a 14-fold higher 
level for the Nanoparticles (x-link & soak) group compared to the Control group (Fig. 5.3b). 
There was an 1 1-fold difference between the Nanoparticles (x-link & soak) and Nanoparticles 
(x-link) groups and a 5-fold difference between the GenePorter (x-link & soak) and GenePorter 
(x-link) groups. Statistical differences between groups for total accumulated IGF-1 were similar 
to the analysis of the IGF- 1 release data. 
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Day 3 Day 6 Day 9 Day 14 
Figure 5.3 IGF-1 detected in each media collection (a) and total accumulated IGF-1 (b) over the course 
of the 2-week 3-D culture period for Control and GSCG scaffolds incorporating GPIIGF complexes or 
CGPIN. n = 12; mean * SEM. 

5.3.4. Biochemical Analysis of Cell-Seeded GSCG Scaffolds 
DNA content at the end of the 2-week culture period showed noticeably lower values for 
GSCG scaffolds supplemented with the GP/IGF complexes (Fig. 5.4a). There was about a 70% 
lower DNA content for the GenePorter (x-link & soak) and GenePorter (x-link) groups and a 
23% decrease for the Nanoparticles (x-link & soak) group compared to the Control group. 
ANOVA and post hoc analysis revealed a significant effect of gene supplementation conditions 
on final DNA content after 2 weeks in culture (P < 0.0001, power = 1) with the GenePorter (x- 
link & soak) and GenePorter (x-link) groups having a significantly lower DNA content 
compared to the rest of the groups (P < 0.005, power = 1). Although there was no significant 
difference in DNA content between the Nanoparticles (x-link) and Control groups, there was a 
significant difference between the Nanoparticles (x-link) and Nanoparticles (x-link & soak) 
groups (P < 0.03, power = 1). 
The GAG/DNA values for CG scaffolds supplemented with CGPIN were similar to the 
Controls after the 2-week culture period (Fig. 5.4b). GSCG scaffolds containing the GP/IGF 
complexes, on the other hand, showed 64% and 47% higher GAGLDNA content for the 
GenePorter (x-link & soak) and GenePorter (x-link) groups, respectively, over the Controls. 
ANOVA and post hoc analysis confirmed a significant effect of gene supplementation condition 
on GAG/DNA content (P < 0.0005, power = 1) and showed significant differences between the 
GenePorter (x-link & soak) group verses the Control, Nanoparticles (x-link & soak), and 
Nanoparticles (x-link) groups (P < 0.0006, power = I), and the GenePorter (x-link) group versus 
the Nanoparticles (x-link & soak) and Nanoparticles (x-link) groups (P < 0.04, power = 1). 
5.3.5. Histology andImmunohistochemistry of 3-D Cultures 
Histochemical staining for all conditions showed most tissue formation in areas 
surrounding greater cell concentrations located mostly in the center of the scaffolds (Figs 5.5 and 
5.6). In general, there were many cells that displayed a rounded morphology in all sample 
conditions, however, cells displaying a rounded morphology and located in lacunae were evident 
only in GSCG scaffolds containing GP/IGF complexes. All sample conditions showed light 
staining for Safranin-0, especially in areas where more tissue was formed (Fig. 5.5). CG 
scaffolds containing the GPIIGF complexes possessed more areas of high cell densities, tissue 
formation, and GAG staining compared to the Control or scaffolds incorporating CGPIN. Type 
I1 collagen immunohistochemical staining revealed type I1 collagen deposition mostly on the 
struts of the scaffolds (Fig. 5.6). Type I1 staining was most evident in scaffolds containing 
GPAGF complexes and least evident for scaffolds containing CGPIN (Fig. 5.6). There was no 
obvious difference comparing the two methods of gene incorporation regarding the resulting 
cellular distribution, morphology, and histochemical staining (i.e. GenePorter (x-link & soak) 
group was similar to GenePorter (x-link) group and Nanoparticles (x-link & soak) group was 
similar to Nanoparticles (x-link) group). For all conditions, a significant amount of residual 
scaffold was present after two-weeks in culture. 
Control GenePorter, x- GenePorter, x- Nanoparticles, Nanoparticles, 
link & soak link x-link & soak x-link 
Control GenePorter, x- GenePorter, x- Nanoparticles, Nanoparticles, 
link & soak link x-link & soak x-link 
Figure 5.4 DNA (a) and GAGIDNA (b) content for Control and GSCG scaffolds incorporating GP/IGF 
complexes or CGPIN at the end of the 2-week 3-D culture period. n = 6; mean * SEM. 

(a) 
Figure 5.5 Safranin-0 staining (redipink is a positive stain) for Control (a) and GSCG scaffolds 
incorporating GPnGF complexes (b) or CGPIN (c) after 2 weeks in 3-D culture. 

Figure 5.6 Type I1 collagen immunohistochemical staining (brown is a positive stain) for Control (a) 
and GSCG scaffolds incorporating GPnGF complexes (b) or CGPIN (c) after 2 weeks in 3-D culture. 

5.4. DISCUSSION 
Of significance in this study was that both GenePorterlpIGF- 1 (GPIIGF-1) complexes 
and cationized gelatin pIGF-1 nanoparticles (CGPIN) incorporated within CG scaffolds could 
result in successll overexpression of IGF-1 by seeded goat articular chondrocytes. Prior 
chondrocyte monolayer studies have shown that GPIIGF complexes have a higher transfection 
efficiency than the CGPIN, and therefore the greater IGF-1 overexpression that resulted from 
cells seeded within scaffolds incorporating the GPIIGF complexes was expected. The fact that 
cells seeded within scaffolds incorporating CGPIN resulted in elevated levels released in the 
medium over the Control scaffolds shows promise in using this approach as an alternative 
method to control gene transfer and to direct the start, amount, and duration of growth factor 
release for articular cartilage repair. Further studies in developing GSCG scaffolds using CGPIN 
is necessary to find the best nanoparticle synthesis conditions and incorporation methods for 
optimal gene transfer to seeded cells. 
An interesting finding in this study is the effect of gene supplementation on cell-mediated 
contraction of the scaffolds. Cell-mediated contraction can be affected by the scaffold cross- 
linking properties (stiffness and degradation), smooth muscle actin (SMA) expression of cells, or 
cell remodeling of the extracellular matrix (ECM). Although the greatest amount of scaffold 
contraction occurred in scaffolds supplemented with the GPIIGF complexes, the cross-link 
density for this group was actually higher than the Control group. It is, therefore, speculated that 
the cause of the increased cell-mediated contraction for scaffolds incorporating the GP/IGF 
complexes is not due to scaffold cross-linking, but rather on either stimulated SMA activity or 
increased remodeling of the matrix that may have been induced by these complexes. Future 
work should further investigate this contraction phenomenom to understand the mechanism of 
contraction induced by the GPIIGF complexes. 
GSCG scaffolds incorporating the gelatin nanoparticles, on the other hand, posessed the 
highest cross-link density and least scaffold contraction over the two-week period. This elevated 
scaffold stifhess may be due to the increased number of potential cross-link sites present when 
the gelatin nanoparticles are added to the collagen scaffold. The carbodiimide cross-linking 
agent not only could have cross-linked the gelatin nanoparticles to the collagen scaffold, but it 
may have also created cross-links between the gelatin molecules, resulting in a stiffer gel within 
the CG scaffold. This higher cross-link density may have also been the cause of the lower IGF-1 
overexpression for scaffolds containing CGPIN compared to scaffolds with the GP/IGF 
complexes (for both Method 1 and Method 2). That is, a higher cross-link density would have 
made it more difficult for seeded cells to degrade the scaffold, and therefore may have resulted in 
a decreased release rate of incorporated CGPIN and a subsequently lower rate of gene transfer. 
Furthermore, as mentioned before, the transfection efficiency of CGPIN has been shown to be 
lower than that of the GPIIGF complexes in monolayer studies and therefore would also explain 
the difference in the amount of IGF-1 released fiom scaffolds synthesized using Method 1 
(where half of the plasmid load was absorbed and not cross-linked to the scaffolds). Future in 
vitro experiments need to investigate other formulations for synthesizing CGPIN for optimal 
transfection efficiencies and other methods of incorporation within CG scaffolds to control 
vector release rates and subsequent IGF-1 expression kinetics over prolonged times. 
As anticipated, cross-linking half of the plasmid load and absorbing the other half within 
the scaffolds resulted in higher levels of IGF-1 compared to cross-linking the full plasmid load. 
Although after one week in 3-D culture there seemed to be a peak in IGF-1 release fiom all 
sample conditions, it remains to be seen if further breakdown or degradation of the scaffold 
would result in another "wave" of vector release and a subsequent increase in IGF-1 production. 
Histological results did confirm an abundance of residual scaffold left after 2-weeks in culture, 
and therefore a significant amount plasmid that is cross-linked to the scaffold may still be 
present. 
Of note is the dramatically lower DNA content for the scaffolds containing GPIIGF 
complexes compared to the other groups at the end of the two-week culture period. It is 
speculated that the significant decrease in scaffold size may have contributed to cell apoptosis 
and a decrease in the number of live cells at the end of 2-weeks. Further studies involving cell 
attachment assays need to verify that this difference in DNA content was not due to initial effects 
on cell attachment. Prior work using adult canine chondrocytes seeded within GSCG scaffolds 
incorporating GPAGF complexes (using Method 2) did not display this decrease in DNA content 
below the Control conditions, however, they also did not show as much scaffold contraction at 
the end of 2 weeks. 
Although the DNA content was significantly lower for scaffolds incorporating the 
GPAGF scaffolds, the GAG/DNA content was the highest for these groups especially for the 
GenePorter (x-link & soak) group. This elevated GAG/DNA level for the GenePorter (x-link & 
soak) group could be the result of the higher production of IGF-1 by seeded chondrocytes 
relative to the other groups. The fact that there was no noticeable increase in GAGDNA content 
for the Nanoparticles (x-link & soak) group compared to the Nanoparticles (x-link) group, 
despite the higher release of IGF-1 for the Nanoparticles (x-link & soak) group, may indicate that 
scaffold conditions (e.g. degradation properties) may not have been ideal to reflect an enhanced 
biosynthetic response that was expected fkom elevated IGF-1 production. This may also be the 
case when comparing the results fkom the GenePorter (x-link) and Nanoparticles (x-link & soak) 
groups. These groups demonstrated similar IGF-1 release levels over the two-week period; 
however, the GenePorter (x-link) group displayed a significantly higher GAGlDNA amount 
compared to the Nanoparticles (x-link & soak) group. The most obvious difference between 
these two groups is the amount of scaffold contraction over the course of the Zweek culture. 
Prior studies 9y10 have shown that cell density has a significant effect on biosynthesis and 
chondrogenesis within 3-D scaffolds. The much higher contraction of the GenePorter (x-link) 
group may have increased the cell density within the scaffold, which may have also contributed 
to the increase in biosynthesis. Future work should fbrther investigate the individual influences 
of scaffold contraction and IGF-1 expression on enhanced biosynthesis within these GSCG 
scaffolds. 
Histochemical evaluation revealed that for all conditions, there was a majority of cells 
displaying a rounded morphology. Although many cells were rounded, the presence of lacunae 
was difficult to assess since not much tissue was evident, especially for the Control and CGPIN 
scaffolds. There was not an even cellular distribution for most of the samples, with sections of 
the scaffold (particularly the center) having a denser cell population, most likely due to the 
pipette seeding method. Greater cell densities were evident for samples containing GPAGF 
complexes, most likely the result of greater scaffold contraction. The fact that a greater amount 
of histogenesis was demonstrated for GSCG scaffolds containing GPAGF complexes supports 
the significant effect that cell density can have on biosynthesis and chondrogenesis. It is difficult 
to assess the result of the type I1 collagen staining since most staining was present on the struts of 
the scaffold. The fact that there was more collagen type I1 staining on the struts for GSCG 
scaffolds containing the GPlIGF complexes, may indicate that cells within the GP/IGF 
complexes did produce more type I1 collagen but it was mostly deposited on the scaffold walls 
due to insufficient tissue synthesis within the scaffold pores. The lack of tissue formation 
(especially for the Control and CGPIN scaffolds) and the amount of residual scaffold left after 2- 
weeks in culture may indicate that the cross-linking conditions were not ideal for sufficient 
biosynthesis. Future studies need to investigate the behavior of these goat articular chondrocytes 
within GSCG scaffolds using other cross-linking conditions. 
In conclusion, incorporation of GPhGF complexes or CGPIN within CG scaffolds has a 
significant effect on cell-mediated contraction of the scaffolds and IGF- 1 overexpression of 
seeded chondrocytes. The initiation, amount, and duration of IGF-1 release can be potentially 
controlled using different nonviral vector formulations and gene incorporation methods. IGF- 1 
overexpression resulting from successful transfection of chondroctyes seeded within GSCG 
scaffolds can result in enhanced biosynthesis, but is also dependent on scaffold contraction and 
degradation characteristics. This study commends further investigation using nonviral gene 
transfer agents incorporated within CG scaffolds for a prolonged and localized delivery of 
growth factors in articular cartilage tissue engineering. 
5.5. REFERENCES 
1. D. Hastreiter. A collagen-GAG matrix for the growth of intervertebral disc tissue. 
Cambridge, MA: Massachusetts Institute of Technology; 2002. 
2. Yannas IVY Lee EO,D.P., Skrabut EM, Murphy GF. Synthesis and characterization of a 
model extracellular matrix that induces partial regeneration of adult mammalian skin. Proc. Nat'l. 
Acad. Sci. USA 1989;86:933-937. 
3. Aoyama T, Hosseinkhani H, Yamamoto S, Ogawa 0, Tabata Y. Enhanced expression of 
plasmid DNA-cationized gelatin complex by ultrasound in murine muscle. J.Control.Release 
2002 Apr 23;80(1-3):345-356. 
4. Fukunaka Y, Iwanaga K, Morimoto K, Kakemi M, Tabata Y. Controlled release of plasmid 
DNA from cationized gelatin hydrogels based on hydrogel degradation. J.Control.Release 2002 
Apr 23;80(1-3):333-343. 
5. Hosseinkhani H, Aoyama T, Ogawa 0 ,  Tabata Y. Ultrasound enhancement of in vitro 
transfection of plasmid DNA by a cationized gelatin. J.Drug Target. 2002 May; 1 O(3): 193-204. 
6. Lee CR, Grodzinsky AJ, Spector M. The effects of cross-linking of collagen- 
glycosaminoglycan scaffolds on compressive stifhess, chondrocyte-mediated contraction, 
proliferation and biosynthesis. Biomat. 200 1 ;22:3 145-3 154. 
7. Kuettner KEY Pauli BUY Gall G, Memoli VA, Schenk RK. Synthesis of cartilage matrix by 
mammalian chondrocytes in vitro. I. Isolation, culture characteristics, and morphology. J Cell 
Biol 1982 Jun;93(3):743-50. 
8. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated 
glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986 Sep 
4;883(2): 173-7. 
9. Mauck RL, Seyhan SL, Ateshian GA, Hung CT. Influence of seeding density and dynamic 
deformational loading on the developing structure/function relationships of chondrocyte-seeded 
agarose hydrogels. Ann.Biomed.Eng. 2002 Sep;30(8): 1046- 1056. 
10. Moretti M, Wendt D, Dickinson SC, Sims TJ, Hollander AP, Kelly DJ, et al. Effects of in 
vitro preculture on in vivo development of human engineered cartilage in an ectopic model. 
Tissue Eng. 2005 Sep-Oct; 1 l(9-10): 1421-1428. 

CHAPTER 6: NONVIRAL IGF-1 GENE TRANSFER TO 
MESENCHYMAL STEM CELLS VIA GENE-SUPPLEMENTED 
COLLAGEN-GLYCOSAMINOGLYCAN (GSCG) SCAFFOLDS 
6.1. INTRODUCTION 
Over recent years, there has been a tremendous increase in research directed towards the 
use of adult bone marrow-derived or mesenchymal stem cells (MSCs) for the purposes of tissue 
engineering. The in vitro expansion of chondrocytes that is essential to obtain sufficient cell 
numbers for articular cartilage tissue engineering applications, and the resulting donor site 
morbidity associated with the use of autologous chondrocytes, commends MSCs as a more 
favorable cell source; as these progenitor cells have a natural ability to regenerate and are more 
readily available in vivo. The simplest procedure for using MSCs as a cell source to enhance 
articular cartilage regeneration in vivo is with a microfiacture procedure, in which small holes 
(-1 mm in diameter) are punctured through the subchondral bone to allow blood and bone 
marrow containing MSCs to infiltrate the defect. Prior in vivo studies in our lab comparing 
microfracture treatment alone, microfracture with a type-I1 collagen scaffold placed in the 
defect, and a type-11 scaffold seeded with cultured autologous chondrocytes demonstrated that 
the greatest amount of defect filling (% of cross-sectional area of the original defect filled with 
reparative tissue) after 15 weeks was found in the dogs whose defects were treated with 
microfracture and implantation of the type I1 collagen scaffold '. Tissue filling in all of the 
defects, however, was predominantly fibrocartilage. 
To improve the quality of tissue formation in vivo to a more hyaline-like cartilage tissue 
using the microfracture procedure in conjunction with a type I1 collagen scaffold, it may be 
advantageous to use various regulators to induce differentiation of MSCs toward the 
chondrogenic phenotype. Several studies have demonstrated successful differentiation of MSCs 
into a chondrogenic phenotype under specific in vitro culture conditions 2". Of interest is that 
both type I1 collagen and insulin-like growth factor (IGF)- 17-' have also been shown to have 
potent chondrogenic effects on MSCs. 
Using a scaffold-based gene delivery approach, the objective of this study was to employ 
a collagen (type 11)-GAG (CG) scaffold incorporating the gene encoding for IGF-1 to determine 
if seeded MSCs could be successfully transfected and provide an elevated and prolonged release 
of IGF- 1. Previous chapters have demonstrated that these gene-supplemented CG (GSCG) 
scaffolds can successfully transfect seeded chondrocytes leading to elevated, localized, and 
prolonged delivery of IGF-1 in vitro. It has also been shown that gene transfer in CG scaffolds 
can be enhanced by the incorporation of a Geneporter@ (GP) transfection reagent complexed to 
the plasmid IGF-1 (GP/IGF). In this study, two methods of incorporating the GP/IGF complexes 
into CG scaffolds (investigated in the previous chapter) were employed. The first method 
(Method 1) involved cross-linking half of the total amount of GPIIGF complexes (5pg plasmid 
load) to the scaffold and then adding the second half of the load (also containing 5pg) by 
solution absorption into scaffold. The second method (Method 2) involved cross-linking the full 
plasmid load (10 pg) to the scaffold. During the 2-week 3-D culture period, media was collected 
at various time points to detect IGF-1 overexpression. At the end of the culture period, scaffolds 
were assayed for DNA and accumulated GAG content. The presence of GAG and total collagen 
was also assessed histochemically. 
6.2. MATERIALS AND METHODS 
6.2.1. Type I1 Collagen-GAG Scaffolds 
Porous sheets of a type I1 CG scaffold were fabricated by freeze-drying a porcine type I1 
collagen-GAG slurry (Geistlich Biomaterials, Wolhusen, Switzerland). Similar scaffolds have 
been reported in prior studies to have a porosity of 89 * 2% (mean A standard deviation) and a 
pore diameter of 125 * 42 pm lo. The collagen sheets were sterilized and cross-linked by a 
dehydrothermal treatment l, and 8 mm diameter disks (-2 mm thick) were prepared using a 
dermal biopsy punch (Moore Medical, New Britain, CA). 
6.2.2. Plasmid Propagation & Isolation 
Multiplication of plasmid encoding for IGF- 1 (pIGF- 1) was accomplished by heat shock 
transformation into Escherichia coli DH5a competent cells grown overnight in Luria-Bertani 
(LB) medium containing ampicillin. Plasmid was isolated and purified using a Mega 
QIAfilterTM Plasmid kit (Qiagen, Valencia, CA). The absorption ratio at 260 nm and 280 nm 
was used to determine plasmid concentration and purity while plasmid integrity was 
demonstrated by polyacrylamide gel electrophoresis. The size the pIGF-1 was 6-7 Kb. 
6.2. 3. Incorporation of GenePorter/plasmid IGF-I (GPLGF) Complexes into CG Scaffolds 
Plasmid IGF-1 (pIGF- 1) was complexed to a lipid mediated transfection reagent 
GenePorter @ (GP) (Gene Therapy Systems, Inc., CA) using a 5: 1 (p1 of GenePorter:pg of pIGF- 
1) ratio. GP/IGF complexes were incorporated into the scaffolds using two methods that would 
result in varied release kinetics of the vectors from the CG scaffolds. The frst method used to 
synthesize GSCG scaffolds, GenePorter (x-link & soak) group, involved placing a 60 pl aliquot 
of the GPIIGF plasmid solution containing 5 pg of plasmid onto the DHT-treated scaffolds 
followed by incubation for an hour at room temperature. A 1 ml aliquot of an aqueous 
carbodiimide solution '* consisting of 14 mM 1 -ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride and 5.5 mM N-hydroxysuccinimide (EDAC; Sigma Chemical Co., St. Louis , 
MO) was added to the scaffold and incubated at room temperature for about 30 minutes. Excess 
EDAC was removed by rinsing the scaffolds in PBS. Scaffolds where then briefly dried on filter 
paper and 30 pl aliquot of GPlIGF solution containing another 5 pg of pIGF-lwas added to each 
scaffold and incubated for another hour before seeding chondrocytes. This method of 
incorporation provided a total plasmid load of 10 pg (complexed to the lipid transfection reagent) 
some of which were cross-linked and not cross-linked to the CG scaffold. 
The second method (Method 2) used to synthesize GSCG constructs involved cross- 
linking the full plasmid load to the scaffold. A 60 p1 aliquot of the plasmid solution containing 
10 pg of plasmid onto the DHT-treated scaffolds followed by incubation for at least an hour at 
room temperature. A 1 ml aliquot of the EDAC solution was added to the scaffold and incubated 
at room temperature for about 30 minutes. Excess EDAC was removed by rinsing the scaffolds 
in PBS. 
6.2.4. Mesen chymal Stem Cell (MSC) Isolation and Monolayer Expansion 
Mesenchymal stem cells (MSCs) were isolated from heparinized bone marrow aspirates 
obtained from the iliac crest of six adult Spanish goats (4-5 yrs old). The cells were isolated 
using a Ficoll-Paque PLUS gradient (GE Life Sciences, NJ). Isolated cells were plated and 
expanded in monolayer culture using a medium consisting of low glucose Dulbecco's modified 
Eagle's medium, DMEM (Invitrogen), containing 10% (vlv) fetal bovine serum (FBS), and 1% 
penicillin/streptomycin. The cells were incubated at 37OC and 5% COz. MSCs were grown 
through two subcultures to obtain Passage 2 cells. 
6.2.5. Monolayer Transfection of Mesenchymal Stem Cells (MSCs) 
For comparison with transfection in 3-D culture, cells were transfected in monolayer 
culture to be subsequently seeded in CG scaffolds. For monolayer transfection, cells were 
expanded to 80-90% confluence in 150 cm2 tissue culture flasks (about 3 million cells per flask) 
and transfected with the GenePorter transfection reagent complexed to pIGF-1 at a 5: 1 ratio (pl 
of GP:pg pIGF- 1) according to the manufacturer's instructions for transfection of adherent cells. 
15 pg of pIGF-1 was added per flask. Approximately 24 hrs later, cells were trypsinized, 
counted, and seeded into CG scaffolds. 
6.2. 6. Cell Seeding CG Scaffolds, IGF-I Detection in the Medium, and Scaffold contraction 
Two million MSCs were seeded onto each scaffold by pipetting a 20 pl suspension 
containing half of the total amount of cells onto each side of the scaffold with a 10 minute 
incubation period in between. Cell-seeded scaffolds were cultured in a serum-free medium 
containing high glucose Dulbecco's modified Eagle's medium, DMEM (high glucose 4.5% 
without L-glutamine), 0.1 mM nonessential amino acids, 1 OmM HEPES buffer, 100 UImL 
penicillin, 100 pg/mL streptomycin glutamate, ITS+' (loox, by Sigma Chemical, St. Louis, MO), 
0. lmM ascorbic acid 2-phosphate, 1.25mg/ml bovine serum albumin, 10ngIm.L of TGF-p1, and 
lOOnM dexamethasone. Medium was collected and changed at various time points over a two- 
week culture period and the amount of IGF- 1 in the collected medium (n=11- 12; 2 scaffolds per 
goat) was detected by a sandwich ELISA kit for the human IGF-1 protein (R&D Systems). At 
each medium exchange, the diameter of each scaffold was measure to monitor any change in 
scaffold size (n=12; 2 scaffolds per goat). Cultures were terminated after 2 weeks for 
histological evaluation and biochemical analysis. For DNA and GAG analysis, scaffolds were 
lyophilized and enzymatically digested using proteinase K (Roche Diagnostics, Indianapolis, 
6.2.7. DNA Analysis 
The DNA content of cell-seeded scaffolds was measured using the Picogreen Dye assay 
kit (Molecular Probes, Inc, Eugene, OR) (n=6). The Picogreen dye was used with the reagents 
and standard provided according to the manufacturer instructions. 
6.2.8. GAG Analysis 
The sulfated GAG content of cell-seeded scaffolds after the 2-week culture period was 
determined by the dimethylmethylene blue (DMMB) dye assay l 3  (n=6). An aliquot of the 
proteinase K digest was mixed with the DMMB dye and the absorbance at 525 nm was measured 
with a spectrophotometer. The results were obtained by extrapolating from a standard curve 
using shark chondroitin-6-sulfate. Newly accumulated GAG was determined by subtracting the 
unseeded values from the sample values. 
6.2.9. Histological Analysis of Cell-Seeded Scaffolds 
Cell-seeded scaffolds (n=6) were fixed in 10% neutral buffered formalin, dehydrated, 
embedded in paraffin, and sectioned (six-micrometer thick) by microtomy. Sections were 
Safi-anin-0 stained to detect the presence of sulfated GAG. For @pe I1 collagen 
immunohistochemical analysis, sections were enzymatically digested by protease type XIV for 
45 minutes and stained with a standard avidin-biotin complex peroxidase-based antibody 
staining technique (Vectastain, Vector Laboratories, Burlingame, CA). Mouse anti-chick 
monoclonal antibody for type I1 collagen was obtained from the Developmental Studies 
Hybridoma Bank (Iowa City, IA). Based on the lack of immunohistochemical staining for type 
I1 collagen, a Mason's Trichrome stain was also performed to assess the presence of total 
collagen. 
6.2.10. Statistical Analysis 
Data were analyzed by one or two-factor analysis of variance (ANOVA), and the Fisher's 
protected least squares differences (PLSD) post-hoc test using StatView (SAS Institute Inc, Cary, 
NC). Data are presented as mean * standard error of the mean. 
6.3. RESULTS 
6.3. I .  Cell-Mediated Con traction of GSCG Scaffolds 
There was a notable decrease in scaffold diameter over the course of the 3-D culture for 
all MSC-seeded scaffolds (Fig. 6.1). Controls (non-transfected MSCs seeded in scaffolds) 
displayed the least amount of contraction with a 30% reduction in diameter after the Zweek 
culture period. The GenePorter (x-link) group demonstrated a 38% size reduction, while the 
Monolayer Transfected and GenePorter (x-link & soak) groups displayed the most contraction, 
with a 44% decrease in diameter. Two-factor ANOVA revealed a significant effect of 
transfection condition (P < 0.004, power = 0.9) and time (P < 0.0001, power = 1) on scaffold 
contraction. Fisher's PLSD post hoc test showed significant differences between the Control 
group versus the Monolayer Transfected and GenePorter (x-link & soak) groups and the 
Monolayer Transfected group versus the GenePorter (x-link) group. 
Control 
- * Monolayer Transfection 
+ GenePorter, x-lln k 
-+ GenePorter, x-link & soak 
3.0 fi I 1 I I 1 
Figure 6.1 Diameter change of MSC-seeded CG scaffolds over the 2-week 3-D culture period. n = 11-12; 
mean * SEM. 
6.3.2. IGF-1 Release in 3-0 Culture Medium 
The GenePorter (x-link & soak) group and the Monolayer Transfected group showed a 
noticeable elevation in IGF-1 expression over the Control group (Fig. 6.2). At the end of the 2- 
week period, total accumulated IGF-1 for the GenePorter (x-link & soak) and Monolayer 
Transfected groups was 1 1-fold and 2-fold higher, respectively, than the Control group (Fig. 
6.2b). For all conditions, there seemed to be a trend in the kinetics of IGF-1 release in the 
medium with a peak expression occurring at the Day 12 collection (Fig. 6.2a). Two-factor 
ANOVA revealed a significant effect of time (P < 0.0001, power = 1) and transfection condition 
on IGF-1 release in the medium (P < 0.0001, power = 1). Post hoc analysis confirmed a 
significant difference in IGF-1 release for the GenePorter (x-link & soak) group versus all other 
groups (P < 0.000 1, power = 1). 
6.3.3. Biochemical Analysis of Cell-Seeded GSCG Scaffolds 
DNA content at the end of the 2-week culture period for the GenePorter (x-link & soak) 
and the Monolayer Transfected groups showed noticeably lower values compared to the Control 
group (Fig. 6.3a). There was a 54% and 30% lower DNA content for the GenePorter (x-link & 
soak) and the Monolayer Transfected groups, respectively, compared to Controls. ANOVA and 
Fisher's PLSD post hoc results revealed a significant effect of transfection condition on final 
DNA content after 2 weeks in culture (P < 0.0008, power = 1) with significant differences 
between the GenePorter (x-link & soak) group versus the Control and GenePorter (x-link) groups 
(P < 0.001, power = 1) and between the Monolayer Transfected group versus the GenePorter (x- 
link) group. GAG/DNA values for the Control, Monolayer Transfected, and GenePorter (x-link) 
groups were all similar (Fig. 6.3b). The GenePorter (x-link & soak) group displayed about a 2- 
fold higher GAG/DNA value above all other conditions. ANOVA and post hoc analysis 
confirmed a significant effect of transfection condition on GAG/DNA content (P < 0.0015, 
power = 0.97) and showed significant differences between the GenePorter (x-link & soak) group 
versus all the other groups (P < 0.003, power = 0.97). 
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Figure 6.2 IGF-1 detected in the medium at each time point from MSC-seeded constructs (a) and total 
accumulated IGF-1 (b) over the course of the 2-week 3-D culture period. n = 11-12; mean * SEM. 
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Figure 6.3 DNA (a) and GAGIDNA (b) contents of MSC-seeded scaffolds at the end of the 2-week 3-D 
culture period. n = 6; mean SEM 

6.3.4. Histological Analysis of 3-D Cultures 
Histochemical staining showed a concentration of MSCs at the periphery of the scaffold 
for Control, Geneporter (x-link) and Geneporter (x-link & soak) groups (Figs. 6.4 and 6.5). In 
these scaffolds, there was an absence of cells and tissue formation in the mid-region of the cross- 
sectional slices. Some of these scaffolds demonstrated a concavity that was observed to be 
facing up in the tissue culture wells when the cultures were ended after 2 weeks. The Monolayer 
Transfected group showed the most contraction over time and a high cell concentration in the 
middle of the scaffold (Fig. 6.5). Vertical cross-sections could not be obtained fi-om the 
Monolayer Transfected group due to the high deformation of these constructs. Safranin-0 
staining revealed very little GAG in all of the constructs with only lightly pink regions in 
between some of the scaffold pores (Fig. 6.4). Tissue that lightly stained for GAG between 
pores was not dense and had a "string-like" appearance. For the Monolayer Transfected group, 
most of the tissue and scaffold were contracted and areas staining positive for Safianin-0 had a 
denser appearance. Some samples in the Monolayer Transfected group and the GenePorter (x- 
link & soak group) showed cells that appeared to be rounded and in lacunae (see arrow on 6.4b). 
The Masson's trichrome stain (Fig. 6.5) more clearly distinguished remnants of the 
remaining scaffold and newly synthesized collagen. Type I1 collagen immunohistochemical 
analysis revealed that the synthesized collagen did not seem to be made up of type I1 collagen as 
there was very little, if any, positive staining. The Monolayer Transfected group showed the 
greatest amount of degradation of the scaffold with very little residual scaffold left in the high 
cell populated middle region. The stages of scaffold degradation can be seen more clearly in the 
Monolayer Transfected scaffolds were the degrading scaffold displayed a more "foamy" 
appearance (see arrow on Figure 6.5b) as opposed to the more glassy and opaque appearance of a 
non-degraded scaffold strut (see arrow on Figure 6.5~).  Collagen synthesized fi-om seeded cells 
displayed a smoother tissue appearance surrounding the cells and had a less opaque blue staining 
compared to the undegraded scaffold struts (see arrow on Figure 6.5d). All regions that were 
more populated by cells (on the periphery of the scaffold) for the Control, Geneporter (x-link) 
and Geneporter (x-link & soak) groups showed more collagen synthesis in between the cells, in 
contrast to the middle cross-sectional region of the scaffold where most nondegraded scaffold 
was apparent. The GenePorter (x-link & soak) group seemed to have more collagen synthesis at 
the top and bottom of the scaffold that penetrated more deeply into the scaffold compared to the 
Control and GenePorter (x-link) groups. 
Figure 6.4 Safranin-0 stain for GAG of MSC-seeded scaffolds after 2 weeks in 3D culture (a) Control 
group, @) Monolayer transfected group, (c) GenePorter, x-link group, (d) GenePorter, x-link & soak group. 
Scale bars: 1'' column is 500 pm and 2nd column is 50 pm. Red is a positive stain for GAG. 

Figure 6.5 Mason's Trichrome stain of MSC-seeded scaffolds after 2 weeks in 3D culture (a) Control 
group, @) Monolayer transfected group, (c) GenePorter, x-link group, (d) GenePorter, x-link & soak group. 
Scale bars: 1" column is 500 pm and 2"* column is 50 pm. Blue stain is collagen and red stain is cytoplasm. 

6.4. DISCUSSION 
Of significance in this study was that MSCs seeded within gene-supplemented CG 
scaffolds can be transfected and produce elevated levels of IGF- 1 over a 2-week 3-D culture 
period. Control scaffolds containing MSCs seeded within CG scaffolds without gene 
incorporation also showed IGF-1 production that increased up to 12 days in culture. This 
increased production of IGF-1 fiom Control scaffolds may indicate that cell interaction with the 
CG scaffold and cultured in a defined serum-free medium may also upregulate IGF- 1 expression. 
The method of gene incorporation within CG scaffolds significantly affected IGF- 1 
overexpression as reflected in the IGF-1 release kinetics for the GenePorter (x-link) group versus 
the GenePorter (x-link & soak) group. Cross-linking the full 10pg plasmid load to the scaffold, 
GenePorter (x-link) group, did not show any elevated expression levels over the Control group 
during the 2-week culture period. When 5pg of the GenePorterIpIGF-1 complex was cross- 
linked and the other half was absorbed onto the scaffold (GenePorter (x-link & soak) group) 
there was a significantly higher IGF-1 release in the media compared to the Control group. This 
may indicate that the IGF-1 overexpression produced by the GenePorter (x-link & soak) group 
within this 2-week culture period, is most likely the result of MSCs being transfected by the 
absorbed GenePorterlIGF-1 complexes that are quickly released fiom the scaffold at early time 
points. Based on the histological evaluation revealing the significant amount of undegraded 
scaffold left at the end of 2 weeks, it is likely that the majority of the cross-linked 
GenePorterIpIGF- 1 complexes was not released within this time frame. Longer-term studies 
need to assess if IGF-1 overexpression will occur at later time points when the scaffold more 
l l l y  degrades releasing the cross-linked GenePorterIpIGF- 1 complexes. 
Interestingly, transfecting MSCs in monolayer did not result in the highest 
overexpression when subsequently seeded in 3-D culture. There was only about a 2-fold higher 
accumulated amount of IGF-1 produced fiom the Monolayer Transfected group compared to the 
1 1-fold higher level of the GenePorter (x-link & soak) group compared to the Controls. The 
amount of GenePorterIpIGF- 1 complexes used for monolayer transfection was approximately the 
same amount per cell used for the MSC-seeded gene-supplemented scaffolds. This demonstrates 
that nonviral transfection of cells in a 3-D culture environment may be more efficient than 
transfection in 2-D. This was also demonstrated in the study by Xie et al. 13, in which cells were 
seeded onto 2-D films or 3-D scaffolds and nonvirally transfected with pCMV-bgal and pEGFP 
reporter vectors. In this study, 3-D transfection was found to promote a higher gene expression 
level and longer expression times compared to 2-D transfection. 
Unexpectedly, for all groups (including the Control group) there was a peak in IGF-1 
production between days 9 and 12 and then a decrease in IGF-1 release between days 12 and 14. 
It is speculated that this decrease in IGF-1 release may be due to cell apoptosis due to scaffold 
contraction over time. This contraction may inhibit sufficient nutrient diffusion throughout the 
entire scaffold, eventually leading to cell death and the decreased production of IGF-1. Of note, 
however, is an apparent correlation between total accumulated IGF-1 released in the medium and 
scaffold contraction. Samples that showed elevated IGF- 1 expression above the Controls (the 
Monolayer Transfection and Geneporter (x-link & soak) groups), also showed the most scaffold 
contraction over the two-week culture period. This may indicate that IGF-1 might play a role in 
affecting scaffold contraction by increasing enzymatic production and/or smooth muscle actin 
expression of seeded cells. Future studies will need to assess the possible role of IGF-1 in 
regulating matrix remodeling and smooth muscle actin expression. 
Biochemical analysis for DNA content showed that the Monolayer Transfected and 
GenePorter (x-link & soak) groups had lower amounts of DNA after 2-weeks in culture. This 
supports the possible association between scaffold contraction and cell apoptosis since these 
groups were also the ones that contracted the most. Despite this decrease in DNA content, 
however, the GenePorter (x-link & soak) group showed the highest amount of accumulated 
GAG/DNA at the end of the culture period. The 2-fold increase in GAGDNA values for the 
GenePorter (x-link & soak) group above all other groups may be the result of the significant 
elevation of IGF- 1 overexpression over time. 
Although GAGDNA values were higher for the GenePorter (x-link & soak group) this 
increased accumulated GAG production was not clearly illustrated in the S a b i n - 0  
histologically stained sections. In all groups, there were few isolated regions of light staining for 
GAG. The cell distribution for the Control, GenePorter (x-link) and GenePorter (x-link & soak) 
groups were highly concentrated on the periphery of the scaffold with very little cell distribution 
in the middle cross-sections of the scaffolds. Future work will need to investigate other methods 
of cell-seeding MSCs into the CG scaffolds to create an even distribution of cells that results in a 
more ideal environment for enhancing biosynthesis throughout the entire scaffold. The higher 
cell concentrated regions, however, did show collagen synthesis by seeded cells (reflected in the 
Mason's trichrome stain), although immunohistochemical analysis revealed an absence of type 11 
collagen. 
Of interest are the evident stages of scaffold degradation, most apparent in the outer 
periphery of the Monolayer Transfected group, where the degrading scaffold starts to have a 
"foamy" appearance together with a swelling of the scaffold struts. The Monolayer Transfected 
group showed the most scaffold degradation and a very high number of cells concentrated in the 
middle region of the scaffold. The high concentration of cells may have produced a higher 
concentration of secreted enzyme to more rapidly break down the scaffold. Since scaffolds from 
the Monolayer Transfected group deformed the most, it was difficult to obtain vertical cross- 
sections of samples to determine if this cell distribution was carried throughout the depth of the 
scaffold. Despite this high concentration of cells in the mid-region of the scaffold, however, 
there was very little tissue synthesis (i.e. most of this region stained red for cell cytoplasm and 
not collagen). Cell debris was also apparent in the high cell-populated regions, perhaps owing to 
insufficient nutrient diffusion to these areas. The increased scaffold degradation and lack of 
biosynthesis in the high cell-concentrated regions indicates that a very high cell density may not 
be ideal for obtaining a balanced rate of scaffold degradation and new tissue biosynthesis that is 
required for enhanced tissue repair. 
It is important to note that the anabolic effects of IGF-1 are highly dependent on the IGF- 
1 tyrosine kinase receptor l4  and the accessibility of IGF-1 to its receptor is regulated by the 
presence of IGF- 1 binding proteins 15. It has been shown that IGF- 1 itself can stimulate the 
production of IGF-binding proteins in ovine and bovine articular and growth-plate chondrocyte 
monolayers and can diminish the bioactivity of IGF-1 16. Therefore, it is possible that despite the 
significant elevation of IGF-1 expression above the Control levels for the GenePorter (x-link & 
soak) group, the modest response in biosynthesis reflected in the histological results may be due 
to the production of IGF-binding proteins that could have potentially inhibited the anabolic 
action of expressed IGF- 1. Future work will need to assess the presence of IGF-binding proteins 
in these cultures to determine to what extent the goat MSCs seeded within GSCG scaffolds are 
producing IGF-binding proteins. 
In conclusion, gene-supplemented CG scaffolds can effectively transfect seeded MSCs 
resulting in elevated IGF-1 expression levels and enhanced GAG biosynthesis (as reflected in 
biochemical analysis) after 2-weeks in vitro. These findings show promise in using MSCs as a 
cell source for seeding within GSCG scaffolds for tissue engineering purposes, or for 
regenerative medicine applications, in which a GSCG scaffold can be implanted in conjunction 
with a microfracture procedure. 
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CHAPTER 7: LIMITATIONS AND FUTURE WORK 
The work presented in this thesis shows significant promise for the use of GSCG 
scaffolds in articular cartilage tissue engineering. The following discussion describes various 
limitations to the work presented and identifies potential areas of research for fbrther developing 
GSCG scaffolds in tissue engineering applications. 
One limitation associated with the use of natural biomaterials for tissue engineering 
scaffolds was the inconsistent properties of the type I1 collagen slurry and resulting Ereeze-dried 
porous scaffolds employed in the various studies conducted. Since the type I1 slurry or freeze- 
dried sheets used to make the type I1 slurry was provided by an outside source, the resulting 
slurry viscosity and subsequent freeze-dried scaffold properties (i.e. porosity, degradation 
properties, etc.) were difficult to predict and control from batch to batch, even when using the 
same protocols for creating porous constructs. This variability in inherent scaffold properties 
made it difficult to directly compare results from multiple experiments if different sluny batches 
were used. Efforts to more fully characterize the raw materials and establish standardized 
criteria for slurry properties (i.e. viscosity, GAG content, collagen typing, etc.) would be 
beneficial for the creation of scaffolds with more consistent batch-to-batch properties. 
Another potential limitation was that cells were obtained and used from only one animal 
in experiments using adult canine articular chondrocytes. Other studies carried out in our group 
using multiple animals and using the same culture conditions as in the presented studies, 
however, demonstrated that interanimal variability using adult mongrel dogs was minimal 
(coefficient of variance about 10-1 5%). This variability is small in comparison to the difference 
in the outcome variables between groups that show a statistically significant difference. Hence, 
the overall findings presented in these experiments would most likely be confirmed if subsequent 
multi-animal experiments were carried out. For future developments, however, it is 
advantageous to use cells from multiple animals to present more robust findings so that 
differences between experimental groups would not be exaggerated or muted, as is the potential 
case when using one animal. 
Although the findings of this thesis clearly demonstrates the potential of using GSCG 
scaffolds as gene delivery vehicles for localized and prolonged release of desired growth factors 
for the ultimate enhancement of articular cartilage regeneration, below is a list of potential areas 
of research for the W e r  development of GSCG scaffolds: 
P Evaluation of GSCG scaffolds in an in vivo model, assessing the ability of these 
scaffolds to enhance articular cartilage regeneration using either a cell-seeded GSCG 
construct or an unseeded GSCG scaffold used in conjunction with a microfiacture 
procedure. 
P Investigation of better seeding techniques using mesenchymal stem cells for a more 
even cell distribution within GSCG scaffolds. 
9 A more thorough understanding of cell interaction with CG scaffolds incorporating 
naked plasmid alone, with the lipid mediated transfection reagent, or within gelatin 
nanoparticles in regards to cell attachment, scaffold contraction (evaluating 
contributions from varying scaffold cross-link density or SMA expression of seeded 
cells), and transfection efficiency. 
P Alternative methods for incorporation of plasmid within CG scaffolds for a better 
control of vector release. For example: 
Cationization of the type I1 scaffold for better naked plasmid retention using a 
soak and freeze-dry method of incorporation (eliminates the interdependence of 
the amount of gene incorporation and the degree of cross-linking of the collagen 
scaffold associated with using the carbodiimide method of incorporation). 
The use of the avidin-biotin system for plasmid attachment to CG scaffolds (may 
provide a way to have better control over the specific amount of plasmid that is 
incorporated). 
P Incorporation of more than one gene within CG scaffolds and controlling the release 
of each individual gene to be expressed at varying time points in the repair process. 
P A more thorough investigation of the effect of plasmid size (when incorporated 
within CG scaffolds) on the ability to transfect seeded cells. 
P Determination of optimal conditions for synthesizing and incorporating gelatin 
nanoparticles within CG scaffolds. 
CHAPTER 8: SUMMARY 
The overall goal of this thesis was to investigate a scaffold-based gene transfer approach 
employing collagen (type 11)-GAG scaffolds as nonviral gene delivery vehicles to provide local, 
elevated, and prolonged release of growth factors for enhancing articular cartilage tissue 
engineering in vitro and ultimately in vivo. The main variables investigated in the process of 
developing gene-supplemented 3-D constructs for implantation in vivo are: 1) media culture 
conditions in both monolayer expansion and 3-D culture, 2) methods to incorporated genes 
within type I1 CG scaffolds, 3) methods to enhance gene transfer using lipid-mediated 
transfection reagents or nanoparticles, and 4) potential cell sources. This chapter provides a 
summary of the significant findings from the experiments presented in the previous chapters in 
relation to the aforementioned hypotheses. 
The fust experiments in Chapter 2 involved comparing two different expansion media for 
growing chondrocytes in monolayer to be subsequently cultured in CG scaffolds using a serum- 
free culture medium. Although the initial purpose of this experiment was to assess specific 
expansion medium culture conditions that would result in better cartilaginous formation when 
using a defined serum-free medium in 3-D culture, an interesting finding was the fact that the 
composition of the expansion medium also had a significant impact on the ability to (nonvirally) 
transfect or (virally) transduce chondrocytes in monolayer. Fortunately, the expansion medium 
(Medium 2) that enhanced biosynthesis and chondrogenesis in 3-D culture also proved to be the 
expansion medium that resulted in improved gene transfer to chondrocytes in monolayer. These 
results commended the use of Medium 2 for expanding chondrocytes in conjunction with a 
defined serum-free culture medium for 3-D culture, throughout the rest of the subsequent 
experiments for evaluating gene-supplemented collagen-GAG scaffolds for articular cartilage 
tissue engineering. 
The findings of this study support the first hypothesis that the make up of the monolayer 
expansion medium not only has a direct effect on biosynthesis and chondrogenesis in 3-0 
culture, but also affects gene transfer to cells. 
Chapter 3 included a comparison of two different gene incorporation methods. One 
method involved soaking the scaffold in the plasmid solution followed by a freeze-drying 
process (Method 1) and the other involved chemically cross-linking the plasmid to the scaffold 
(Method 2). This study evaluated these two incorporation methods regarding the kinetics of 
IGF-1 plasmid release from the scaffolds, the ability to maintain plasmid integrity, and the 
resulting IGF- 1 expression kinetics from cells seeded and subsequently transfected within the 
GSCG scaffolds. Another aspect of this study was a comparison between supplementing CG 
scaffolds with either naked plasmid IGF-1 alone or plasmid complexed to a (Geneportem) lipid- 
mediated transfection reagent (GPIIGF), evaluating the differences in IGF- 1 gene expression 
over time and the effects on biosynthesis and chondrogenesis. The significant findings from 
these studies are as follows: 
P Cross-linking plasmid DNA to CG scaffolds (Method 2) results in a greater 
retention of plasmid DNA as opposed to the quick passive release of plasmid 
(majority of plasmid is released within 24 hrs in buffer) from the soak and freeze- 
dry method of gene incorporation (Method 1). 
9 Plasmid integrity is maintained for plasmid released or retained in GSCG scaffolds 
for both methods of incorporation. 
P Plasmid release kinetics from GSCG scaffolds dictates the kinetics of IGF-1 
expression from chondrocytes seeded and subsequently transfected within GSCG 
scaffolds; scaffolds synthesized by Method 2 result in a more steady and prolonged 
IGF- 1 release compared to scaffolds synthesized by Method 1. 
9 Incorporation of a lipid-mediated transfection together with the IGF-1 plasmid 
results in enhanced gene transfer and higher IGF-1 release compared to using naked 
plasmid alone. 
9 A localized, elevated, and prolonged release of IGF-1 from chondrocytes seeded and 
subsequently transfected within GSCG scaffolds (with as little as 4-10pg of plasmid 
IGF-1) results in enhanced biosynthesis and chondrogenesis in vitro. 
The results from these studies support the second hypothesis that cross-linking naked 
plasmid DNA to the CG scaffold can result in a more prolonged delivery of genes and expression 
of the encoded growth factor compared to plasmid addition without cross-linking; and the third 
hypotheses that a lipid transfection reagent complexed to the plasmid can be successfully 
incorporated and cross-linked to CG scaffolds, and can enhance gene transfer to seeded cells. 
Chapter 4 included the development and characterization of cationized gelatin plasmid 
IGF-1 nanoparticles (CGPIN) and evaluates 1 .) the potential use of these nanoparticles as 
nonviral gene transfer reagents in chondrocyte monolayers and 2.) the behavior of CGPIN- 
transfected cells seeded within CG scaffolds in regards to the IGF-1 release kinetics and 
subsequent effects on GAG biosynthesis. The results from these studies showed that: 
9 Gelatin nanoparticles formed by a complex coacervation method using cationized 
gelatin and plasmid IGF- 1 can effectively form uniformly-sized nanoparticles that 
can successfully transfect chondrocytes with the IGF-1 (and GFP) genes in 
monolayer culture. 
9 Nanoparticle morphology and zeta potential (which is affected by gelatin 
cationization), the weight ratio of gelatin to plasmid used to synthesize the 
nanoparticles, and the plasmid amount applied to cells during transfection 
significantly affects the resulting transfection of chondrocytes in monolayer. 
9 CGPIN-transfected cells subsequently seeded within CG scaffolds can maintain an 
elevated and prolonged expression of IGF-1 up to 2-weeks in culture. 
9 As demonstrated in previous studies, the effect of IGF- 1 overexpression localized 
within CG scaffolds can result in a significant improvement in GAG biosynthesis 
compared to the control conditions. 
This experiment corroborates the fourth hypothesis that gelatin nanoparticles can 
successfully enhance the transfection of chondrocytes and can be used in conjunction with a CG 
scaffold to produce a localized and prolonged release of encoded protein. 
Based on promising results from monolayer transfection studies using CGPIN, Chapter 5 
evaluated methods to synthesize GSCG scaffolds using either CGPIN or GPAGF complexes 
using two different modes of incorporation: 1 .) cross-linking half the total plasmid load to the 
scaffold and allowing the other half of the load to be absorbed into the scaffold (Method 1) or 2.) 
cross-linking the full amount of plasmid load (Method 2-also used in prior experiments). The 
significant conclusions from these studies are the following: 
CGPIN and GP/IGF complexes can be successfully incorporated within type I1 CG 
scaffolds and can result in elevated IGF- 1 release into the 3-D culture medium. 
Method 1 -synthesized GSCG scaffolds results in higher IGF- 1 release levels 
compared to Method 2 over the 2-weak period for scaffolds containing either CGPIN 
or GPDGF complexes. 
Scaffolds incorporating GPDGF complexes demonstrate higher IGF- 1 expression 
levels compared to scaffolds containing CGPIN. The type of gene supplementation, 
however, also significantly affects the cross-link density as well as the resulting cell- 
mediated contraction of GSCG scaffolds. 
IGF- 1 overexpression resulting from successful transfection of chondroctyes seeded 
within GSCG scaffolds can result in enhanced biosynthesis and chondrogenesis in 3- 
D culture. 
These findings also support the third and fourth hypothesis that a lipid-mediated 
transfection reagent or gelatin nanoparticles can successfilly enhance the transfection of 
chondrocytes and can be successfilly incorporated within a CG scaffold to produce a localized 
and prolonged release of encoded protein. 
Chapter 6 evaluated mesenchyrnal stem cells (MSCs) as an alternative cell source to be 
used in conjunction with GSCG scaffolds for articular cartilage tissue engineering, by assessing 
the the ability of MSCs to be transfected within GSCG scaffolds and to maintain prolonged 
overexpression of the encoded protein. The results fi-om this study showed that: 
> MSCs can be successfully transfected by incorporated gene vectors when seeded 
within the CG scaffolds and can maintain prolonged IGF-1 overexpression up to 2 
weeks in culture. 
These results accept the fifth hypothesis that MSCs can be transfected using GSCG 
scaffolds and can maintain overexpression of desired proteins over prolonged times. 
Based on these investigations, the optimal GSCG scaffold commended for subsequent in 
vivo studies for articular cartilage repair (particularly with a microfi-acture procedure) would 
consist of a type I1 CG scaffold supplemented with 10-20 pg of total plasmid IGF-1 complexed 
with a lipid-mediated transfection reagent (Geneportem), incorporating half of the total amount 
of the GenePorterIpIGF-1 complexes using a carbodiimide cross-link method and incorporating 
the other half by simple absorption. This type of construct will allow immediate transfection of 
cells through passive release of the absorbed plasmid complexes, and prolonged transfection and 
protein overexpression as the cross-linked GenePorterIpIGF- 1 complexes are released upon 
scaffold degradation over time. 

CHAPTER 9: CONCLUSIONS 
Below are the main conclusions that this thesis supports: 
1. The composition of the monolayer expansion medium not only has a direct effect on 
biosynthesis and chondrogenesis in 3-D culture, but also on gene transfer to cells in 
monolayer. 
2. Cross-linking plasmid DNA to the CG scaffold achieves a more steady delivery of genes, 
resulting in a more stable and prolonged overexpression of the encoded growth factor 
from seeded chondrocytes compared to plasmid incorporation without cross-linking. 
3. A lipid mediated transfection reagent complexed to plasmid DNA can be successfilly 
incorporated and cross-linked to CG scaffolds and results in enhanced gene transfer to 
seeded cells. 
4. Cationized gelatin nanoparticles can successfully enhance gene transfer to chondrocytes, 
and when used in combination with a CG scaffold, can produce a localized and prolonged 
release of encoded protein. 
5. IGF- 1 overexpression resulting from successful IGF- 1 gene transfer to chondrocytes 
seeded within GSCG scaffolds enhances the resulting synthesis of cartilage matrix 
molecules and chondrogenesis. 
6. MSCs can be transfected when seeded into GSCG scaffolds and can maintain 
overexpression of desired proteins over prolonged times. 
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APPENDIX A: IMPORTANCE OF TRANSFORMING GROWTH 
FACTOR (TGF)-p 1 AND/OR OSTEOGENIC PROTEIN (0P)-1 IN 
THE 3-D SERUM-FREE CHONDROGENIC CULTURE MEDIUM 
A.1. INTRODUCTION 
Several studies have demonstrated the favorable effects of human recombinant 
transforming growth factor (TGF)-f31 and human recombinant osteogenic protein (0P)- 
1 (or bone morphogenetic protein-7, BMP-7) '-I4 on chondrogenesis in vitro and on 
cartilage repair in vivo. The current study investigated the effects of supplementing the 
3-D serum-free differentiation medium w/ TGF-f3 1, OP- 1, or TGF-f3 1 & OP- 1 together, 
on chondroctyes grown in collagen (type 11)-GAG (CG) scaffolds. This investigation 
was performed to assess the necessity of adding TGF-f31 in the 3-D culture medium for 
evaluating CG scaffolds incorporating the gene encoding for OP-1 and to also verify that 
OP-1 has beneficial effects on tissue regeneration in our 3-D culture system. 
A.2. MATERIALS AND METHODS 
A.2.1. Type 11 Collagen Scaffold Fabrication 
Porous sheets of type I1 collagen were fabricated by freeze-drying a porcine 
cartilage-derived slurry (Geistlich Biomaterials, Wolhusen, Switzerland). The collagen 
sheets were sterilized and cross-linked dehydrothermally by placing the samples in a 
vacuum oven at 105 "C for 24 hours. Eight-mm diameter disks (-2 mm thick) were 
punched out with a dermal punch (Moore Medical, New Britain, CA) and additionally 
cross-linked by a ten minute carbodiimide treatment containing an aqueous solution of 14 
mM 1 -ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and 5.5 mM N- 
hydroxysuccinimide (EDAC; Sigma Chemical Co., St. Louis , MO). Excess EDAC was 
removed by rinsing in PBS. 
Am2m2m Chondrocyte Isolation and Expansion 
Chondrocytes were isolated from the trochleae of both knees (stifle joints) from 
one adult mongrel dog (approximate age 2-4 years). The cells were isolated using a 
sequential digestion of pronase (20 Ulml, 1 hr) and collagenase (200 Ulml, overnight). 
The cells were then expanded in monolayer culture using a medium consisting of high 
glucose Dulbecco's modified Eagle's medium, DMEM (4.5 g/L D-glucose, without L- 
glutamine and with 1 mM sodium pyruvate), containing 10% (vlv) fetal bovine serum 
(FBS), 0.1 mM nonessential amino acids, 10 mM N-2-Hydroxyethylpiperazine-N'-2- 
ethanesulfonic (HEPES) buffer, 100 UImL penicillin, and 100 yg/mL streptomycin 
glutamate. The medium was supplemented with the following growth factors (all from 
R&D Systems, Minneapolis, MN): 5 ng1m.L of fibroblast growth factor-2 (FGF-2), 10 
ngIrnL of platelet-derived growth factor-bb (PDGF-bb), 1 n g / d  of transforming growth 
factor- fl1 (TGF-fll). The cells were incubated at 37OC and 5% C02. Once cells reached 
confluence, they were trypsinized, re-suspended, and re-plated to obtain passage (P) 1 
cells for seeding into the scaffolds. 
A.2.3. Cell Seeding and Chondrocyte Culture in Collagen (type 10-GAG Scaffolds 
For seeding collagen type I1 scaffolds, hydrated scaffolds (previously cross- 
linked) were briefly dried on filter paper and placed on pre-warmed agarose-coated wells. 
Four million cells were added to each scaffold by pipetting a suspension of 2 million cells 
(in 20 pl medium) onto each side with a 10 minute incubation period in between. Cell- 
seeded scaffolds were cultured in a defined serum-free medium (SFM) which consisted 
of high glucose DMEM (4.5 glL D-glucose, without L-Glutamine and with 1mM Sodium 
Pyruvate), 0.1 mM nonessential amino acids, 10 mM HEPES buffer, 100 UImL 
penicillin, 100 p g / d  streptomycin glutamate, ITS" (1 OOx, by Sigma Chemical, St. 
Louis, MO), 0.1 mM ascorbic 2-phosphate, 1.25 mg/ml bovine serum albumin, and 100 
nM dexamethasone. To examine the effects of adding human recombinant TGF-PI 
andlor OP-1 to the SFM, the following conditions were investigated: 1 .) no growth 
factor addition (NoGF group), 2.) addition of 10 ng/ml TGF-P 1 (TGF group), 3 .) 
addition of 10 ng/ml OP-1 (OP(10) group), 4.) addition of 10 ng/ml TGF-PI + 10 ng/ml 
OP- 1 (TGFlOP(10) group), or 4.) addition of 10 ng/ml TGF-P 1 + 100 ng/ml OP- 1 
(TGF/OP(100) group). Media was changed every 2-3 days (1.5 ml per scaffold). At each 
medium change, the diameters of the scaffolds were monitored to assess scaffold 
contraction over time. Cultures were terminated after 2 weeks for histological evaluation 
and biochemical analysis. For DNA and GAG analysis, scaffolds were lyophilized and 
enzymatically digested using proteinase K (Roche Diagnostics, Indianapolis, IN). 
A. 2.4. DNA Analysis 
The DNA content of cell-seeded scaffolds was measured using the Picogreen Dye 
assay kit (Molecular Probes, Inc, Eugene, OR) (n=4). The Picogreen dye was used with 
the reagents and standard provided according to the manufacturer instructions. 
A. 2.5. GAG Analysis 
The sulfated GAG content of cell-seeded scaffolds after the 2-week culture period 
was determined by the dimethylmethylene blue (DMMB) dye assay l 5  (n = 4). An 
aliquot of the proteinase K digest was mixed with the DMMB dye and the absorbance at 
525 nm was measured with a spectrophotometer. The results were obtained by 
extrapolating from a standard curve using shark chondroitin-6-sulfate. Newly 
accumulated GAG was determined by subtracting the unseeded values fi-om the sample 
values. 
A.2.6. Histology of Cell-Seeded Scaffolds 
Cell-seeded scaffolds (n = 2-3) were fixed in 10% neutral buffered forrnalin, 
dehydrated, and embedded in paraffin. Six-micron thin sections were stained with 
Safranin-0 to assess the presence of sulfated GAG. 
A. 2.7. Statistical Analysis 
Data were analyzed by one- or two-factor analysis of variance (ANOVA), and the 
Fisher's protected least squares differences (PLSD) post-hoc test using StatView (SAS 
Institute Inc, Cary, NC). Data are presented as mean 2 standard error of the mean. 
A.3. RESULTS 
A.3.1. Macroscopic Appearance and Contraction of Cemeeded CG Scaffolds 
There was an obvious difference in appearance and contraction comparing 
scaffolds grown with or without the addition of TGF-PI at the end of the 2-week culture 
period (Fig. A. 1). Scaffolds grown with TGF-f31 (Figs. A. ld-f) seemed to have more 
tissue formation and possessed a more homogeneous opaque appearance throughout the 
entire scaffold. In contrast, scaffolds grown without TGF-f31 (Figs. A. 1 a-c) were much 
smaller in size, had greater deformation, and showed an opaque area mostly in the center 
of the scaffold (around the periphery, the scaffold appeared more transparent). The color 
of the resulting medium was also more pink for cultures grown without TGF-PI. There 
was no obvious macroscopic difference in scaffold appearance after 2 weeks resulting 
from the addition of OP- 1 at either concentration (10 nglml or 100 ng/ml) with or without 
TGF-p1 . 
Measurements of scaffold diameter at the end of 2 weeks showed that scaffolds 
grown in medium without TGF-f31 contracted to 3.5-4 mm in diameter, whereas, the 
scaffolds cultured with TGF-P1 supplementation had diameters in the range of 5-6 mm 
(Fig. A.2). Two-factor ANOVA revealed a significant effect of time (P < 0.0001, power 
= 1) and type of growth factor supplementation (P < 0.0001, power = 1) on cell-mediated 
contraction. Additional post hoc analysis showed significant differences between all 
scaffolds grown with TGF-P1 versus all scaffolds grown without TGF-p1 (P < 0.0001, 
power = 1). Of the scaffolds grown without TGF-PI, the NoGF group was significantly 
different fiom the OP(10) group (P < 0.0005, power = 1). For the scaffolds grown with 
TGF-PI supplementation, there was a significant difference between the TGF and 
TGFlOP(10) groups (P < 0.0001, power = 1). 
Figure A. 1 Macroscopic view of cell-seeded 3-D scaffolds grown in serum-free medium 
supplemented with no growth factors (a), lOnglml OP-1 (b), 100nglml OP-1 (c), 10nglml TGF-pl (d), 
l0ngIml TGF-$l+lOnglml OP-1 (e), l0nglml TGF~1+100nglml OP-1. Scale bar is 400pm. 
I 4 4.0 4 + NoGF 
.I - A - OP(l0) 
Figure A. 2 
t SEM. 
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Contraction of cell-seeded CG scaffolds over the 2-week culture period. n = 6; mean 

A.3.2. Biochemical Analysis of Cell-Seeded CG Scaffolds 
At the end of the 2-week culture, DNA (Fig. A.3a) and accumulated GAGIDNA 
content (Fig. A.3b) were noticeably higher for scaffolds grown in TGF-pl-supplemented 
medium. ANOVA showed a significant effect of type of growth factor supplementation 
on DNA content and on accumulated GAGDNA content (P < 0.0001, power = 1) with 
significant difference between all scaffolds grown with TGF-PI versus those grown 
without TGF-PI (P < 0.0001, power = 1). Post hoc analysis revealed that for scaffolds 
grown without TGF-p 1 supplemented in the medium, the addition of OP- 1 at 100 nglml 
did result in a significantly higher DNA content (-20% higher value) compared to the 
NoGF and OP(10) groups (P < 0.002, power = 1). Additionally, there was a slight 
significant difference (-10%) in DNA content between the TGFlOP(10) and the 
TGFlOP(100) groups (P < 0.04, power = I). There was no significant difference in 
GAGIDNA content among the cultures grown without TGF-PI. For scaffolds grown 
with TGF-p1, however, there was a significant effect of adding OP- 1 at the 100 nglml 
concentration on GAG/DNA at the end of the 2-week period, with a 22% and 3 1 % higher 
GAGIDNA value compared to the TGF group and the TGFlOP(10) group, respectively 
(P < 0.004, power = 1). 
A.3.3. Histological Analysis of Cell-Seeded CG Scaffolds 
Safranin-0 staining for GAG revealed an obvious difference in tissue formation 
and staining between scaffolds grown without TGF-81 (Figure A.4a and b) verses 
scaffolds cultured with TGF-PI (Figure A.4c). There were no obvious differences in 
histological appearance when OP- 1 was added at either concentration (with or without 
TGF-PI). Scaffolds that were cultured without TGF-p1 showed a very dense population 
of cells in the middle of the scaffold with very little tissue formation and Safranin-0 
staining (Figure A.4a and b). In contrast, scaffolds grown in medium with TGF-p1 
demonstrated significantly more tissue formation that stained intensely and uniformly for 
GAG. Some cells within these scaffolds were also rounded and located in lacunae 
(Figure A.4c). 

NoGF TGF OP(10) TGFIOP('I0) OP(100) TGFIOP(IO0) 
- 
NoGF TGF OP(10) TGFtOP(10) OP(100) TGFtOP(l00) 
Figure A. 3 DNA content (a) and GAGlDNA content (b) at the end of the 2-week 3-D culture 
period. n = 4; mean * SEM. 

Figure A. 4 Representative sections stained with Saffranin-0 (red is positive stain for GAG) of 




The results of this study verified the importance of adding TGF-PI in the 3-D 
serum-fiee culture medium. The addition of TGF-p1 significantly increased tissue 
formation, GAG biosynthesis, and chondrogenesis in chondrocyte-seeded CG scaffolds. 
The increased tissue formation in scaffolds cultured with TGF-f31 resulted in a larger 
construct size compared to scaffolds grown without TGF-f31. Without TGF-PI 
supplementation, the cells contracted the scaffold (resulting in high cell densities in the 
scaffold center), but hardly any tissue or GAG was produced. The effects of OP-1 were 
not as obvious in the macroscopic or histological appearance of scaffolds cultured with 
OP- 1, however, there was a significant beneficial effect on accumulated GAG/DNA at 
the end of the 2-week culture when using 100 ng/ml of OP- 1 (with 10 ng/ml TGF-f31) 
supplemented in the medium compared to using TGF-f31 alone. This demonstrates the 
potential synergistic effects of TGF-p1 and OP-1 on cartilage formation. Future work 
should determine the concentrations of OP-1 (when used with TGF-p1) required for 
optimal biosynthesis and chondrogenesis in CG scaffolds. 
These findings commend the continued use of TGF-P1 as a supplement in the 3-D 
culture medium for evaluating gene-supplemented collagen-GAG (GSCG) scaffolds, and 
justify the development of GSCG scaffolds incorporating the gene encoding for OP- 1. 
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APPENDIX B: GENE-SUPPLEMENTED COLLAGEN-GAG 
SCAFFOLDS FOR NONVIRAL GENE DELIVERY OF 
OSTEOGENIC PROTEIN (0P)-1 
B.1. INTRODUCTION 
The recombinant protein for osteogenic protein (0P)- 1 or bone morphogenetic 
protein (BMP)-7 has been shown to have favorable affects on chondrogenesis in vitro 
and to stimulate cartilage formation and aggrecan synthesis in vivo 5-7. A local and 
prolonged administration of OP- 1 may be beneficial for articular cartilage formation. 
Therefore, a plasmid encoding for (0P)- 1 was another plasmid of interest to use in 
conjunction with the collagen (type 11) scaffold for providing a prolonged, elevated, and 
local release of OP- 1 via a nonviral scaffold-based approach. This preliminary study 
investigates the potential use of CG scaffolds for the delivery of a plasmid containing the 
OP- 1 gene (supplied by Stryker Biotech). Plasmid OP- 1 (POP- 1) was cross-linked to the 
CG scaffold with or without a Geneportem transfection reagent. The OP- 1 released in 
the 3-D serum-free medium fiom seeded chondroctyes was assessed over a 2-week 
culture period. At the end of the 2-weeks, scaffolds were allocated for biochemical and 
histological analysis. 
B.2. MATERIALS AND METHODS 
B. 2.1. Type 11 Collagen- GA G Scaffold Fabrication 
Porous sheets of type I1 collagen were fabricated by freeze-drying a porcine 
cartilage-derived slurry (Geistlich Biomaterials, Wolhusen, Switzerland). The collagen 
sheets were sterilized and cross-linked dehydrothermally by placing the samples in a 
vacuum oven at 105 "C for 24 hours. Eight-mm diameter disks (-2 mm thick) were 
punched out with a dermal punch (Moore Medical, New Britain, CA). 
B.2.2. OP-I Plasmid Propagation and Isolation 
Multiplication of plasmids encoding for OP- 1 (POP- 1) was accomplished by heat 
shock transformation into Escherichia coli DH5a competent cells grown overnight in 
Luria-Bertani (LB) medium containing ampicillin. Plasmid was isolated and purified 
using a Mega QIAfilterTM Plasmid kit (Qiagen, Valencia, CA). The absorption ratio at 
260 nm and 280 nm was used to determine plasmid concentration and purity while 
plasmid integrity was demonstrated by polyacrylamide gel electrophoresis. The size of 
POP-1 was 1 1 - 12kb. 
B. 2.3. Plasmid In corporation into CG Scaffolds 
Plasmid OP-1 was cross-linked to the CG scaffold with or without a Geneporter@ 
(GP) transfection reagent. An aliquot of diluted POP-1 solution containing 10 or 50 pg 
of POP-1 was placed onto the DHT-treated scaffolds followed by incubation for an hour 
at room temperature. For scaffolds incorporating the GP/pOP-1 complexes, a 10 pg 
plasmid load per scaffold was employed and a 5: 1 (pllpg) ratio of GP:plasmid was used 
to synthesize the GPIpOP-1 complexes. An aliquot of an aqueous carbodiimide cross- 
linking solution consisting of 14 mM 1 -ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride and 5.5 mM N-hydroxysuccinimide (EDAC; Sigma Chemical Co., St. 
Louis , MO) was then added to the scaffold and incubated for about 30 minutes to allow 
cross-links to form among the collagen molecules and between the plasmid and collagen. 
Excess EDAC was removed by rinsing the scaffolds in PBS. The resulting OP-1 plasmid 
load was assessed by enzymatically digesting unseeded GSCG scaffolds using proteinase 
K (Roche Diagnostics, Indianapolis, IN) and assessing the amount of DNA using the 
Picogreen Dye assay kit (Molecular Probes, Inc, Eugene, OR). 
B. 2.4. Ch ondrocyte Isolation and Expansion 
Chondrocytes were isolated from the trochleae of both knees (stifle joints) from 
one adult mongrel dog (approximate age 2-4 years). The cells were isolated using a 
sequential digestion of pronase (20 Ulml, 1 hr) and collagenase (200 Ulml, overnight). 
were expanded in monolayer culture using a medium consisting of high glucose 
Dulbecco's modified Eagle's medium, DMEM (4.5 g/L D-glucose, without L-glutamine 
and with 1mM sodium pyruvate), containing 10% (vlv) fetal bovine serum (FBS), 0.1 
mM nonessential amino acids, 1 0 mM N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic 
(HEPES) buffer, 100 U/mL penicillin, and 100 pg/mL streptomycin glutamate. The 
medium was supplemented with the following growth factors (all fiom R&D Systems, 
Minneapolis, MN): 5 ng/mL of fibroblast growth factor-2 (FGF-2), 10 ng/mL of platelet- 
derived growth factor-bb (PDGF-bb), 1 ng/mL of transforming growth factor- p1 (TGF- 
PI). The cells were incubated at 37OC and 5% CO2. Once cells reached confluence, they 
were trypsinized, re-suspended, and re-plated to obtain passage (P)1 cells for seeding into 
the scaffolds. 
B. 2.5. Nonviral Gene Transfer in GSCG Scaffolds and Scaffold Contraction 
For seeding GSCG scaffolds, hydrated scaffolds were briefly dried on filter paper 
and placed on pre-warmed agarose-coated wells. Four million cells were added to each 
scaffold by pipetting a suspension of 2 million cells (in 20 p1 medium) onto each side 
with a 10-minute incubation period in between. Cell-seeded scaffolds were cultured in a 
defined serum-free medium (SFM) which consisted of high glucose DMEM (4.5 gR. D- 
glucose, without L-Glutamine and with l mM Sodium Pynwate), O. l mM nonessential 
amino acids, 10 mM HEPES buffer, 100 U/mL penicillin, 100 pg/mL streptomycin 
glutamate, ITS" ( 100x, by Sigma Chemical, St. Louis, MO), 0.1 m M  ascorbic 2- 
phosphate, 1.25 mg/ml bovine serum albumin, 10 ng/mL of TGF-P1, and 100 nM 
dexamethasone. Medium was collected and changed at various time points over a two- 
week culture period, and the amount of OP-1 in the collected medium (n = 6) was 
detected by an OP- l DuoSet ELISA kit (R&D Systems). During each medium change, 
the diameters of the scaffolds were monitored to assess scaffold contraction. Cultures 
were terminated after 2 weeks for histological evaluation and biochemical analysis of the 
resulting DNA and GAG content. For DNA and GAG analysis, scaffolds were 
lyophilized and enzymatically digested using proteinase K (Roche Diagnostics, 
Indianapolis, IN). 
B. 2.6. DNA Analysis 
The DNA content of cell-seeded scaffolds was measured using the Picogreen Dye 
assay kit (Molecular Probes, Inc, Eugene, OR) (n = 4). The Picogreen dye was used with 
the reagents and standard provided according to the manufacturer instructions. 
B.2.7. GAGAnalysis 
The sulfated GAG content of cell-seeded scaffolds after the 2-week culture period 
was determined by the dirnethylmethylene blue (DMMB) dye assay * (n = 4). An aliquot 
of the proteinase K digest was mixed with the DMMB dye and the absorbance at 525 nm 
was measured with a spectrophotometer. The results were obtained by extrapolating 
from a standard curve using shark chondroitin-6-sulfate. Newly accumulated GAG was 
determined by subtracting the unseeded values from the sample values. 
B.2.8. Histology of Cell-Seeded GSCG Scaffolds 
Cell-seeded scaffolds (n = 2-3) were fixed in 10% neutral buffered formalin, 
dehydrated, and embedded in paraffin. Six-micron thin sections were stained with 
Safranin-0 to assess the presence of sulfated GAG. 
Statistical Analysis 
Data were analyzed by one- or two-factor analysis of variance (ANOVA), and the 
Fisher's protected least squares differences (PLSD) post-hoc test using StatView (SAS 
Institute Inc, Cary, NC). Data are presented as mean e standard error of the mean. 
B.3. RESULTS 
B. 3.1. OP- I Plasm id Load in Unseeded GSCG Scaffolds 
OP- 1 plasmid detected in unseeded scaffolds after plasmid incorporation using the 
carbodiimide cross-linking method revealed -85% incorporation of the 10 yg load within 
the scaffold for the OP(10) group (without the GP reagent) and 24% incorporation of the 
50 pg load for the OP(50) group (Fig. B.l). It appeared that the GenePorterIpOP-1 
complexes incorporated within the CG scaffold for the GPlOP(l0) group could not be 
detected by the Picogreen assay. 
OP(10) OP(50) GPlOP(1O) 
Figure B. 1 Incorporated POP-1 alone or with the GP transfection reagent. n = 2; mean * SEM. 
B. 3.2. Cell-Mediated Con traction of Chon drocyte-Seeded GSCG Scaffolds 
Over the 2-week culture period, the GPlOP(l0) group displayed the most cell- 
mediated contraction with a 28% decrease in scaffold diameter. The OP(10) and OP(50) 
groups both showed about a 20% size reduction and the Control group had a 10% 
decrease in scaffold diameter at the end of the culture period. Two-factor ANOVA 
revealed a significant effect of type of gene supplementation (P < 0.0001, power = 1) and 
time (P < 0.0001, power = 1) on cell-mediated contraction. Post hoc analysis showed a 
significant difference between the Control group and all the other groups (P < 0.0001, 
power = 1) and between the GPlOP(l0) group verses the rest of the groups (P < 0.0001, 
power = 1). 
Figure B. 2 Contraction of cell-seeded GSCG scaffolds over the 2-week culture period. n = 6; 
mean * SEM. 
B.3.3. OP-I Release in the 3-0  Culture Medium 
Detectable OP-1 in the medium (Fig. B.3a) was not apparent for any of the groups 
until about 8 days in culture (at the Day 11 and Day 14 collections). At these time points, 
OP-1 release in the medium from the Control group was about 27 pglml. The GP/OP(lO) 
group showed a noticeably higher elevation in OP-1 compared to the rest of the groups. 
Two-factor ANOVA revealed a significant effect of type of gene supplementation (P < 
0.01, power = 0.8) on resulting OP-1 expression, but no significant effect of time. Post 
hoc analysis showed a significantly higher elevation in OP-1 release for the GP/OP(lO) 
group above all other groups (P < 0.03, power = 0.8). There was no significant 
difference in OP- 1 expression between the Control group and scaffolds supplemented 
with POP-1 alone. Total accumulated OP-1 at the end of the 2-week period showed a 
30% higher level for the GPlOP(10) group compared to the Control group (Fig. B.3b). 
45 U Day 11 Collection 1 
III Day 14 Collection 
Control 
(b) Control OP(10) OP(50) GPlOP(10) 
Figure B. 3 OP-1 detected in the media (a) at Day 11 and Day 14 and total accumulated OP-1 
(b) produced from chondrocytes seeded in control and GSCG scaffolds over the 2-week culture 
period. n = 6; mean * SEM. 

B.3.4. Biochemical Analysis of GSCG Scaffolds Incorporating POP-1 
The GPlOP(10) group had a slight, but significantly higher (1 1%) DNA content 
(Fig. B.4) compared to the other groups at the end of the 2-week culture (P < 0.03, power 
= 0.8). Since DNA content detected by the Picogreen assay includes both nuclear 
material and POP-1 remaining in the scaffold after the 2-week period, GAG contents 
were not normalized to DNA values. The GPlOP(10) group showed a 16%, 34%, and 
47% higher accumulated GAG after 2-weeks compared to the Control, OP(10), and 
OP(50) groups, respectively (Fig. B.5). ANOVA and post hoc analysis revealed a 
significant effect of the type of gene supplemenation on accumulated GAG with 
significant differences between the Control group versus the other groups (P < 0.05, 
power = 1) and the GPlOP(10) group compared to the rest of the groups (P < 0.05, power 
= 1). 
Control OP(l0) OP(50) GP/OP(IO) 
Figure B. 4 DNA content at the end of the 2-week 3-D culture period. n = 4; mean SEM. 
Control 
Figure B. 5 Accumulated GAG content at the end of the 2-week 3-D culture period. n = 4; mean 
* SEM. 
B. 3.5. Histological Analysis of GSCG Scaffolds Incorporating POP-1 
Cell-seeded scaffolds from the Control group displayed a high concentration of 
tissue formation and GAG staining in the center of the scaffold with a significant amount 
of scaffold still remaining after 2 weeks in culture (Fig. B.6a). The morphology of the 
cells in the control scaffolds appeared more elongated and fibroblast-like compared to the 
other groups. Scaffolds incorporating POP- 1 alone (Fig. B.6b) demonstrated tissue 
synthesis throughout most of the scaffold, although GAG staining was more diffuse with 
a lighter pink appearance. Interestingly, there was a high number of cells in this group, 
that seemed to display a chondrocytic phenotype, with a rounded morphology and located 
in lacunae (see arrows in Fig. B.6b). The GP/OP(10) group displayed the most tissue 
formation and GAG staining, but also with a higher concentration in the center of the 
scaffold. Some cells in this group were also rounded and located in lacunae. In most of 
the scaffolds, a significant amount of residual scaffold still remained (undegraded 
scaffold struts stained green) mostly in the outer palphery of the scaffolds where the 
least amount of cells and tissue was present. 
Figure B. 6 Saffranin-0 stained sections (red is positive stain for GAG) of scaffolds from the 
Control group (a), OP(10) group (b), and GPlOP(l0) group (c) after 2 weeks in 3-D culture. 

B.4. DISCUSSION 
Of significance in this study is that the plasmid containing the gene for OP-1 
could be successfully incorporated within the CG scaffold by a carbodiimide cross- 
linking treatment. Addition of the GP transfection reagent resulted in successful gene 
transfer to and subsequent OP-1 expression by seeded chondrocytes. Interestingly, at the 
lower plasmid load (10 pg), a high percentage (85%) of the plasmid was incorporated 
within the scaffold, whereas, at a higher plasmid load (50 pg) only 24% of the plasmid 
was successfully incorporated. This indicates that when incorporating naked POP- 1 
alone by this cross-linking method, there seems to be a limit as to how much plasmid can 
be incorporated. The large size of the OP- 1 plasmid (between 1 1 - 12 Kb) may also be a 
limiting factor in the amount of plasmid that can be incorporated within the scaffold. 
Unfortunately, the quantitative amount of incorporated POP- 1 that was complexed with 
the GP transfection reagent could not be detected with the Picogreen assay. It is 
speculated that the complexation of the plasmid to the GP reagent interferes with the 
binding of the Picogreen dye to the plasmid DNA and, therefore, detection was not 
possible. The presence of the GPIOP complexes within the scaffold, however, was 
apparent due to the resulting OP-1 overexpression detected from cells seeded within 
scaffolds incorporating the GPIOP complexes above the control levels. Future work 
should investigate other methods of tracking the plasmid amounts incorporated within the 
CG scaffold when employing the GP transfection reagent (e.g. tagging the plasmid with 
small fluorescent molecules prior to mixing with the GP reagent). 
Of interest is the effect of gene incorporation on resulting cell-mediated 
contraction during 3-D culture. In this study, control scaffolds contracted the least, 
scaffolds incorporating POP-1 alone contracted a little more than the controls, and 
scaffolds incorporating the GPIOP complexes contracted the most. Cell-mediated 
contraction can be affected by the scaffold cross-linking properties (stiffness and 
degradation), smooth muscle actin (SMA) expression of cells, or cell remodeling of the 
extracellular matrix (ECM). Histological analysis verified that there was a greater 
amount of residual scaffold and the least amount of scaffold degradation in the control 
scaffolds compareQto the other groups. This may be an indication that these scaffolds 
b 
may have been more cross-linked than the other groups. The difference in contraction 
between scaffolds incorporating POP- 1 alone and scaffolds incorporating GPIOP 
complexes also indicates that these vectors may significantly affect the resulting scaffold 
mechanical and degradation properties, induce cell expression of SMA, or stimulate 
remodeling of the ECM. Future work needs to more fully understand the mechanism(s) 
by which vector incorporation within CG scaffolds affects cell-mediated contraction. 
Interestingly, measurements detecting OP- 1 in the culture medium revealed that 
OP-1 was produced by cells seeded in control scaffolds after about a week in culture. 
This delayed response in OP-1 expression fkom controls seems to indicate that interaction 
between the cell and the type 11 collagen scaffold with time, may induce the expression of 
OP- 1. At this collection point, there was also an indication of OP-1 overexpression from 
chondrocytes seeded in scaffolds incorporating the GPIOP complexes above control 
levels. Compared to prior work employing the plasmid containing the gene encoding for 
insulin-like growth factor (1GF)-1 within GSCG scaffolds, there seems to be a slower 
gene transfer rate and lower expression levels when using plasmid OP-1. Past studies 
have shown that IGF-1 overexpression can be detected as early as 3 days after seeding 
cells within the GSCG scaffolds using this scaffold-based approach. This difference in 
gene transfer kinetics and expression levels may be due to the significantly larger plasmid 
size of the POP- 1 compared to the IGF- 1 plasmid (with POP- 1 being about 2 times larger 
in size than pIGF-I). The lack of overexpression fiom scaffolds incorporating the naked 
POP-1 alone (i.e. without the GP transfection reagent) may also be due to the size of the 
OP-1 plasmid. The vector size may have been too large for sufficient cellular uptake. 
The addition of the GP transfection reagent, however, may have helped condense the 
plasmid, increasing the probable entry into the cell and leading to the resulting OP-1 
overexpression above the control levels. Future work needs to M e r  investigate the 
effect of plasmid size on the ability to use this scaffold-based nonviral gene transfer 
approach for efficient gene transfer to seeded cells. 
Of significance is that the 30% higher accumulated OP-1 level for the GPIOP 
group compared to controls resulted in a slight but significantly higher DNA content and 
-20% higher accumulated GAG content found in the scaffolds after 2 weeks in culture. 
Since the Picogreen assay could not detect plasmid complexed to the GP transfection 
reagent, the higher DNA content of the GP/OP group is most likely a reflection of cell 
proliferation and not due to the residual plasmid left in the scaffold. DNA content 
detected for the OP(10) and OP(50) groups, however, could have contained both nuclear 
material and POP- 1 still remaining in the scaffold. Since histological analysis revealed a 
considerable amount of residual scaffold left after 2 weeks for these groups, it is likely 
that POP-1 was still present within the constructs and contributed to the DNA amount 
detected by the Picogreen assay for scaffolds incorporating POP-1 alone. Accumulated 
GAG content was therefore reported per scaffold and not normalized to the DNA values. 
The quantitative accumulated GAG values determined biochemically seemed to 
coincide with the histological findings. Safranin-0 staining for GAG revealed the most 
tissue formation and GAG staining for the GPIOP group and the least amount of GAG 
staining in scaffolds incorporating POP-1 alone. Interestingly, the scaffolds incorporating 
10 pg of POP-1 without the GP reagent still contained a high percentage of cells that 
were rounded and located in lacunae despite the lack of GAG biosynthesis. In contrast, 
the control scaffolds showed a high concentration of GAG present in the center of the 
scaffold, but cells displayed a more elongated and fibroblast-like appearance. It is 
important to note that differences in biosynthesis and chondrogenesis between groups 
could have also been affected by the resulting cell-mediated contraction of the scaffold. 
Future work needs to further understand the contributions of cell-mediated contraction, 
the presence of plasmid vectors within the scaffold, and localized OP-1 overexpression 
on the resulting biosynthesis and chondrogenesis within GSCG scaffolds. 
In conclusion, plasmid vectors containing the OP-1 gene are able to be 
incorporated within CG scaffolds and can result in successful gene transfer to seeded 
chondrocytes when incorporated with the GP transfection reagent. The large size of the 
plasmid OP-1 may be a significant factor inhibiting gene transfer to chondroctyes when 
incorporated alone. Supplementation of these vectors within the CG scaffold also has a 
significant effect on the resulting cell-mediated contraction. These findings warrant 
further research in the development of GSCG scaffolds for OP-1 gene delivery in 
articular cartilage tissue engineering. 
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APPENDIX C: FABRICATION OF COLLAGEN (TYPE 11)-GAG 
SCAFFOLDS 
C.1. TYPE I1 COLLAGEN SLURRY PREPARATION 
For I OOml type 11 collagen slurry: 
1. Prepare 0.001N HCl (pH-3): add 25ul of 12N HCl to 3.25m1 dH20 to make 
0.1N HCl (pH-1.1); add lml of 0.1N HCl to 99ml dH20 to make 0.001N HCl 
(pH-3) 
2. Add l g  of type I1 Chondrocell sponge--cut collagen sheet into small pieces with 
clean scissors 
3. Blend at 1500 rpm (slightly past setting 3) for 5 minutes-use a small glass 
container (-1 50 ml) and place on ice to keep cool during blending 
4. Degas (vacuum or centrifuge on low setting) and freeze-dry (50ml per -5in. x 5in. 
metal pan) with normal ramping protocol 
C.2. VITREOUS FREEZE-DRYING "RAMP" PROTOCOL 
1. The ramp program used for freeze-drying a collagen slurry consists of a hold at 
20°C for 5 minutes, ramp down to -40°C over 65 minutes (fastest cooling time 
when actual time is set for 15min), and held at -40°C for a minimum of 60min 
(set time for this step is longer than 60 minutes) 
Auto set program reads: Step 1 T = 2 0  t = 5  Hold 
Step 2 T = -40 t =  15 Ramp 
Step 3 T = -40 t = 165 Hold 
2. Press auto switch off, turn on heater and freezer switches, and set temperature to - 
40°C 
3. Make sure chamber release button is off and turn on the vacuum. Press door shut 
while vacuum is being pulled until a sufficient seal is produced 
4. Once vacuum is below 200 mtorr (dOmin), set the temp. to O°C. Leave 
overnight or at least 12 hrs for sublimation 
5. Set temp to 20°C and turn off freeze button 
6. When freezer is at 20°C, turn off the heat, vacuum, and condenser buttons. 
Release the chamber and drain the condenser chamber. After defrosting, chamber 
and condenser should be wiped dry. 
APPENDIX D: SWELLING RATIO 
1 SWELLING RATIO PROTOCOL TO DETERMINE DEGREE OF 
CROSS-LINKING 
D. 1.1. Materials 
Distilled water 
Hot plate 
100 ml beaker 
Tweezers 
Thermometer 
Filter paper sheets (Whatman #1) 
1.0 kg weight 
D.l.2. Procedure 
1. Fill beaker w/ distilled water and heat to 90°C on hot plate. Place thermometer 
inside beaker to adjust the hot plate over time. 
2. Place matrix in the hot water bath for 2 min. in order to denature the collagen and 
allow it to swell w/ water--samples will shrink in size 
3. Expel water from pores by placing hydrated matrix between sheets of filter paper 
W/ the 1.0 kg weight placed on top for 20 seconds. Need sufficient number of 
filter paper so that there is no water visible on the outer layers of the filter paper 
when the weight is taken off. Usually 7 pieces of filter paper on the bottom and 4 
pieces on top of the matrix is sufficient 
4. Immediately weigh sample after being pressed and record mass as the wet mass 
(WM) 
5. Dry samples in the DHT oven overnight at 1 10°C 
6. Weigh samples after taken out of the oven and record mass as dry mass (DM) 
7. Calculate the swelling ratio (which is the inverse of the volume fraction of dry 
collagen, Vf) using this equation: 
I)-* = 1Nf = [(DMIrc) + ((WM-~M)/rwater)]*rc/~~I 
where rc = 1.32 g/cm3 (density of collagen) and rwater = 1 .00g,/cm3 (density of water) 
APPENDIX E: SYNTHESIS OF GENE-SUPPLMENTED 
COLLAGEN-GAG SCAFFOLDS 
E l  BACTERIAL TRANSFORMATION AND PLASMID ISOLATION 
E.l.1. Materials Needed 
P LB Broth Base (LENNOX L BROTH BASE, Invitrogen, Cat# 12780-052): 
follow instructions 
P LB Agar (LENNOX L AGAR, Invitrogen, Cat# 22700-025): follow instructions 
on bottle; plate in petri dishes overnight (store in cold room) 
Antibiotic (see chart below) 
P Plasmid 
P Mega ~ 1 ~ f i l t e r ~ ~  Plasmid kit (Qiagen, Cat #I228 1) 
TE buffer for plasmid storage: 
P lml 1M Tris (pH=8) (UltraPure Tris, Invitrogen, Cat# 15504-020, FW=12 1.1; 
or use 1M Tris (pH=8.0), Ambion, Cat# 98556) 
P 0.2 ml0.5M EDTA (pH=8) (Disodium Ethenediamine Tetraacetate, Fisher, 
Cat#S311, FW=372.24; or use 0.5M EDTA (pH=8.0), Invitrogen, Cat# 15575- 
03 8) 
P 98.8mldH20 
Em 1.2. Bacterial Transformation Protocol Using Heat Shock 
(Place LB agar plates in warm room) 
1. Take competent E.coli cells (DH5a, Invitrogen, Cat# 18258-012) fiom -80C 
freezer and thaw them on ice (-20min). 
2. Turn on water bath to 42C. 
3. Put 50ul competent cells in 1.5 ml tube (Eppendorf or similar) for transforming a 
DNA construct and keep tubes on ice. 
4. Add 1 - 10 ng of circular DNA into E. coli cells. Never exceed (1/10) of the total 
volume. Ideally add 5ul of construct to 50 ul of competent cells. Mix gently by 
swirling pipette tip in solution (DO NOT pipette up and down). 
5. Incubate on ice for 30 min. 
6. Put tube(s) with DNA and E.coli into water bath at 42C for 45 seconds. 
7. Put tubes back on ice for 2 minutes to reduce damage to the E.coli cells. 
8. Add 500 ul of pre-warmed LB (with no antibiotic added). 
9. Incubate tubes for 1 hour at 37C and shake at 225 rpm. 
10. Spread about 100 ul (can include also a different spread volume on another 
plate-20 to 200ul) of the resulting culture on LB plates (with appropriate 
antibiotic added - usually Ampicillin or Kanamycin.)--wait until plates are dry 
before putting in the cold room. Grow overnight. 
1 1. Pick and grow colonies about 12- 16 hours later. 
Bacterial Growth and Isolation 
Place 5 ml of LB medium wl Ampicillin (1 00ugIml) in culture tube. 
Pick isolated colony w/ a sterile stick and place it in the tube. 
Spin at max revolutions in the warm room for 6-8hrs (medium should look cloudy 
when ready). 
For mega prep, transfer whole contents of tube into a sterilized 3000ml flask 
containing 1000ml of LB medium w/ antibiotic. 
Put on shaker (-260rpm-max to prevent severe shaking of bench) overnight. 
Isolate plasmid wl Qiagen Plasmid Purification kit. 
Check amount of plasmid isolated w/ spectrophotometer and integrity w/ gel 
electrophoresis (cutting w/ appropriate restriction enzymes). 
E. 1.4. Antibiotics Used for GSCG Scaffolds 
Ampicillin (sodium salt) 
(Sigma Cat# A-835 1) 
Stored in Iml aliquots at -20C and used 1 tube per 1L LB medium 
Ampicillin used for pIGF-1 prep; Kanamycin used for pEGFP prep 
Kanamycin Sulfate 
(Invitrogen Cat# 1 1 8 1 5- 
024) 
100 mglml in 
water 
50 mglml in 
water 
-20°C 100 pglml (111 000) 
-20°C 50 pglml ( 1  / 1000) 
E.2. PABRICATION OF GELATINIPLASMID NANOPARTICLES 
E. 2.1. Materials Needed 
P Gelatin from porcine skin, Type A, -1 75 bloom (Sigma, Cat #G2625- 100G) 
P Ethylenediamine (Sigma, Cat# 107- 1 5-3) 
P N-(3-Dimethylaminopropyl-N'-ethyl) carbodiimide hydrochloride, EDAC- 
commercial grace (Sigma, Cat # E7750) 
P HCL (Fisher Scientific, Cat # A508-212) 
P Plasmid DNA 
P 50mM Sodium Sulfate solution (Fisher, Cat # 42 1 - 1) 
P PBS solution (0. lM, pH = 5.0)-Mix equal volumes of the following solutions & pH 
W/ HCl: 
P 0.1M Sodium phosphate dibasic (Mw = 141.96g/mol, Sigma, Cat # S0876) 
0.1M Sodium phosphate monobasic (Mw = 1 37.99g/mol, Sigma, Cat # S9638) 
E. 2.2. Gelatin Cationization 
1. Add 2.5g gelatin in 125ml PBS solution (0.1 My pH 5.0) 
2. Stirr and put in waterbath (37C) or on a hotplate in a container w/ water, until 
gelatin is completely dissolved 
3. Under hood, add 7.9ml ethylendiamine and 1.34g EDAC 
4. Adjust pH to 5 with 5-6N HCl 
5. Stirr (medium-fast setting) for 16- 18h, overnight (in a hood) 
6. Soak dialysis tubing overnight in dH20 
7. Next day, open dialysis tubing completely, add the gelatin solution, and clamp 
securely 
8. Soak for dialysis 48hrs, changing dH20 preferably every 8hrs 
9. Pour gelatin solution in containers for freezedrying and put in freezer until 
solution is fiozen (-2hrs) 
10. Lyophilize until gelatin is completely dry (1-2 days depending on amount) 
E. 2.3. Preparation of Cationized Gelatin-Plasmid Nan oparticles (Complex 
Coacervation Method) 
1. 200nglul plasmid DNA in 50mM filtered Na2S04, keep at 5 5 ' ~  
2. Mix 5-8% (w/v) lyophilized cationized gelatin (in dH20), filter, keep at 55C 
3. mix equal volume of 1) and 2) lmin, usually 100- 150ul 
E.3. GENE INCORPORATION OF CG SCAFFOLDS 
* Scaffolds previously DHT crosslinked, 105C-24hrs in vacuum oven & 8mm diameter 
discs cut out with dermal biopsy punch (Moore Medical, Cat# 52443) 
E. 3.1. EDAC Calculations-1 :1:5 (EDAC:NHS:COOH) 
(Change calculations accordingly depending on number of scaffolds) 
100 discs x 0.0023g collageddisc x 0.0012mol COOWg collagen x 5mol EDAC15mol 
COOH x 19 1.7g EDACImol EDAC = 0.05298 EDAC (small bottle) 
100 discs x 0.0023g collageddisc x 0.0012mol COOWg collagen x 2mol NHSI5mol 
COOH x 1 16.0g NHSImol NHS = 0.0128g NHS 
E.3.2. Gene supplementation by soak and freeze-dry 
E. 3.2.1. EDA C Cross-linking of CG scaflolds 
1. Place scaffolds previously DHT cross-linked in sterile petri dishes. 
2. Hydrate scaffolds w/ sterile dH20 (0.5ml/scaffold). 
3. Weigh out necessary EDAC and NHS and dissolve in same volume amount of 
dH20 used to hydrate scaffolds and sterile filter. 
4. Add EDACINHS solution to hydrated scaffolds (pipette over scaffolds several 
times to ensure good mixing) and cross-link at room temperature for -3Ominutes. 
5. Remove EDACINHS solution and rinse in PBS by swirling petri dish. 
6. Transfer scaffolds in falcon tubes containing fresh PBS and rinse for at least lhr 
on rocker. 
7. Transfer scaffolds back to petri dishes and remove PBS. 
E. 3.2.2. Plasmid Incorporation 
1. Place 60- 100ul diluted plasmid solution onto scaffolds (briefly dry on filter paper 
before adding plasmid aliquot if supplementing right after PBS rinse). 
2. Incubate for at least and hour. 
3. Freeze-dry scaffolds using similar fieeze-drying protocol used to make scaffolds 
from slurry (See Appendix C). 
E.3.3. Gene supplementation of Scaffolds by EDAC Cross-linking 
E.3.3. I .  Plasmid Supplementation by EDAC Cross-linking 
1. Hydrate scaffolds wl aliquots of plasmid solution or TE buffer (-60ul/scaffold). 
2. Dissolve the EDAC and NHS in 50ml dH20 and sterile filter (0.45 mm). 
3. Pipette 0.5ml solution/scaffold over scaffolds to ensure good mixture. 
4. Allow chemical cross-link at room temperature for about 15 minutes. 
5. Pipette 0.5ml sterile dH2Olscaffold over scaffolds to ensure good mixture. 
6. Allow chemical cross-link at room temperature another 15 minutes. 
7. Remove EDACMHS solution wl pipette, rinse w/ PBS and transfer scaffolds to 
15ml falcon tubes containing sterile PBS and rock for -1hr. (prepare cells & SF 
medium during this time). 
8. Transfer back to petri dish, remove PBS wl pipetteready to seed. 
APPENDIX F: MEDIA PREPARATIONS FOR CHONDROCYTE 
AND MESENCHYMAL STEM CELL CULTURES 
(modzfied protocol from Jakob et. al, J Cell Biochem 2001;81(2):368- 77) 
1 MEDIUM FOR EXPANDING CHONDROCTYES 
F. I. I. J-Base Medium 
9 500 ml hg-Di\lEM ( high glucose: 4.5%) without L-Glutamin with Sodium 
Pyruvate (by GIBCO@) 
9 5 ml MEM Nonessential Amino Acids (NEAA) (solution lOmM, by GIBCO@ 
cat. No. 11 140 050) 
9 5 ml Hepes Buffer (solution 1 M, by GIBCO@ cat. No. 1 5630 056)-can also 
make 1M solution wl Hepes powder (238.3glmol) in distilled water (ie. 0.2383g 
Hepes powderlml dHzO--need to sterile filter) 
9 5 ml PSG consisting in 10000U/ml penicillin, 10000mg/ml streptomycin 
glutamate (by GIBCO@, cat. No. 10378 0 16) 
* J-Base is the base medium used for both making both expansion and serum-free 
medium 
F. 1.2. J-FBS 
P 450ml J-Base medium 
> 50 ml FBS (by GIBCO@ , cat. No. 10270 106 or equivalent) 
F. 1.3. J-Expansion Medium 
P J-FBS medium 
ADD growth factors just before use: 
9 human 'I'GFfi 1-1 nglml of media (R&D Systems, cat. No. 240-B-002) 
+Reconstitute in sterile 4mM HCl containing at least lmg/ml human serum 
albumin or bovine serum albumin in the vial to prepare a stock solution of no less 
than lug/ml of TGFP 1 
Obtain sterile eppendorf tubes (preferably G5ml tubes) 
166.5u1(7.5% glml) BSA solution + 500~10.1 N HCl + 1 1.5ml H 2 0  in 
5ml centrikge tube and vortex (we have HCl plus that is 12.1N HC1 so 
add 0.5ml of 12.1N HCl + 60.51111 H20 to get 0.1N HCl) 
Sterile filter lOml of the bdfer and add it to l m g  of TGF-f3 (concentration 
= lug of TGF-f3 llml) 
-- Per ml of media, add lul of the TGFpl stock to have lng TGFBl per ml of 
media 
Aliquot in sterile microtubes and store @ -70°C for three months wlout 
detectable loss of activity 
Avoid repeated freeze-thaw cycles for all growth factors 
> human FGF basic (FGF-2)-5 nglml (R&D Systems, cat. No. 233-FB-025) 
-.Reconstitute in sterile PBS containing at least 0.1% (lmglml) human serum 
albumin or bovine serum albumin and 1mM DTT (154.3glmol) in the vial to 
prepare a stock solution of no less than l0uglml of cytokine: 
Obtain sterile eppendorf tubes (preferably 0.5ml tubes) 
Add 0.0025g B S A m  33.3u1(7.5% g/ml) BSA solution +0.0004gDTT 
+ 2.5 ml PBS 
Sterile filter wl syringe, and add to the 25ug of FGF-2 in vial 
--Per ml of media, add 0.5ml of the FGF-2 stock to have 5ng FGF-2 per mi 
of media 
Aliquot in sterile microtubes and store @ -70°C for three months wlout 
detectable loss of activity 
Avoid repeated freeze-thaw cycles for all growth factors 
> human PDG.Fb f3-10 nglml (R&D Systems, cat. No. 220-BB-0 1 0) 
+Reconstitute in sterile 4mM HCl containing at least 0.1% human serum 
albumin or bovine serum albumin in the vial to prepare a stock solution of no less 
than 10uglml of cytokine 
Obtain sterile eppendorf tubes (preferably 0.5ml tubes) 
Add 0.0025g bovine serum albumin + lOOul0.1N HCl + 2.4ml H 2 0  OR 
33.3u1(7.5% g/ml) BSA solution + 50ul O.2N HCl + 2.4ml H 2 0  in 5ml 
centrifuge tube and vortex (we have HCl plus that is 12.1N HCl so add 
0.5ml of 12.1N HCl + 60.5ml H20 to get 0.1N HCl) 
Sterile filter lml of the buffer and add it to the lOug of PDGFPP 
(concentration = 1 Oug of PDGFPPlml) 
-- Per ml of media, add lul of the PDGFPP stock to have 1 Ong PDGFPP per 
ml of media 
Aliquot in sterile microtubes and store @ -70°C for three months wlout 
detectable loss of activity 
Avoid repeated freeze-thaw cycles for all growth factors 
F.2. MEDIUM FOR EXPANDING MESENCHYMAL STEM CELLS 
9 500mL low glucose DMEM (Invitrogen # 1 1885-092) 
9 50mL FBS (Invitrogen # 16000-044) 
9 5mL penicillin/streptomycin 
F.3. 3-D CULTURE DIFFERENTIATION MEDIUM 
F. 3.1. SF Base Medium 
9 500ml J-Base medium 
9 5 ml IrrS+l (100X) (SIGMA-Cat. No. 12521) 
9 9 ml(7.5% glml) BSA solution (1.25mg BSAIml of media 17ul(7.5% glml) 
RSA solutionlml of media) 
F. 3.2. SF Medium 
ADD supplements at the last minute before use: 
> TGFPl (1 0nglml)-Add 1 Om1 of TGFPl stock solution per ml of media 
9 Dexnmethasoee (100 nM) non-water soluble (MW=392.5g/mol-Sigma D-4902) 
or water soluble (-65mg dexamethasone/gram of powder-MW of dexamethasone 
= 392.5g/mol-by Sigma 29 15) 
+ 1 Oul of a 111 00 dilution of M dexamethasone stock solution/ml of media 
Make M dexamethasone (DM) stock in 100% ethanol (stable for 1 yr, 
stored @ -20°C) by adding 3.92mg of dexamethasone (non-water soluble) 
per lOml of 100% ethanol or 6.03mg of dexamethasone (water soluble) per 
lml of 100% ethanol 
(Calc: lml 10~3~DMx0.001molDM/1000mlx392.5gDM/lmol DMx lg  
powder1 0.065g DM = 0.00603g powder -- in lml of ethanol) 
Make M dexamethasone in low glucose DMEM (LG) by adding 20ul of 
M dexamethasone stock + 1.98 ml LG-DMEM 
Store as sterile aliquots @ -20°C 
L-Ascorbic acid 2iPhosphate (0.1 m . )  
- lOul of a 11100 dilution of ascorbate 2-phosphate (MW = 289.54glmol) 
Add 37.5 mg ascorbate 2-phosphate (Wako Chemical) + lOml Tyrodes 
solution (Sigma) 
Sterile Nter the ascorbate 2-phosphate solution and store cozen (-20°C) in 
2ml aliquots 
APPENDIX G: CELL ISOLATION METHODS 
1 CHONDROCYTE HARVEST PROTOCOL 
(modifiedfrom H. A. Breinan, B WH Orthopaedics Research Lab and Kuettner et al., 
1982 and C. Lee Thesis, 2001 ) 
Gm 1.1. Materials 
G. I. I. I. OR Supplies 
Scalpel handle (#3) 
Scalpel blades (2 #lo) 
Sterile gloves 
Ifremoving whole joint: 
Surgical saw 
Sterile specimen bags (plastic bags in histo room) 
Sterile towelslwrap 
Sterile PBS to moisten towels 
I f  removing shavings (ie: for subsequent autologous seeding): 
Extra scalpel blades 
50 ml tubes w/ complete PBS: 40 ml D-PBS (Gibco #14190-144) + 
0.4 ml PedStreplFungizone cocktail (1 OOX; Gibco #15240-062) 
G. 1.1.2. Lab Supplies 
Sterile petri dish (100 mm diameter) 
Sterile spatula 
Sterile forceps (2) 
Sterile razor blades (flat edges are easiest to use) 
Sterile centrifuge tubelbottle with sterile stir bar 
Clean stir plate in incubator (one that doesn't heat up too much during prolonged 
operation) 
10-20 mlljoint complete PBS (see above) 
T-75 and/or T-25 tissue culture flasks 
G. 1.1.3. Solutions 
1. Pronase solution (20 Ulml) - - 40mV2 joints 
a. Dissolve appropriate amount of pronase (Sigma protease type XIV #P 5 147) in 
lOml HG-DMEM (high glucose: 4.5%, without L-Glutamin with Sodium 
Pyruvate by GIBCO@) 
where V-'=volume of solution 
b. Sterile filter (0.2 mm) solution (use syringe filter; it will take a while for pronase 
to dissolve and it will be difficult to pass solution through filter) 
c. Add remaining volume of DMEMIF 12 (ex: 3 0 ml if making 40 mV2 joints) 
d. Add 1 % vlv of 1 OOX pedstreplfungizone cocktail (antibiotic) (ex: 0.4 ml) 
2. Collagenase solution (200 Ulml) - approx 40mV2 joints 
a. Dissolve appropriate amount of collagenase (Worthington Biochemical CLS2) in 
10 ml HG-DMEM (this dissolves quickly) 
where V = volume of solution 
b. Sterile filter solution using a 0.2 mm syringe filter 
c. Add remaining volume of HG-DMEM 
d. Add 1 % vlv 1 OOX pen/strep/fungizone cocktail 
3. Jakob Base or Expansion Media (see Appendix H) 
G. 1.2. Procedure 
1. Using scalpel blades, remove slices of articular cartilage fiom joint surfaces and 
place in complete PBS (or in tubes and store on ice if harvesting in OR) 
Don't dig into the hard calcified cartilage or subchondral bone, cartilage should 
offer little resistance to the blade; full thickness slices should be 0.5-1.5 mm thick 
depending on joint location 
If harvesting whole joint, open joint in sterile hood, cutting ligaments and 
removing menisci; take cartilage from tibial, femoral and patellar surfaces 
If slices are large, use razorlscalpel blade to cut into pieces no larger than 
3x3xlmm 
Using forceps and spatula, transfer cartilage pieces into tubelbottle with stir bar 
and pronase solution, cap loosely 
Incubate 1 hr (37"C, 5% C02) on spinner plate (or shake every 15 minutes or so if 
can't use spinner plate in incubator) 
Centrifuge the pronase and tissue solution, remove the pronase, and resuspend 
pellet in collagenase solution 
Incubate overnight (maybe as short as 4-6 hours until all tissue is digested) on 
spinner plate; make sure cap is loose! 
Strain through 40-70 mm pore strainer into new 50ml centrifuge tube 
Centrifuge (10 min @ 1500 rpm) 
Remove supematent and resuspend in -30 ml complete media; centrifuge again 
and resuspend in known amount of complete media to do cell count (usually 
20ml) 
Count cells and assess viability (should have at least -7-8x10~ cellsljoint with 
>90% viable if cap was loose during digestion) 
G.2. MESENCHYMAL STEM CELL HARVEST AND EXPANSION 
1. Aspirate cells from the iliac crest into tube containing heparin 
2. To a 15mL tube, add 2mL of anticoagulant treated blood to equal volume of PBS 
3. Mix well with pipette 
4. Mix Ficoll-Paque by inverting bottle several times 
5. Using 20mL syringe and 18 gauge needle - add 5mL air and add 3mL Ficoll to 
15mL tubes (Falcon 352059 tubes) 
6. Layer 4mL diluted blood onto 3mL Ficoll - carefully so as not to mix 
7. Spin at 3000 for 30 minutes 
8. Transfer lymphocyte layer to clean 15mL tube with 5mL PBS 
This means: 
-- Carefully aspirate the Ficoll above the lymphocyte layer leaving 
-1 5mm above. With p1000, carefully remove the lymphocyte band PLUS the 
material above and below. You can take the mixture almost to the bottom pellet. 
This should be about 2 ml total volume per tube. 
9. Put all bands from the same animal in one 15 ml conical tube 
10. Mix with pipette 
1 1. Centrifuge 1500 rpm for 10 minutes 
12. Aspirate supernatant (note - leave a little bit above pellet) 
13. Resuspend lymphocytes and MSCs in DMEM - 1mL 
14. Add 29mL DMEM in 50 mL Falcon tube and mix gently 
15. Put in T- 150 (count) 
16. Check cells after 2-3 days for attachment. 
17. After 3 days - Aspirate cell that are not adhered to the plate 
18. And feed remaining MSCs with 30mL of warm medium. 
19. Subsequently change medium twice a week. 
20. Passage cells or freeze when they have reached 90% confluence 
2 1. Reseed cells in T- 150 flasks at 1000 cells/cm sq in T- 150 flasks. 
22. Freeze cells PO at 0.5 ml at 5E5 
23. Thaw cell at 5E5 and seed new flask (PI) 
APPENDIX H: CHONDROCYTE MONOLAYER CELL CULTURE 
H.1. THAWING CELLS 
H. 1.1. Materials 
J-FBS Medium 
75 cm2 TC flasks 
Sterile pipettes and pipetteman 
Flame 
Sterile glass pasteur pipettes 
Vacuum flask and tubing to hook up to vacuum 
15 ml tube@) 
H. 1.2. Procedure 
Place cells directly into a 37OC water bath. Agitate gingerly while cells thaw for 
40-60 seconds. 
When defrosted minimally (liquid appears around outer edges) add a drop of 
complete medium. 
Wait a minute and add another drop of medium. Repeat until tube is full- 
ensures that the cells thaw into the medium. 
Transfer cells suspension in a 15 ml centrifuge tube and spin for 10 minutes at 
1500 rpm. 
Resuspend the pellet and count the number of cells. 
Add appropriate amount of medium to obtain the desired concentration. 
Should culture the cells at least 3-4 days before being used for experimentation 
(or before changing medium). 
H.2. FREEZING CELLS 
H. 2.1. Materials 
J-FBS Medium 
Dimethyl Sulfoxide (DMSO) 
0.45 pm sterile filter 
Sterile pipettes and pipetteman 
Sterile cryogenic tubes 
H.2.2. Procedure 
1. Add 10% v/v DMSO to J-FBS medium. 
2. Filter solution through the 0.45 urn sterile filter. 
3. Adjust cell concentration to 1x10~ cellslml of J-FBSIDMSO solution. 
4. Aliquot cell suspension in sterile cryogenic tubes (be sure to account for 
expansion during freezing-1 -1.5ml in 2 ml cryogenic tubes is a safe amount) 
5. Freeze in the -20°C freezer for 2-4 hrs (longer the better) and then transfer to the 
-80C keezer or use isopropanol fieezing containers and place straight into -80C 
freezer. For long-term storage, place cells in liquid nitrogen tank. 
H.3. PASSAGING CELLS 





Collagenase type I1 (in fiidge, Rm 108) 
50ml centrifuge tubes 
Centrifuge tube holders 
Sterile pipettes and pipetteman 
Vacuum flask and tubing to hook up to vacuum 
150 cm2 culture flasks (5) 
H. 3.2. Procedure: 
1. Warm the medium, trypsin, and PBS in 37°C water bath. 
2. Make necessary amount of J-FBS (See Appendix H)-8ml/150cm2 flask; 
5d75cm2 
3. Remove the medium in flasks w/ the vacuum pipettes. 
4. Rinse once w/ solution of 0.15% collagenase I1 in PBS (g/ml)-for 1, 75cm2 flask 
need -5ml (ie. 0.0015 g Collagenase + 5 ml PBS, sterile filter w/ syringe filter)- 
incubate 3-5 minutes 
5. Remove CollII/PBS solution from flask w/ a pipette and put this solution in a 
50 ml centrifuge tube-DO NOT ASPIRATE wl vaccum (cells do get 
detached during this rinse so we need to keep this). 
6. Add trypsin (3-5 ml for 75 cm2 flask) 
7. Incubate for 3-5 minutes. Tap on the sides of the flask to loosen the cells and 
check under the microscope to ensure cells are no longer attached. If some are 
still attached, incubate longer checking every minute until all are unattached. 
8. Once the cells are floating, collect trypsin and add it to the collected collagenase 
type I1 solution. 
9. Add J-FBS medium to rinse the flask, collect, and add to the collagenase/trypsin 
solution to inactivate the trypsin (-5 ml for 75 cm2 flask) 
10. Balance the tubes and centrifuge for 10 minutes at 1500 rpm. 
11. Once the pellet is on the bottom, draw off the medium w/ the vacuum pipette. 
12. Resuspend in J-Expansion medium (20ml) and count number of cells (see 
following protocol for cell counting). 
13. Once the cells are counted and recorded, split the cell suspension into 5 flasks by 
adding 4ml of the cell suspension in each 150cm2 flask. 
14. Bring volume of medium in each flask to 30ml by adding 26ml more of J- 
Expansion medium to each flask. 
H.4. PLATING DENSITIES MONOLAYER CULTURES 
H.5. CELL COUNTING PROTOCOL 
Ha 5.1. Materials 
Jakob-FBS Medium + 3GFs (J-FBS-GF) 
Trypan Blue 
Hemacytometer & glass slide cover 
Micropipetter 





H. 5.2. Procedure 
1. Resuspend pellet by adding 20 ml of J-FBS-GF media to cell pellet and mix well 
WI pipette to ensure equal spacing of cells. 
2. Clean the hemacytometer and cover slide wl alcohol and a kimwipe. 
3. Place the cover slide on top of the hemacytometer so that it covers the tip of the 
grove near the edge of the hemacytometer. 
4. For a dilution factor of 2, mix a 1 : 1 ratio of a 15pl aliquot of trypan blue wl a 
1 5 ~ 1  aliquot of the cell suspension into a microcentrifbge tube (use the sterile 
pipette extender to obtain the aliquot of cell suspension if needed)--mix well by 
pipetting mixture up and down. 
5. Obtain a 15ml aliquot of the trypan blue1 cell suspension mixture and release it 
into the groove at the edge of the hemacytometer so that the mixture reaches the 
edges of the silvered surface-try not to overfill as this may make the count 
inaccurate. 
6. Place the hemacytometer on the microscope stage, remove yellow glass filter, 
and view with standard lox objective. 
7. Count cells in each of the four comer squares and the central square (clear 
"glowing" cells are viable, blue stained cells are dead). To prevent overcounting, 
count cells that lie on the top and left lines but not those on the bottom or right 
lines of each square. 
8. Calculate the viability wl the following equation: 
9. Calculate and record the total cell number wl the following equation: 
Where T = Total number of cells in suspension 
Nc = Number of viable cells counted 
Ns = Number of squares counted (ie. 5 boxes) 
D = Dilution factor (ie. 2) 
V = Volume of media used to suspend the cell pellet (ie. 20ml) 
--For this case, I would like to split the PO cells (in the 75cm2 flask) into 5 flasks 
(1 50cm2 flasks) with at least 4 million cells per flask using 30 ml of media in each 
150cm2 flask (I'm estimating we'd get 20-30 million PO cells from first plating). 
However, regardless of the number of cells counted (if less than 20 million or more than 
30 million), still split the total number into 5 flasks and note what the exact plating 
number is. 
H.6. STAINING CELLS WITH CELLTRACKER DYE FOR CONFOCAL 
MICROSCOPY ANALYSIS 
H. 6.1. Materials Needed 
P ~ e l l ~ r a c k e r ~ ~  Red CMTPX Fluorescent Stain (Molecular Probes) 
9 Sterile PBS (Gibco) 
P Trypsin-EDTA (Invitrogen) 
9 Culture medium (Expansion & Serum-free) 
9 Polystyrene cell culture 12-well plate (Falcon, VWR) 
9 Ultra-low Attachment 6-well plate (Coming, Fisher Scientific) 
9 Sterile filter paper 
9 8 mm dermal biopsy punch (Moore Medical) 
H. 6.2. Procedure 
1. Cut scaffolds to desired dimension with 8 mm dermal biopsy punch. 
2. After EDAC cross-linking scaffolds, scaffolds should be rinsed in sterile PBS for 
-1 hour. 
3. While rinsing scaffolds, start the fluorescent cell staining process in parallel. 
Thaw CMTPX in hand. Mix 1 ul CMTPX stain per 1 ml medium (1 : 1000). (use 
expansion medium w/ FBS) 
Stock CMTPX (1 OmM in DMSO): 
--Add 250ul sterile DMSO to lmg CMTPX powder provided. 
--Aliquot into 1 Oul stocks (to be mixed w/ 1 Om1 media-1 : 1000 dilution) 
4. Aspirate medium from expansion flask & add Medium + CMTPX solution to 
flask (30ml/150cm2 flask). Place flask back into incubator for 20 minutes. 
5. Aspirate medium. Add sterile PBS to wash. Aspirate PBS and continue basic 
procedures for trypsinizing monolayer cultures. 
H.7. MONOLAYER TRANSFECTION OF CHONDROCYTES WITH 
GENEPORTER TRANSFECTION REAGENT 
1. Expand PO chondrocytes in 24-well plates, plated at 50,000 cells per well. 
2. At confluence, prepare dilute GenePorter solution and plasmid solutions in SF 
medium (For 24-well plate, according to manufacturer's instructions, per well): 
P 2ug plasmid in 125111 SF medium (if stock is at lmglml, add 2ul) 
1 Oul GP reagent in 125111 SF medium (5: 1, GP:plasmid) 
Add diluted DNA to the diluted GP reagent, vortex, and incubate at room 
temperature for 30minutes 
3. Aspirate medium from well, add an aliquot of the GP/plasmid solution 
(25OuVwell) and incubate at 37C for 4 hrs. 
4. Four hours later, remove GPIplasmid solution and replace with 0.5ml of SF 
medium. 
5. Collect and change every 2-3 days after infection (Day 2, 5,7,9. 12, and 14) 
6. Assess amount of expressed protein released in the medium w/ the sandwich 
ELISA kit for the human IGF-1 protein (R&D Systems). 
H.8. TRANSFECTING MONOLAYERS WITH GELATIN NANOPARTICLES 
1. Seed chondrocyte at a density of 20,000 cells per well for a 24-well tissue culture 
plate in expansion medium. Change media every 2-3 days until cells become 
confluent. 
2. At 80-90% confluence, remove media and wash with PBS (500~1). 
3. Add 250ul NPIplasmid solution (-l Oug plasmid per well)-diluted in serum-free 
medium. 
4. Incubate 4 hrs. 
5. Remove NPIplasmid solution and add 500ul of fresh serum-free medium to each 
well. 
APPENDIX I: 3-D CHONDROCYTE CULTURES 
1.1. MAKING CHONDROCYTE CELL PELLETS 
1. After expanding cells to PI, collect cells in monolayer and resuspend in SF 
medium at 1 x lo6 cells/ml. 
2. Aliquot 500ul of cell suspension in sterile tubes (15ml falcon tubes or 
microcentrifuge tubes). 
3. Centrifuge at 4500rpm for 30 seconds. 
4. Vent caps and place in incubator. 
5. Change medium every 2-3 days. 
1.2. MAKING MSC CELL PELLETS 
1. After expanding MSCs to P2, collect cells in monolayer and resuspend in SF 
medium at 400,000 cells/ml. 
2. Aliquot 500ul of cell suspension in sterile tubes (15ml falcon tubes or 
microcentrifuge tubes). 
3. Centrifuge at 1 500rpm for 10 minutes. 
4. Vent caps and place in incubator. 
5. Change medium every 2-3 days. 
1.3. CELL SEEDING SCAFFOLDS 
Day of seeding for seeding density of #million celldscaffold): 
1. EDAC cross-link scaffolds. 
2. Trypsinize confluent cells and count. 
3. Resuspend in serum-fiee medium @ 100,000 cellsful. 
4. Prewet scaffolds (in PBS after EDAC), dry on sterile filter paper (-6-8 scaffolds 
at a time) then transfer to warm agarose-coated 12-well TC plates. 
5. Seed 2million per side (20uVside) with -1 Omin incubation in between. 
6. Incubate for 2hrs and then add 0.5ml SF medium-dispense slowly against well 
wall. 
7. Next day, add 0.5 ml medium. 
8. Change media every 2-3 days. 
1.4. SCAFFOLD MEASUREMENT TEMPLATE 
APPENDIX J: BIOCHEMICAL ASSAYS 
1 PROTEINASE K SAMPLE DIGESTION 
(Lyophilize samples prior to digestion) 
1. Digest samples overnight (12-24 hours) at 60°C in the following solutions: 
--If digesting 8mm scaffolds, use 500ugAml proteinase K solution: 
For 100 ml solution: 100 ml Tris-HC1 buffer (see below) 
50 mg proteinase K powder (Sigma, Cat# P-6556, -20C) 
--If digesting cell pellets (or 4mm scaffolds), use 100ug/ml proteinase K solution: 
For 100 ml solution: 100 ml Tris-HC1 buffer (see below) 
10 mg proteinase K powder 
2. Sterile filter proteinase K solution & keep left over solution at 4C 
3. Add lml of Proteinase K solution per sample 
4. Vortex before putting in water bath & once again before leaving it overnight 
5. Keep digested samples at -20C until used for biochemical analysis 
Tris-HC1 buffer (1L)-keep at room temperature 
0.05M Ultrapure Tris--6.1 g/L (Mw=12 1.14gImo1, Invitrogen, Cat #15504-020) 
9 1 mM CaC12 Dihydrate-0.147glL (Mw=147.02g/mol, Sigma (Fluka), Cat #2 1097) 
9 Dissolve above salts in 900 ml distilled water 
P Adjust pH to 8.0 with IN NaOH 
P Bring to IL with distilled water 
5.2. DETERMINING DNA CONTENT USING THE PICOGREEN ASSAY 
J.2. I. Materials Needed 
Quant-iT PicoGreen dsDNA Assay Kit (Molecular Probes, Cat# P75 89) contains: 
P PicoGreen dye reagent (1mL solution in DMSOFlight sensitive (keep covered) 
P 20X TE (25mL of 200mM Tris-HC1,20mM EDTA, pH 7.5) 
P Lambda DNA standard (1m.L of 100 mg/mL in TE) 
TE buffer for diluting samples: 
P 1 ml 1 M Tris (pH=8) (Ultrapure Tris, Invitrogen, Cat# 15504-020, FW=12 1.1 ; 
or use 1M Tris (pH=8.0), Ambion, Cat# 98556) 
P 0.2 ml0.5M EDTA (pH=8) (Disodium Ethenediamine Tetraacetate, Fisher, 
Cat#S3 1 1, FW=372.24; or use 0.5M EDTA (pH=8.0), Invitrogen, Cat# 15575- 
03 8) 
P 98.8 mldH20 
96-well plate-Black Isoplate (Clear bottom plates, Wallac, Cat# 1450-57 1) 
J.  2.2. Procedure 
1. Assay Buffer Preparation: Add 25ml(20X TE) + 500 ml sterile, dH20 
2. DNA std working solution (2mg/ml): Add 294ml of TE buffer + 6ml DNA stock 
(1 00 mg/mL) 
3. Dilute all digested samples I:IO with TE buffer (not from kit): I80ul TE + 20ul 
digest (can be diluted in microcentrifbge tubes or 96-well plate) 
4. Prepare the DNA standards as follows in the first 8 wells of Picogreen 96-well 
plate: 
5. Add 20ul of diluted digested sample to each well-vortex samples before adding 
6 .  Add 80ul TE buffer (from lut) to each well (for total of lOOul solution per well) 
7. Dilute PicoGreen dye stock with TE buffer (from kit), 200X-Prepare just before 
use 
-- 1 00 ul of working dye solution needs to be added to well used 
--Make more working dye then needed (i.e. add solution for 5 additional wells) 
For example, if there are 96 wells to fill, make enough dye for 110 wells: 
11 0 x 1 OOul = 11 OOOul (or 1 lml); 11 000/200 = 55ul of PicoGreen stock + l l m l  
TE 
8. Dispense 100 ul PicoGreen working dye solution to each well being used 
9. Take fluorescence reading on microplate reader (WALLAC  VICTOR^ 1420 
Multilabel Counter, Perkin Elmer Life Sciences)): Protocol assigned in computer 
program under DNA Assay-"Fluorescein (485nm/535nm7 1 .Os)" (includes a 5 
min incubation period & shake) 
* If samples end up having a reading greater than the highest standard, samples need 
to be diluted more and re-run 
5.3. GAG ASSAY USING DIMETHYLMETHYLENE BLUE (DMMB) DYE 
J.  3.1. Solutions Needed: 
Color Reagent 
For 500ml of DMMB dye solution, mix the following: 
P 425m1dH20 
P 1.52 g glycine (Sigma, Cat# G-8898) 
P 1.19 g NaC1 (Fisher, Cat# S642) 
a. Adjust pH to 3.0 with concentrated HCl and NaOH 
b. Add more dH20 to bring volume up to 500rnl 
P Add 8mg of DMMB dye 
P Solution good for 3 months and should be kept in a light-protected bottle (stir 30 
min prior to use) 
TE buffer for diluting samples 
1 ml 1M Tris (pH=8) (Ultrapure Tris, Invitrogen, Cat# 1 5504-020, FW=12 1.1 
or use 1M Tris (pH=8.0), Ambion, Cat# 98556) 
0.2 ml0.5M EDTA (pH=8) (Disodium Ethenediamine Tetraacetate, Fisher, 
Cat#S3 1 1, FW=372.24) 
or use 0.5M EDTA (pH4.0) (Invitrogen, Cat# 1 5575-03 8) 
J.  3.2. Procedure 
1. Stir DMMB dye working solution at least 30min before use 
2. Prepare the Chondroitin Sulfate (CS) stock solution at 2 mg/mL (keep in -20C 
freezer) 
3. CS working solution (200mglml): Add 100 ml of CS stock + 900 ml dH20 
4. Prepare the CS standards as follows: (Start wI7 labeled tubes filled w/ 200ul TE 
buffer) 
5. Dilute all digested samples 1:10 with TE buffer: 180ul TE + 20221 digest 
(can be diluted in microcentrifuge tubes or 96-well plate) 
6. Add 20ul of each standard and sample to the 96-well plate (Clear plates, Packard 
Bioscience Spectraplate-96, Cat# P 12- 106-043)-good to do this in duplicate, at 
least for the standard (Use 20ul aliquot of TE buffer as blank) 
7. Dispense 200 mL of DMMB dye solution to each well used 
8. Take reading at 530 nm on microplate reader (WALLAC  VICTOR^ 1420 
Multilabel Counter, Perkin Elmer Life Sciences): Protocol assigned on computer 
program for the microplate reader is under GAG Assay-"GAG-DMMB Assay 
protocol (530nm- 1 s)" 
* If sample reading is outside the standard curve range (or at the extremes of the 
standard curve), it is recommended that another dilution and reading of the sample be 
performed-the ideal is to have the reading land on the mid-range of the standard 
curve (usually a znd order polynomial is the bestj?t curve for this standard) 
5.4. IGF-1 DUOSET SANDWICH ELISA ASSAY (R&D SYSTEMS CAT. 
#DY291) 
J.  4.1. Solutions Needed 
PBS: 137 mM NaCl, 2.7 mM KC1,g.l mM Na2HP04, 1.5 mM KH2P04, pH 7.2-7.4 
--Used lpacket powdered PBS + 1L DI water, 0.2pm filtered 
Wash buffer: 0.05% Tween 20 in PBS, pH 7.2-7.4 
1L PBS + 0.5g Tween 20 (per liter) or 0.5L PBS + 0.25g Tween 20 (per liter) 
(Weigh out Tween 20 in 15 rnl falcon tube and dissolve in PBS before adding to rest of 
PBS solution-Tween 20 very viscous) 
Block buffer: 5% Tween 20 + 0.05% NaN3 in PBS 
For 100ml: 100 ml PBS + 5g Tween 20 + 0.05g NaN3 
Reagent Diluent (RD): 5% Tween 20 in PBS-0.2pmunfiltered 
For 50ml: 5 h l  PBS + 2.5g Tween 20 
Substrate Solution: 1 : 1 mixture of Color Reagent A (H202) and Color Reagent B 
(Tetramethylbenzidine) (R&D Systems Cat. # DY999) 
Stop Solution: 2 N H2S04 
X 4.2. Day I: Plate Preparation 
Coat plates: Capture Antibody (R&D, Part 840264stock concentration 720 pglml, 
reconstituted wl 1.0 ml PBS, working concentration 4pglml in PBS, 1 00 pVwell 
Ex (96 wells): 58 p1 Capture Ab stock + 10.4 ml PBS 
(adjusted for weak signal: 70ul CapAb stock + 10.5 ml PBS) 
Tap plate to cover bottom of wells, check for bubbles 
Cover plate with plate sealer, incubate overnight at room temperature 
J.4.3. Day 2: IGF-1 ELISA 
1. Wash plate 3x with wash buffer, 400uVwell-after last wash, invert plate and blot 
against clean paper towels 
2. Block plates w/ Block Buffer, 300 yllwell 
3. Cover plate, RT, 1 hr minimum 
4. Wash plate 3x 
5. Prepare IGF- 1 standard dilutions: 
--Standard (R&D, Part 840266, 1 vial)-stock concentration 70 nglml, reconstituted 
W/ 0.5 ml Reagent Diluent. Store reconstituted standard at 2-8OC for up to 60 days 
10-point standard curve using 2-fold serial dilutions in Reagent Diluent w/ high standard 
at 2ng/ml: 
STOCK 8 7 5 2 1 Tube# 
(70ng/ml) 
582.9~1 300yl 3 0 0 ~ 1  3 0 0 ~ 1  3 0 0 ~ 1  3 0 0 ~ 1  300yl 3 0 0 ~ 1  Reagent 
Diluent 
6. Wash plate 3x 
7. Add standards or samples: run standard in duplicate, 100uVwell-Include blank 
well w/ Reagent Diluent only 
8. Cover plate, RT, 2 hrs 
9. Wash plate 3x 
10. Add Detection Antibody (Part 840265)-stock concentration 14.4 yglml, 
reconstituted w/ 1.0 ml Reagent Diluent (store at 2-8C up to 6 months), working 
concentration 80nglml in Reagent Diluent, 100 yllwell 
Example (96 wells): 56ul Det. Ab stock, 10 ml Reagent Diluent 
(adjusted for weak signal: 8Ou1 Det. Ab stock + 10.5 in1 RD) 
Cover plate, RT, 2 hrs 
1 1. Wash plate 3X 
12. Add Streptavidin HRP (Part 890803, store at 2-8C up to 6 months)--working 
concentration: dilute stock solution 1 :200 in Reagent Diluent, 100 pllwell 
Example (96 wells): 50ul Streptavidin HRP stock, 10 ml Reagent Diluent 
(adjusted for weak signal: 80ul CapAb stock + 10.5 ml RD) 
Cover plate, RT, 20 minutes-Avoid direct light 
13. Wash plate 3X 
14. Substrate Solution: mix 1 : 1 Color Reagent A & Color Reagent By lOOul/well 
Example (96 wells): 5.2 ml A, 5.2 ml B 
Wipe pipette tips with paper towel in between rows 
Cover plate, RT, 20 minutes-Avoid direct light 
15. Add Stop Solution-5Oul per well, gently tap plate to ensure thorough mixing 
16. Determine optical density immediately using microplate reader set to 450 nm. 
Subtract readings at 540nm or 570 nm fiom 450nm readings for wavelength 
correction (corrects for optical imperfections in the plate). 
APPENDIX K: HISTOCHEMICAL STAINS 
1 HEMATOXYLIN AND EOSIN STAIN 
Formalin fmed, parafin embedded specimens 
K. 1.1. Solutions 
Harris Hematoxylin Solution (Sigma Cat# HHS-128)-filter 200ml of stock 
solution into staining dish 
Eosin Y Solution Aqueous (Sigma Cat# HT 1 10-2- 128) 
Acid Alcohol 0.5 % in 80% alcohol (99.5ml of 80% alcohol + 0.5 ml HC1) 
K. 1.2. Other Materials 
Cytoseal60 (Cat# 18006, Electron Microscopy Sciences) 
K. 1.3. Methods 
Deparaffinize and Rehydrate 
Xylene (or substitute) 2 x 5 min. 
100% alcohol 2 x 3 min. 
95% alcohol 2 x 2min. 
80% alcohol 1 min. 
Wash in tap water 5 min. 
Hematoxylin, 3 min. Note: be sure to filter hematoxylin prior to use! 
Wash in tap water for 5 min. 
One quick dip in acid alcohol. 
Wash in tap water for 5 min. 
Eosin, 3 quick dips. 
Dehydrate 
100% alcohol 
Xylene (or substitute) 
Coverslip with Cytoseal 
2 x 3 min. 
2 x 3 min. 
K.2. SAFRANIN-0 STAIN 
K2. I.  Solutions 
9 Safranin-0: 0.2% wlv. Add 1 ml acetic acid per 100 ml dH20. 
Example: 0.2 g Saf-0 + lml acetic acid + 100 ml dH20. 
9 Fast Green Stock Solution: 0.2g Fast green + 1 ml acetic acid + 100 ml dfiO. 
Fast Green Working Solution: 1~500 dilution of stock solution in M20. 
9 0.5% Acetic Acid: 1 ml acetic acid in 200 ml dH20. 
K 2.2. Other Materials 
Cytoseal60 (Cat# 18006, Electron Microscopy Sciences) 
Gill's Hematoxylin 
K.2. 3. Methods 
1. Deparaffinize and Rehydrate: 
Xylene (or substitute) 2 x 5 min. 
100% EtOH 2 x 3 min. 
% EtOH 2 x 2min. 
80% EtOH 1 min. 
Wash in tap water 5 min. 
2. Hematoxylin, 3 min. Note: be sure to filter hematoxylin! 
3. Wash in tap water for 5 min. 
4. Fast green - 3 quick dips. 
5. 0.5% acetic acid - 3 quick dips. 
6. Safranin-0 - 30 minutes 
7. Dehydrate 
95% EtOH a few quick dips 
100% EtOH 2 x 3 min. 
Xylene (or substitute) 2 x 3 min. 
8. Coverslip with Cytoseal 
K.3. TYPE It COLLAGEN IMMUNOHISTOCHEMISTRY 
1. Put slides on hot plate (setting 6 for 2 hours or overnight at setting 4 or 5) 
2. Prepared TBS solution as necessary (from Dako packets - box on shelf) 
3. Set up protocol on autostainer & fill all necessary reagents (see steps below) 
- Open "Scott" file 
- 150ul on bottom and middle position of each slide 
4. Prior to loading in autostainer, de-paraffin and rehydrate 
- Xylene 2 x 5min 
- 100% alcohol 2 x 3min 
- 95% alcohol 2 x 2min 
- 80% alcohol 1 min 
- Water 5min 
5. Keep slides wet with TBS while loading in autostainer. 
6. Prime the pumps (make sure fluids fieely moving) and start the program 
7. The autostainer steps: 
* Rinse 
* Proteolytic digestion to unmask antigenic sites (40 min.) 
--Prepared 0.1 % (wlv) Protease XIV (0.0 1 5g in 1 5ml TBS) 
* Rinse 
* Endogenous peroxidase quench (10 min.) 
--Use from Dako kit 
* Rinse 
* Block non-specific binding (30 min.) 
--Prepared 5% horse serum. (0.75ml serum in 14.25ml TBS) 
* Rinse 
* Primary Antibody or negative control (30 min.) 
--Prepare 1:20 dilution of CIICI collagen 2 antibody in Dako diluent 
(Add 0.375ml antibody to 7.125ml diluent) 
--If using diluent with BSA as a protein block, incubation with horse serum may 
not be necessary 
* Rinse 
* Secondary Antibody (1 0 min.) 
--Biotinylated link: biotin labeled goat anti-rabbit and goat anti-mouse IgG. 
--Yellow liquid in Dako kit. (Prepared 15ml) 
* Rinse 
* Tertiary reagent (10 min.) 
--Streptavidin HRP: streptavidin conjugated to horseradish peroxidase 
--Red liquid in Dako kit (prepared 1 5ml) 
* Rinse 
* ''switch" 
* Subtrate-Chromogen solution (1 0 min.) 
--Diaminobenzidine (DAB) 
--Add 1 drop (20ul) of DAB Chromogen per lml of buffered substrate (fiom 
D AKO kit). 
--Mix in supplied graduated test tube and transfer pipette. (prepared 151x11) 
8. Remove slides from autostainer 
9. Wash in dH20 (3 min.) 
10. Stain with hematoxylin (3min. Be sure to filter hematoxylin prior to using) 
1 1. Wash in dH20 (3 min.) 
12. Acid Alcohol - a few quick dips 
--Prepare 1% acid alcohol (lml HCl in 99ml of 80% ethanol) 
13. Wash in dH20 (3 min.) 
14. Dehydrate through xylenes (times rather arbitrary) 
-40% ethanol, a few dips 
--95% ethanol, a few dips 
--loo% ethanol, 1 minute 
--Xylene 
1 5. Coverslip 
K.4. MASON'S TRICHROME STAIN 
1. Dehydrate (as described in previous protocols) 
2. Hematoxylin (Gill or Harris-do not use the Weigert hematoxy1in)-5min 
3. Rinse-5min 
4. Rinse in deionized water-a few dips 
5. Biebrich-Scarlet Acid Fuchsin (deep red)-for 10 rnin 
6. Phosphotungstic/Phosphomolybid Acid (Prepare by mixing equal volumes of 
each)- lmin 
7. Aniline Blue-5 min 
8. 1% Acetic Acid-2 quick dips 
9. Rehydrate rapidly and coverslip 
APPENDIX L: TRASMISSION ELECTRON MICROSCOPY OF 
UNSEEDED GSCG SCAFFOLDS 
1 FIXATION 
L. 1.1. Solutions 
9 0.2M cacodylate stock buffer: Sodium Cacodylate 4.28 g + loom1 distilled water 
Note: addition of acid produces Arsenic gas, work in the hood ifpossible 
Store in refrigerator 
For pH 7.2 add 8.4 ml of 0.2N Hydrochloric Acid to 100 ml of the Sodium 
cacodylate buffer. 
For pH 7.4 add 5.6 ml of 0.2N Hydrochloric Acid to 100 ml of the Sodium 
cacodylate buffer. 
L. 1.2. Procedure 
L. 1.2.1. Primary Fix 
10 ml8% glutaraldehyde 
6 ml0.2M buffer 
6 ml distilled water 
9 Fix specimens in 2% glutaraldehyde in 0.1M cacodylate buffer, on ice, 20 minutes 
rinse with 0.1 M cacodylate working buffer 5 minutes, x3 
L. 1.2.2. Post Fixation 
9 2% osmium tetraoxide in 0.1 M cacodylate buffer for 1 hr on ice in dark 
9 Rinse with 0.1 M cacodylate buffer 5 minutes, x 3 
L.2. ENBLOC STAINING 
9 2% Uranyl Acetate in 50% EtOH for 20 min. 
L.3. DEHYDRATION 
P 70% ethanol, 5 minutes 
80%, 90%, 10 minutes each 
9 100% ethanol x 3, 10 minutes each 
50% ethanol, 50% propylene oxide (PO) for 5 min 
9 Pure PO for 5min x 2 
L.4. INFILTRATION 
Spurr's embedding resin: medium hard mixture; can use 50ml tri-pour beakers to 
measure this out 
> Mix Spurr's embedding resin gently for 5 min with tongue depressor 
> 1 : 1 Spurr:PO o/n on rotator 
> 100% Spurr's mixture (not more than 24 hours old) for 4-6 hours on rotator 
> Embed 70C for 24 hours 
L.5. MICROTOMY 
Trim specimens to lmm square block face 
> Thick sections can be cut 0.51nm, stained with toludine blue to check morphology 
> Thin sections approx 60nm thick (silver to gold) 
Pick up sections on 400 mesh copper grids 
L.6. POST STAIN 
In Evaporator, clean grids by glow discharging 
On bench set up two petri dishes and 3 50-ml beakers of distilled wate 
Place drop of 2%-8% uranyl acetate in petri dish on parafilm 
On each drop place grid sample side down, 15 min in darkness 
Rinse 3x in series of 50 ml beakers containing H20 
Blot dry on lens paper 
While the samples are staining in UA, place one drop of Reynold's lead citrate (with 4 
or 5 pellets of NaOH). Do not breathe on lead! 
Stain grids 7- 10 min, covered petri dish 
Rinse 3x in series of beakers containing H20 and dry on lens paper 
Store in grid box 
* Protocol provided by Patricia Reilly (Assistant Director, DuPont MIT Alliance) 
